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Abstract	From	2015-2016	 I	 undertook	 the	Master	 of	 Philosophy	 in	Applied	Epidemiology	(MAE)	whilst	under	the	employment	of	the	Murdoch	Childrens	Research	Institute	(MCRI)	 in	 Melbourne	 as	 a	 research	 officer	 for	 a	 study	 based	 in	 the	 People’s	Democratic	Republic	of	Laos	(Lao	PDR).	To	satisfy	the	requirements	of	the	MAE,	I	completed	 projects	 in	 the	 areas	 of	 data	 analysis,	 public	 health	 surveillance,	epidemiological	research	and	outbreak	investigation.		The	 work	 I	 was	 employed	 for	 with	 MCRI	 formed	 the	 basis	 of	 my	 data	 analysis	competency.	The	aim	of	this	project	was	to	determine	the	pneumococcal	conjugate	vaccine	 (PCV)	 coverage	 required	 to	 achieve	 herd	 immunity	 using	 pneumococcal	carriage	surveillance	at	Mahosot	Hospital	in	Lao	PDR.	Beyond	the	analysis	of	these	data,	I	was	responsible	for	overseeing	and	coordinating	the	larger	body	of	work	for	this	project	based	in	Lao	PDR.	This	work	is	ongoing	and	a	final	publication	will	be	published	later	in	2017.			With	 guidance	 from	 my	 field	 supervisor,	 I	 was	 responsible	 for	 establishing	 the	epidemiology	 of	 acute	 gastroenteritis	 (AGE)	 in	 Kiribati	 pre-	 and	 post-rotavirus	(RV)	 vaccine	 introduction.	 As	 part	 of	 this	 review,	 I	 established	 post-marketing	surveillance	of	intussusception	(IS)	as	part	of	RV	vaccine	introduction.	The	World	Health	 Organization	 (WHO)	 recommends	 the	 surveillance	 of	 IS	 post-RV	 vaccine	introduction	due	 to	experiences	with	a	previous	 formulation	of	 the	vaccine.	This	evaluation	is	ongoing	and	will	be	completed	in	2017.		In	 response	 to	 vaccine	 preventable	 disease	 (VPD)	 outbreaks	 in	 Lao	 PDR,	 the	Ministry	 of	 Health,	 National	 Immunization	 Programme	 (NIP)	 requested	information	 regarding	 evidence	 of	 serological	 protection	 of	H.	 influenzae	 type	 b	(Hib)	in	their	population.	This	study	was	the	basis	of	my	epidemiological	research	for	the	MAE.	The	results	from	this	study	would	provide	data	on	Hib	protection	in	their	 population	 to	 help	 inform	 NIP	 if	 changes	 to	 their	 current	 schedule	 were	necessary.		
		 vii	
For	my	outbreak	investigation	competency,	I	was	involved	with	the	team	at	WHO	Lao	PDR	 country	 office	 in	 responding	 to	 a	 circulating	 vaccine-derived	poliovirus	type	1	(cVDPV1)	outbreak	in	Lao	PDR	from	October	2015	to	mid-2017.	As	part	of	this	work	I	will	contribute	to	the	outbreak	investigation	section	of	the	larger	WHO	report	to	be	submitted	to	NIP.			This	thesis	presents	my	experience	as	a	MAE	scholar;	the	skills	gained,	knowledge	learnt	 and	 the	 impact	 this	 body	of	work	had	on	public	 health	 in	 the	Asia-Pacific	region	for	VPD.		
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Introduction	As	 part	 of	 the	 Masters	 of	 Applied	 Epidemiology	 (MAE)	 program,	 I	 was	 lucky	enough	to	be	placed	in	the	field	in	Vientiane,	Laos,	where	I	conducted	the	bulk	of	my	 work.	 Through	 my	 program	 I	 was	 able	 to	 experience	 field	 epidemiology	throughout	 the	 Asia	 Pacific	 region	 in	 the	 realm	 of	 vaccine-preventable	 disease	(VPD).			My	 place	 of	 employment	 was	 with	 the	 Pneumococcal	 Research	 Group	 at	 the	Murdoch	 Childrens	 Research	 Institute	 (MCRI).	 Murdoch	 Childerns	 Research	Institute	was	established	in	1986	with	a	broad	focus	on	child	health	research	from	infant	 to	 adolescent	 health.	 Their	 beliefs	 and	 purpose	 is	 to	 give	 all	 children	 the	opportunity	 to	 live	 a	 healthy	 and	 fulfilled	 life.	 Murdoch	 Childrens	 Research	Institute	 is	 the	 largest	 child	 health	 research	 institute	 in	 Australia,	 employing	approximately	1500	researchers	who	work	from	basic	research	to	translation	into	practice.	 Researchers	 work	 across	 5	 key	 areas;	 infection	 and	 immunity,	 cell	biology,	 clinical	 sciences,	 genetics	 and	 population	 health1.	 The	 Pneumococcal	Research	Group	sits	under	the	Infection	and	Immunity	research	theme	at	MCRI,	led	by	Prof.	Kim	Mulholland,	 and	aims	 to	develop,	 evaluate	and	enhance	vaccination	strategies	worldwide.	As	part	of	the	Pneumococcal	Research	Group,	I	am	employed	as	 a	 research	 officer	 working	 as	 an	 epidemiologist	 for	 the	 PneuCAPTIVE	 study	(Chapter	 2),	 primarily	 based	 in	 Laos,	 whilst	 providing	 support	 to	 the	 site	 in	Goroka,	Papua	New	Guinea	at	the	beginning	of	my	employment.		My	primary	 field	placement	was	at	 the	Laos-Oxford-Mahosot	Hospital-	Wellcome	Trust-Research	 Unit	 (LOMWRU)	 in	 Vientiane	 Capital,	 Laos.	 LOMWRU	 was	established	 in	 2000	 as	 collaboration	 between	Mahidol	 Oxford	 Tropical	Medicine	Research	 Unit	 (MORU)	 and	 Laos’	 main	 internal	 medicine	 hospital,	 Mahosot	Hospital	 in	 the	capital	Vientiane.	The	work	conducted	 is	designed	to	provide	Lao	health	 workers	 and	 the	 Lao	 government	 with	 key	 data	 that	 will	 allow	 them	 to	make	 evidence-based	 decisions	 for	 individual	 patients	 and	 for	 health	 policy.		
																																																								1	Murdoch	Childrens	Research	Institute	Website.	Accessed	5th	April	2015.	Available	from:	https://www.mcri.edu.au		
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LOMWRU’s	 principal	 research	 areas	 are	 the	 epidemiology	 and	 treatment	 of	malaria,	typhoid,	typhus,	community-acquired	septicaemia,	meningitis	and	causes	of	 acute	 febrile	 illness.	 Acute	 febrile	 illness	 is	 the	 most	 common	 medical	presentation	in	the	country.	LOMWRU	also	work	on	many	other	tropical	diseases	with	the	aim	to	increase	the	understanding	of	these	diseases	in	the	country2.		The	 work	 I	 completed	 at	 LOMWRU	 contributed	 to	 2	 of	 my	 core	 competencies	(Chapter	 2	 &	 4)	 for	 the	 MAE	 program.	 The	 first	 was	 the	 PneuCAPTIVE	 study	(Chapter	2)	where	I	acted	in	a	study	coordinator	position,	investigating	the	use	of	nasopharyngeal	 carriage	 surveillance	 in	 children	 to	 measure	 the	 direct	 and	indirect	 effects	 of	 pneumococcal	 conjugate	 vaccine	 (PCV).	 The	 second	 was	 an	epidemiological	study	to	describe	the	coverage	by	written	record	of	H.	influenzae	type	b	(Hib)	vaccine	(given	as	part	of	DTPw-Hib-HepB)	and	evidence	of	serological	protection	to	Hib	from	these	same	children	(Chapter	4).	For	both	of	these	studies	I	was	 responsible	 for	 ensuring	 data	was	 collected	 and	 entered,	 whilst	 addressing	issues	 of	 errors	 and	 completeness.	 The	 data	 collected	 from	 the	 PneuCAPTIVE	project	was	presented	at	multiple	 international	 conferences	 (ISPPD	2016,	ACPID	2016,	TEPHINET	2016)	either	as	a	poster	or	an	oral	presentation.	In	addition	the	PneuCAPTIVE	project	was	presented	at	the	monthly	microbiology	seminars	held	at	MORU	in	Bangkok	to	keep	the	larger	unit	abreast	of	the	work	being	conducted	at	LOMWRU.	Post-MAE,	 the	Hib	 chapter	 results	will	 be	presented	 informally	 to	 the	NIP	team	as	a	presentation	and	a	short	report	to	update	them	on	the	outcome	of	the	work.		Early	2015,	A/Prof	Fiona	Russell	was	asked	to	conduct	an	evaluation	in	Kiribati	for	rotavirus	vaccine	by	WPRO.	This	was	recognised	as	an	opportunity	 to	satisfy	 the	surveillance	core	competency	as	part	of	my	MAE.	Kiribati	had	planned	to	introduce	rotavirus	vaccine	mid-2015	and	had	no	baseline	data	established	for	evaluation	or	safety	 monitoring.	 For	 the	 first	 part	 of	 the	 evaluation	 we	 were	 contracted	 to	identify	 the	 baseline	 incidence	 of	 hospitalised	 acute	 gastroenteritis	 (AGE)	 and	describe	 the	 characteristics	 of	 cases	 in	 the	 5	 years	 pre-vaccine	 introduction.	 As	part	of	the	introduction	we	were	also	required	to	establish	post-marketing	vaccine																																																									2	Laos-Oxford-Mahosot	 Hospital-Wellcome	 Trust-Research	 Unit	 Website.	 Accessed	 April	5th	2015.	Available	from:	https://www.tropmedres.ac/lomwru-laos	
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safety	 surveillance,	monitoring	 intussusception	 (IS).	 The	 establishment	 of	 the	 IS	surveillance	made	up	my	surveillance	competency	(Chapter	3).	We	will	complete	the	evaluation	 late	2017	and	present	 the	early	 impact	of	rotavirus	vaccine	 in	 the	Kiribati	population	to	WPRO	for	the	stakeholders.	This	work	has	been	presented	at	multiple	international	conferences	(ACPID	2016,	TEPHINET	2016)	as	both	an	oral	presentation	and	poster.	A	 late	draft	manuscript	describing	 the	 incidence	of	AGE	pre-vaccine	introduction	in	Kiribati	will	be	submitted	for	publication.			At	 the	 beginning	 of	 2016,	 I	 was	 given	 an	 opportunity	 by	 both	WHO	 and	 NIP	 to	participate	in	the	outbreak	response	to	circulating	vaccine-derived	poliovirus	type	1	(cVDPV1).	The	outbreak	began	in	October	2015	and	was	spread	over	4	provinces	north	of	Vientiane	Capital.	Due	to	the	complexity	and	inherent	language	barriers,	I	was	 primarily	 an	 observer,	 but	when	 appropriate	 did	 assist	 in	 the	 investigation	and	response	to	the	best	of	my	abilities.	 I	was	very	fortunate	 in	being	allowed	to	experience	 all	 aspects	 of	 the	 investigation	 and	 response	 effort	 mounted	 by	 the	government	 and	 NGO’s	 to	 stop	 the	 outbreak	 from	 spreading.	 This	 was	 the	 first	outbreak	of	polio	in	Laos	since	certification	in	2000.	I	was	given	permission	to	use	the	outbreak	investigation	data	to	satisfy	my	outbreak	investigation	and	response	competency	 (Chapter	 5).	 Post-MAE	 I	 will	 assist	 with	 the	 writing	 of	 the	 official	report	for	WHO	and	NIP.	
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Summary	of	MAE	core	activity	requirements	I	completed	the	following	requirements	for	the	Master	of	Philosophy	(Applied	Epidemiology)	qualification:	
Core	competencies	
Epidemiological	study	
• Chapter	4	-	Haemophilus	influenzae	type	b	(Hib)	Serosurvey	
Analysis	of	public	health	data	
• Chapter	2	 -	Using	nasopharyngeal	 carriage	 surveillance	 in	 children	hospitalised	with	acute	 respiratory	 illness	 to	 demonstrate	 direct	 and	 indirect	 effects	 of	 pneumococcal	conjugate	vaccine	(PneuCAPTIVE	Laos)		
Establishment/Evaluation	of	public	health	surveillance	system	
• Chapter	3	–	Kiribati	 rotavirus	vaccine	 introduction;	Establishment	of	post-marketing	surveillance		
Outbreak	investigation	
• Chapter	5	–	Circulating	vaccine-derived	poliovirus	type	1	(cVDPV1)	outbreak	 in	Laos	PDR		
Additional	requirements	
Public	health	report	
• World	Health	Organization	mission	and	findings	report:	Retrospective	review	of	acute	gastroenteritis	and	intussusception	and	establishment	of	intussusception	surveillance	post-rotavirus	vaccine	introduction	in	Kiribati	Mission	 and	 findings	 report	 submitted	 to	 WHO	 (WPRO)	 June	 2015	 (Chapter	 3,	Appendix	D)	and	April	2016	(Chapter	3,	Appendix	E),	respectively	
Scientific	manuscript	for	a	peer-reviewed	journal	
• Jana	Lai,	Beia	Tabwaia,	Agnes	Nikuata,	Ereti	Timeon,	Andre	Reiffer,	Stephanie	Davis,	Kimberly	 Fox	 and	 Fiona	 Russell.	High	 rates	 of	 hospitalised	 acute	 gastroenteritis	
and	 severe	 acute	 malnutrition	 in	 Kiribati	 children	 prior	 to	 rotavirus	 vaccine	
introduction:	 a	 retrospective	 review	 –	 late	 draft	 for	 submission	 to	 the	 Western	Pacific	Surveillance	and	Response	Journal	(WPSAR)	(Chapter	2)	
Chapter	1	–	Introduction	
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Teaching	
• LFF	
• Participated	in	all	‘Lessons	from	the	Field’	hosted	by	the	group	of	my	colleagues	I	was	assigned	to	
• Group	teaching	of	1st	year	MAE	2016	colleagues	(Chapter	6)	
Oral	presentation	at	a	national/international	conference	
• Lai	 JYR,	Tabwaia	B,	Nikuata	AB,	Timeon	E,	Reiffer	AE,	Fox	K,	Russell	F.	High	rates	of	
hospitalised	 acute	 gastroenteritis	 and	 severe	 acute	 malnutrition	 in	 Kiribati	
children	prior	to	rotavirus	vaccine	introduction:	a	retrospective	review.	Results	presented	at	 the	8th	Asian	Congress	of	Pediatric	 Infectious	Diseases	November	2016,	Bangkok,	Thailand	and	8th	Southeast	Asia	and	Western	Pacific	Bi-regional	TEPHINET	Scientific	Conference	November	2016,	Siem	Reap,	Cambodia	
• Lai	 JYR,	Xeuatvongsa	A,	Dance	DAB,	Nguyen	CD,	Lim	R,	Vilivong	K,	Phommachanh	S,	Vongsakid	M,	Siladeth	C,	Dunne	EM,	Morpeth	M,	Datta	SS,	Newton	PN,	Hinds	J,	Satzke	C,	Fox	K,	Mulholland	EK,	Russell	FM.	Using	pneumococcal	nasopharyngeal	carriage	in	
hospitalised	 children	 to	 determine	 the	 pneumococcal	 conjugate	 vaccine	
coverage	 required	 to	 show	 herd	 immunity	 in	 Lao	 PDR.	 	 Preliminary	 results	presented	at	 the	8th	Asian	Congress	of	Pediatric	 Infectious	Diseases	November	2016,	Bangkok,	Thailand	
Other	requirements	
• A	 literature	 review	 was	 completed	 for	 each	 of	 the	 field	 projects	 to	 satisfy	 the	 core	competencies.	
• To	 fulfil	 the	 lay	 communication	 requirement,	 a	 poster	 describing	 the	 PneuCAPTIVE	study	(Chapter	2,	Appendix	B)	was	prepared	and	hung	in	the	relevant	paediatric	wards	to	 inform	 both	 the	 staff	 and	 patients	 of	 the	 purpose	 and	 preliminary	 results	 of	 the	study.	This	was	written	in	both	English	and	Lao	language.		
Courseblock	residentials	
• I	attended	all	three	residentials	during	2015	and	2016		
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1.	Prologue	
1.1.	Role	For	my	Masters	of	Philosophy	in	Applied	Epidemiology	(MAE),	I	was	employed	to	work	 on	 this	 project	 by	 A/Prof	 Fiona	 Russell	 as	 my	 supervisor	 through	 the	Murdoch	Childrens	Research	Institute	(MCRI),	Melbourne.	The	project	was	funded	by	 the	 Bill	 &	 Melinda	 Gates	 Foundation	 (BMGF)	 to	 demonstrate	 how	nasopharyngeal	 (NP)	 carriage	 surveillance	 in	 hospitalised	 children	 with	 acute	respiratory	 illness	 (ARI)	 or	 pneumonia	 could	 be	 used	 to	 estimate	 the	pneumococcal	 conjugate	 vaccine	 (PCV)	 coverage	 required	 to	 show	 evidence	 of	herd	 immunity	 and	 monitor	 the	 vaccine’s	 impact	 on	 carriage.	 This	 would	 help	inform	national	planners	on	the	coverage	required	to	gain	maximum	effectiveness	of	PCV	from	their	respective	immunisation	programs.	The	People’s	Democratic	of	Laos	(Lao	PDR)	is	one	of	3	sites,	with	the	other	2	being	in	Mongolia	and	Papua	New	Guinea.	The	final	analysis	for	the	project	will	pool	together	the	results	of	all	3	sites	to	estimate	the	coverage	required	for	herd	immunity	effects.	The	larger	study	will	continue	through	to	the	end	of	2018.		I	acted	 in	a	coordinator	role	based	 in	Vientiane,	Lao	PDR	working	 in	conjunction	with	Australian	doctors,	managing	a	local	team.	My	responsibilities	on	the	project	were	to	oversee	the	day	to	day	work,	set	the	priorities	for	the	project,	design	and	implement	 data	 collection	 tools	 for	 PCV	 coverage,	 assist	with	 the	writing	 of	 the	study	 analysis	 plan,	 have	 input	 and	 maintain	 the	 relevant	 study	 databases,	participate	 in	 field	 work	 when	 needed,	 train	 local	 staff	 for	 non-clinical	 work,	monitor	 and	 monthly	 reporting	 to	 investigators	 of	 the	 project.	 My	 role	 will	continue	on	this	project	until	the	end	of	2017,	but	for	the	purposes	of	the	MAE,	I	will	only	include	data	up	until	July	2016,	as	this	was	the	microbiological	data	that	was	available	at	the	time	of	writing.				From	this	work	I	have	presented	preliminary	data	at	3	international	conferences	in	both	oral	and	poster	format.	I	have	presented	informal	talks	regarding	this	study	at	our	 collaborator	 meetings	 in	 both	 Bangkok	 and	 Lao	 PDR.	 A	 publication	 will	 be	prepared	and	published	at	the	end	of	the	study	in	late	2017.	
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1.2.	Lessons	learnt	The	 concept	 of	 the	 study	 design	 was	 challenging	 and	 took	 me	 time	 to	 grasp.	Through	my	role	I	had	to	learn	to	manage	a	team	to	achieve	the	goals	of	the	study,	with	 the	added	complications	of	working	 in	a	non-English	speaking	environment	coupled	with	constant	staff	changes.	 I	spent	time	 in	the	 field	to	develop	different	survey	methods	for	our	study	to	estimate	vaccination	coverage	for	our	cases.	To	do	this	I	had	to	organise	the	relevant	approvals	from	National	Immunisation	Program	(NIP)	and	then	plan	with	staff	the	schedule	of	district	hospital/health	centre	visits.	Through	 this	 exercise	 I	 learnt	 about	 the	 nuances	 of	 administrative	 data,	 how	 to	adapt	 and	 fit	 a	 systematic	method	 for	 all	 the	 different	 scenarios	we	 faced	when	collecting	data.	A	key	part	of	this	was	formulating	a	list	of	questions	we	would	ask	district	hospital/health	 centre	 staff	 and	how	 to	 cross-check	 their	 responses	with	the	 data	 recorded	 in	 the	 immunisation	 registries.	 Health	 centre	 staff	 received	limited	training	on	how	to	record	the	data	and	frequently	received	different	data	recording	 tools.	 It	was	 important	 to	 understand	 the	 process	 followed	by	 staff	 at	each	centre	with	their	routine	immunisation.	This	was	because	each	health	centre,	even	within	districts,	 recorded	data	differently.	To	manage	 the	 situation	 I	kept	a	detailed	 diary	 of	 these	 visits	 including	 date	 of	 the	 visit	 so	 we	 could	 match	 the	information	 given	 verbally	 to	 us	 by	 staff,	 to	 the	 photos	 we	 took	 of	 the	immunisation	registries	at	each	centre.	This	 information	 fed	 into	development	of	the	 data	 analysis	 methods	 in	 conjunction	 with	 the	 biostatistician	 and	epidemiologist	for	the	project.	I	learnt	how	to	conduct	monitoring	and	the	process	of	 reporting	 to	 investigators	 on	 a	 regular	 basis.	 I	 was	 responsible	 for	 the	preparation	 of	 the	 vaccination	 status	 and	 coverage	 reporting	 to	 investigators	 as	well	as	hosting,	 running	and	noting	 the	discussions	each	meeting.	Through	 this	 I	learnt	how	to	interact	with	different	stakeholders	in	the	project,	correct	methods	of	note	taking	and	how	to	use	these	data	for	forward	project	planning	to	meet	the	goals	of	the	study,	either	for	reporting	or	data	analysis.		
1.3.	Public	Health	implications	and	impact		The	purpose	of	this	study	was	to	test	a	new	method	to	be	used	for	determining	the	maximum	benefit	of	PCV	use	 in	a	population.	The	maximum	benefit	of	PCV	 for	a	
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population	 lies	 in	 the	 effect	 of	 herd	 immunity.	Many	 countries	 in	 resource-poor	settings,	 such	as	Southeast	Asia,	do	not	have	 robust	 systems	 to	monitor	 invasive	pneumococcal	 disease	 (IPD),	 pneumonia	 and/or	 community	 carriage,	 making	 it	difficult	to	determine	the	herd	immunity	effects	of	PCV	in	the	population.	Beyond	the	added	benefit	of	describing	pneumococcal	carriage	in	Lao	PDR,	the	data	from	this	study	will	add	to	the	body	of	data	in	the	PCV	evaluation	being	prepared	for	the	NIP,	 continuing	 the	 support	 for	use	of	PCV	 in	Lao	PDR.	The	 surveillance	method	proposed	in	this	study	can	be	implemented	quickly	in	sentinel	hospital	sites,	with	an	easily	accessible	population	and	isn’t	dependent	on	pre-vaccine	data,	making	it	adaptable	 to	 other	 low	 and	 middle-income	 countries	 (LMICs).	 However	determination	 of	 PCV	 coverage	 is	 a	 challenge	 and	 novel	 methods	 need	 to	 be	considered.	This	is	 important	as	many	countries	are	considering	the	introduction	of	 PCVs	 in	 the	 region	 and	 face	 a	 similar	 situation	 to	 Lao	 PDR.	 The	 use	 of	 this	method	will	 provide	 other	 LMICs	with	 a	method	 to	 observe	 the	 effect	 of	 PCV	 in	their	country,	supporting	their	use.		
1.4.	Acknowledgements	I	would	like	to	thank	A/Prof	Fiona	Russell	for	first	of	all	for	allowing	me	to	work	on	this	 study	 and	 subsequently	 guiding	 me	 through	 this	 complex	 body	 of	 work.	Additional	 thanks	also	goes	out	to	Dr	Ruth	Lim	who	I	worked	closely	with	at	 the	beginning	of	the	study	to	get	it	to	the	strong	state	it	is	in	today.	My	gratitude	to	Dr	Anonh	Xeuatvongsa,	Dr	Siddhartha	Datta	and	the	rest	of	the	NIP	team	for	always	supporting	 our	 work	 and	 providing	 the	 necessary	 knowledge	 and	 assistance	 to	ensure	the	study	ran	smoothly.	At	LOMWRU	I	would	firstly	like	to	thank	Dr	David	Dance	and	Prof	Paul	Newton	for	the	unfaltering	support	and	guidance.	My	thanks	to	 the	Pneumococcal	Research	Group	 at	MCRI;	 Prof	Kim	Mulholland,	Dr	Cattram	Nguyen	and	Dr	 Jocelyn	Chan	 for	 support	 and	 the	microbiology	 team	 for	all	 their	assistance	in	not	only	helping	us	process	our	samples	but	also	for	making	sure	we	met	 our	 reporting	 deadlines.	 Finally,	 my	 eternal	 gratitude	 goes	 out	 to	 our	PneuCAPTIVE	team	in	Lao	PDR	who	without	the	dedication	we	would	not	be	able	to	present	this	data	today.	
1.5.	Funding	Bill	&	Melinda	Gates	Foundation	
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2.	Abstract	
Background/aims:	 People’s	 Democratic	 of	 Laos	 (Lao	 PDR)	 introduced	 13-valent	pneumococcal	 conjugate	 vaccine	 (PCV13)	 in	October	 2013	 for	 children	 up	 to	 12	months	of	age.	The	primary	aim	of	this	study	is	to	determine	the	PCV13	coverage	needed	 to	 show	 evidence	 of	 herd	 immunity	 using	 nasopharyngeal	 (NP)	pneumococcal	carriage	surveillance	in	hospitalised	children	in	Lao	PDR.	Secondary	aims	 were	 to	 describe	 the	 epidemiology	 of	 cases	 and	 describe	 overall	pneumococcal	 carriage,	 VT	 carriage	 and	 NVT	 carriage	 among	 vaccinated	 and	undervaccinated	cases.		
Methods:	 Children	 2-59	 months	 of	 age	 admitted	 to	 Mahosot	 Hospital,	 Vientiane	with	acute	respiratory	infection	(ARI)	were	prospectively	enrolled	from	December	2013	to	July	2016,	and	had	a	NP	swab	collected.	Pneumococcal	carriage	status	was	determined	 using	 lytA	 real-time	 quantitative	 PCR	 (qPCR),	 with	 positives	 and	equivocals	 serotyped	 by	 microarray.	 Monthly	 PCV13	 vaccine-type	 (VT)	 carriage	rates	 were	 determined	 in	 undervaccinated	 and	 vaccinated	 children.	 The	 PCV13	vaccination	rate	was	calculated	using	7-month	rolling	intervals	each	month	by	the	number	of	cases	vaccinated	based	on	written	records	(mother	child	health	(MCH)	card	 or	 health	 centre	 immunisation	 registry)	 and	 the	 total	 number	 of	 cases	enrolled	 each	month.	Herd	 immunity	 effects	were	determined	by	 calculating	 the	risk	 of	 VT	 carriage	 among	 vaccinated	 and	undervaccinated	 children.	A	 risk	 ratio	equivalent	 to	 1	 was	 deemed	 as	 herd	 immunity	 effects	 being	 achieved	 in	 the	population.		
Results:	From	December	2013	to	July	2016,	800	cases	were	enrolled	into	the	study.	Of	those,	53%	had	pneumonia	and	the	majority	resided	in	Vientiane	Capital.	PCV13	vaccinated	 cases	 were	 significantly	 younger	 (12	 months,	 IQR	 8-17)	 than	undervaccinated	 cases	 (21	 months,	 IQR	 8-33)	 (p<0.001).	 Cases	 residing	 in	 the	provinces	 were	 significantly	 less	 likely	 to	 be	 vaccinated	 (p<0.001).	 Overall	pneumococcal	carriage	was	40%,	with	vaccinated	cases	significantly	less	likely	to	carry	 a	 VT	 (p<0.001)	 than	 undervaccinated	 cases.	 Over	 time,	 VT	 carriage	 in	vaccinated	cases	declined,	whilst	VT	carriage	 in	undervaccinated	cases	 remained	relatively	 unchanged	 over	 time.	 The	 vaccination	 rate	 in	 cases	 steadily	 increased	
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over	the	study	period	from	16%	to	70%	by	July	2016.	The	risk	ratio	of	VT	carriage	in	vaccinated	and	undervaccinted	did	not	equal	1	over	the	study	period.			
Summary	 and	 Conclusions:	 Direct	 effects	 have	 occurred	 shown	 by	 VT	 carriage	decreasing	 in	 vaccinated	 cases.	 However	 herd	 immunity	 has	 not,	 indicated	 by	 a	risk	 ratio	 of	 VT	 carriage	 between	 vaccinated	 and	 undervaccinated	 cases	 greater	than	 1.	 Further	 analysis	 is	 required	 to	 adjust	 for	 confounding	 in	 carriage.	 The	reasons	 for	absent	herd	 immunity	effects	are	related	to	 the	case	vaccination	rate	overestimating	community	coverage,	lack	of	an	active	catch-up	campaign	and	early	post-PCV	data	(over	2	years)	being	shown.	Surveillance	will	 continue	 for	5	years	and	 if	 herd	 immunity	 effects	 do	 occur,	 they	 will	 occur	 within	 this	 time	 period.	These	 data	 are	 important	 to	 not	 only	 inform	 decision	 makers	 what	 PCV13	coverage	 is	 required	 to	 maximise	 the	 benefits	 of	 PCV13	 but	 also	 to	 monitor	changes	to	pneumococcal	epidemiology	due	to	use	of	the	vaccine.	
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3.	Introduction	
3.1.	Pneumococcal	disease		In	 2000,	 it	 was	 estimated	 pneumococcal	 infections	 were	 responsible	 for	 about	826,000	 deaths	 in	 children	 1-59months	 of	 age	 (1).	 Pneumonia	 is	 the	 second	leading	 cause	 of	 deaths	 in	 children	 under	 the	 age	 of	 5	 years	 globally	 (2),	 with	pneumococcus	being	the	most	common	cause	of	bacterial	pneumonia	(3).	Almost	all	pneumonia-related	deaths	occur	 in	 low	and	middle-income	countries	 (LMICs)	where	children	are	poor,	timely	access	to	health	services	may	be	difficult	or	even	impossible	 and	 where	 risk	 factors	 for	 more	 frequent	 and	 severe	 disease	 are	common	(4).	Ninety-eight	percent	of	all	pneumonia	deaths	in	children	less	than	5	years	of	age	occur	in	just	68	LMICs	(5).			
Streptococcus	 pneumoniae	 or	 pneumococcus	 is	 a	 Gram-positive	 bacterium	 that	naturally	resides	in	the	nasopharynx	of	humans.	Nasopharyngeal	(NP)	carriage	is	common	and	most	carriers	are	healthy	(6).	Transmission	occurs	via	direct	contact	with	 respiratory	 secretions	 from	 carriers	 to	 non-carriers	 (1).	 Acquisition	 and	subsequent	 infection	with	pneumococcus	 is	 the	precursor	 to	disease	 (7,	 8),	with	the	highest	pneumococcal	carriage	rates	in	children	during	their	first	2	years	of	life	(8).	From	this	point,	pneumococcus	can	be	spread	to	others	and	also	gain	access	to	other	sites	 in	 the	body	such	as	 the	 lungs,	which	 then	can	 lead	 to	pneumonia	 (8).	Thus	 far	 there	 have	 been	 over	 90	 unique	 serotypes	 identified	 however	 not	 all	serotypes	 cause	 disease.	 Diseases	 caused	 by	 pneumococcus	 include	 pneumonia,	meningitis,	febrile	bacteraemia,	otitis	media,	sinusitis	and	bronchitis	(1).			
3.2.	Pneumococcal	Conjugate	Vaccine	(PCV)	In	2007,	WHO	recommended	the	use	of	pneumococcal	conjugate	vaccines	(PCVs)	in	all	countries,	urging	the	highest	priority	for	introduction	given	to	countries	with	high	 pneumonia	 and	 under	 5	 mortality	 rates	 (1).	 In	 February	 2000,	 the	 United	States	 (US)	Food	and	Drug	Administration	 (FDA)	 licenced	 the	 first	PCV,	 7-valent	PCV	 (PCV7)(9).	 PCV7,	 also	 known	 as	 Prevenar®,	 contained	 7	 pneumococcal	polysaccharides	 (4,	 6B,	 9V,	 14,	 18C,	 19F	 and	 23F)	 conjugated	 to	 a	 non-toxic	diphtheria-toxin	 variant	 carrier	 protein,	 CRM197	 (9).	 Because	 of	 issues	 with	
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serotype	 replacement	 and	 coverage	 of	 other	 important	 serotypes	 in	 LMICs,	 new	formulation	PCV’s	are	now	available,	with	the	two	currently	licenced	being	PCV10	and	 PCV13,	 licenced	 in	 2009	 and	 2010	 respectively.	 PCV13,	 also	 known	 as	Prevenar13®,	has	the	same	components	as	PCV7,	with	the	addition	of	addition	of	6	serotypes;	1,	3,	5,	6A,	7F	and	19A.			
3.3.	Impact	of	PCV	on	invasive	pneumococcal	disease	(IPD)	Evidence	 from	 high	 income	 countries	 (HICs)	 that	 have	 adopted	 PCVs	 into	 their	National	 Immunization	 Programmes	 (NIPs),	 have	 shown	 their	 use	 can	 prevent	much	 morbidity	 and	 mortality	 (9,	 10).	 Since	 the	 use	 of	 PCV7,	 countries	 that	adopted	the	use	of	the	vaccine	reported	significant	declines	in	IPD.	In	a	review	by	Feikin	 et	 al.	 (2013),	 reductions	 in	 invasive	 pneumococcal	 disease	 (IPD)	 up	 to	 7	years	post-PCV7	 introduction	were	summarised.	Feikin	et	al.	 (2013)	 included	21	datasets	 for	 their	 analysis	 from	 4	 geographical	 regions	 (North	 America,	 Europe	Australasia,	South	America).	In	children	<5years	of	age,	by	the	first	year	of	use,	IPD	caused	by	vaccine-types	(VTs)	significantly	decreased	from	a	risk	ratio	of	0.34	to	0.14,	 further	 decreasing	 after	 7	 years	 of	 use	 to	 0.03(11).	 Focusing	 on	pneumococcal	 meningitis,	 Htar	 et	 al.	 (2013)	 assessed	 the	 impact	 of	 PCV7	 on	pneumococcal	 meningitis.	 Seventeen	 articles	 were	 included	 in	 this	 review	 from	two	 continents;	 Western	 Europe	 and	 North	 America.	 Comparing	 pre-	 and	 post-vaccination	periods,	reductions	ranging	from	59.2%	in	the	US	to	100%	in	Belgium	in	VT	pneumococcal	meningitis	incidence	were	shown	in	vaccine-eligible	children	(12).			
3.4.	Herd	immunity	The	 reductions	 in	 IPD	 after	 PCV	 introduction	 were	 not	 limited	 to	 vaccinated	populations,	extending	to	unvaccinated	groups,	namely	older	children	and	adults.	Herd	 immunity,	 or	 herd	 protection/indirect	 effect	 of	 vaccination,	 is	 where	unvaccinated	populations	are	also	protected	from	disease.	For	PCV,	the	reduction	in	 NP	 carriage	 of	 VTs	 caused	 by	 vaccine	 use	 interrupts	 transmission	 to	unvaccinated	 contacts	 (9,	 13).	 The	 use	 of	 PCV	 resulted	 in	 reductions	 of	pneumococcal	disease	burden	in	the	non-immunised	adult	population,	where	the	burden	 in	 terms	 of	 mortality,	 morbidity	 and	 hospitalisation	 costs	 of	 IPD	 and	
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community-acquired	pneumonia	(CAP)	is	larger	than	in	children	(13).	In	terms	of	cost	 saving,	 Ray	 et	 al.	 (2006)	 estimated	 a	 15-fold	 increase	 in	 cost-effectiveness	when	herd	immunity	was	considered	in	US	estimates	(14).	In	terms	of	actual	dollar	value,	McIntosh	et	al.	(2005)	estimated	that	the	direct	cost	of	per	life	year	gained	in	the	UK	when	herd	immunity	was	considered	equated	to	4,360	pounds	(15).	Thus	to	get	the	maximum	benefit	of	PCV	use	in	a	population,	herd	immunity	needs	to	be	considered.		Figure	1	is	an	excerpt	from	Feikin	et	al.	(2013)	and	illustrates	the	impact	of	PCV7	on	 VT	 IPD	 in	 HICs	 up	 to	 7	 years	 post	 PCV7	 introduction.	 From	 Figure	 1,	 the	greatest	 reductions	 are	 seen	 in	 children	 <5	 years	 of	 age,	 as	 described	 in	 the	previous	section,	but	there	are	also	reductions	in	adult	age	groups	over	this	7-year	period	(11).			
Figure	1:	Post-PCV7	introduction	invasive	pneumococcal	disease	caused	by	vaccine	types	summary	rate	ratios	from	random	effects	meta-analysis.	Adapted	from	Feikin	et	al.	(2013)	
		In	a	recent	systematic	review	and	meta-analysis	by	Shiri	et	al.	(2017),	IPD	due	to	PCV7	 serotypes	 in	 countries	 with	 mature	 PCV	 programmes	 has	 been	 all	 but	eliminated	due	 to	herd	 immunity	 (16).	They	also	predicted	 that	 the	 residual	 IPD	caused	 by	 the	 additional	 6	 VTs	 in	 PCV13	will	 be	 halved	 after	 a	mean	 period	 of	about	3	years	and	nearly	eradicated	(90%	reduction)	after	about	9	years	of	PCV13	use	 (16).	However	 as	 highlighted	by	Goldblatt	 et	 al.	 (2017)	using	 the	 Shiri	 et	 al.	(2017)	paper,	most	of	 the	data	 for	 the	 indirect	 effect	 of	PCV	are	 from	HICs	with	mature	 surveillance	 systems	 where	 PCV	 was	 introduced	 into	 the	 infant	immunisation	programmes	 soon	after	 licensure	 (16,	17).	 Shiri	 et	 al.	 (2017)	used	data	 from	 only	 4	 LMICs,	 with	 none	 of	 them	 from	 Asia,	 raising	 questions	 of	 the	applicability	of	the	data	on	indirect	effect	of	PCV	to	LMICs	(16,	17).	
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	The	extent	of	herd	immunity	is	dependent	on	coverage	and	serotype	distribution	in	 the	 population.	 This	 becomes	 particularly	 important	 when	 considering	 the	impact	 of	 PCV	 in	 LMICs.	 Tsaban	 et	 al.	 (2017),	 stated	 that	 ‘profound	 indirect	protection	 can	 only	 be	 achieved	 in	 populations	 with	 high	 (>70-80%)	 vaccine	coverage’,	where	extensive	sustained	interruption	of	VT	transmission	occurs	(13).	The	length	of	time	since	PCV	introduction	also	plays	a	role;	countries	with	mature	PCV	 programmes	 seeing	 a	 greater	 vaccine	 impact	 in	 both	 child	 and	 adult	populations	(13).	However	 in	a	comment	piece	by	Klugman	and	Rodgers	(2017),	reported	IPD	reduction	 incidence	 in	Europe	 is	 less	 than	that	seen	 in	 the	US	(18).	Reasons	for	this	are	the	variety	in	vaccine	coverage	rates	in	different	countries	and	a	wider	diversity	of	pneumococcal	serotypes	causing	disease	(19).	These	reasons	are	a	concern	for	LMICs,	which	see	lower	coverage	of	PCV	and	greater	diversity	of	pneumococcal	 serotypes	 causing	 disease	 (16,	 18).	 However,	 the	 ecology	 of	pneumococcal	transmission	in	LMICs	may	be	very	different	to	what	is	seen	in	HICs	(16).	 Thus	 perhaps,	 different	 levels	 of	 vaccine	 coverage	 may	 be	 adequate	 to	achieve	herd	immunity.	Also	different	formulations	of	pneumococcal	vaccines	may	have	a	greater	impact	on	pneumococcal	disease	in	LMIC	settings.	More	research	is	required	to	assess	the	indirect	affects	of	PCV	in	these	settings.			
3.5.	Measuring	direct	and	indirect	effects	of	PCV	on	pneumococcal	
disease	Determining	 direct	 and	 indirect	 effects	 of	 PCV	 on	 pneumococcal	 disease	 are	difficult	because	of	the	complex	nature	of	pneumonia	and	also	the	low	sensitivity	in	identifying	pneumococcus	as	the	cause	of	invasive	disease	(20).	Pneumonia	can	be	caused	by	range	viruses,	bacteria	or	fungi,	with	the	progression	of	disease	also	affected	by	a	range	of	socioeconomic	factors.	In	addition,	as	the	lungs	are	internal,	the	 methods	 for	 diagnosis	 range	 from	 invasive,	 such	 as	 a	 lung	 puncture	 to	observatory	such	as	a	chest	x-ray	to	try	and	determine	the	aetiological	agent	(21).	Furthermore,	to	definitively	diagnose	IPD,	pneumococcus	must	be	isolated	from	a	sterile	 site	 such	 as	 blood,	 cerebrospinal	 fluid,	 ascetic	 fluid,	 etc.	 Pneumococcus	 is	difficult	 to	detect	 in	 the	 laboratory,	and	newer	diagnostic	 tests	are	adding	 to	our	understanding	of	 the	burden	of	disease.	 In	addition	 to	 the	 inherent	difficulties	of	pneumococcal	 isolation	 from	 patient	 samples,	 LMICs	 have	 the	 added	
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disadvantages	 of	 problems	 with	 basic	 microbiological	 culture	 of	 organisms,	leading	to	further	reductions	in	culture	sensitivity	(20,	22).	Due	to	the	limitations	of	 current	 diagnostic	 methods	 and	 pre-diagnostic	 antibiotic	 use,	 pneumonia	aetiology	 studies	 often	 underestimate	 the	 true	 burden	 of	 pneumococcal	 disease	(20,	23).		The	cornerstone	for	support	of	PCV	introduction	and	continued	use	in	NIPs	is	IPD	surveillance	 (22).	 The	 recommendation	 for	 accurate	 vaccine	 assessment	 is	consistent	 surveillance	 for	 a	 minimum	 2	 years	 pre-vaccine	 and	 5	 years	 post-vaccine	introduction	(22).	The	reality	for	most	LMICs	is	they	are	unable	or	do	not	have	 systems	 in	 place	 for	 robust	 disease	 surveillance	 to	 show	 herd	 immunity,	making	 it	 very	 difficult	 to	 determine	 if	 they	 are	 getting	 the	maximum	benefit	 of	PCV	 in	 their	population	 (6).	This	becomes	even	more	crucial	when	assessing	 the	value	of	PCV	in	their	immunisation	programs.	Thus	for	LMICs,	new	methods	need	to	be	assessed	such	as	syndromic	surveillance	(22)	or	the	use	of	a	proxy	such	as	VT	carriage	to	determine	the	impact	of	PCV	in	their	population.			
3.6.	PCV	and	pneumococcal	carriage	Nasopharyngeal	 carriage	 is	 of	 great	 interest	 in	 terms	 of	 PCV	 impact	 as	 it	 is	 the	natural	biological	niche	for	pneumococcus,	other	upper	respiratory	pathogens	and	commensals	(8).	Pneumococcal	carriage	is	highest	in	children	<5years	of	age	with	peak	carriage	occurring	between	3-11	months,	making	young	children	the	primary	source	of	pneumococcal	transmission	(24,	25).			There	are	many	studies	showing	the	impact	of	PCV	on	VT	carriage.	A	study	in	Kilifi,	Kenya	 by	Hammitt	 et	 al.	 (2014)	 illustrated	 this	 effect	 succinctly.	 Figure	 2	 below	shows	the	reductions	in	VT	carriage	following	PCV10	introduction.	In	children	<5	years	of	age,	carriage	prevalence	of	VTs	significantly	decreased	from	34%	to	13%,	2	 years	 after	 PCV10	 introduction	 into	 the	 population.	 In	 children	 and	 adults	 >5	years	of	age,	there	were	also	significant	reductions	in	carriage	of	VTs	in	the	same	period	 from	 8%	 to	 4%.	 A	 net	 total	 reduction	 in	 VT	 carriage	 for	 all	 ages	 was	observed.	Based	on	the	surveillance	system	used,	coverage	of	PCV10	was	67%	by	the	second	year	of	PCV10	introduction	(26).			
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Figure	2:	Nasopharyngeal	carriage	prevalence	of	S.	pneumoniae	vaccine-type	serotypes	in	all	ages,	Kilifi	Kenya.	Adapted	from	Hammitt	et	al.	(2014)	
		Carriage	is	becoming	frequently	included	in	PCV	evaluation	studies,	as	PCV	use	has	seen	the	decrease	and/or	near	elimination	of	VTs	from	the	nasopharynx.	This	has	led	 to	 a	 decrease	 in	 transmission	 of	 VTs	 and	 subsequent	 reductions	 in	pneumococcal	 disease	 (18).	 Therefore,	 the	 PCV	 effect	 of	 NP	 carriage	 in	 healthy	carriers	plays	a	major	role	in	the	control	of	pneumococcal	disease	and	may	be	the	key	to	the	control	of	pneumococcal	disease	in	countries	that	are	unable	to	achieve	PCV	coverage	 in	 their	entire	population	(18).	However	questions	remain	on	how	the	NP	carriage	decline	of	VTs	can	be	extrapolated	to	declines	 in	VT	IPD	and	the	role	of	NVTs	in	IPD,	as	not	all	serotypes	carried	cause	disease	(6).		
3.7.	Carriage	surveillance	and	herd	immunity	Therefore,	could	carriage	surveillance	be	used	to	estimate	the	coverage	required	to	show	herd	immunity	in	these	populations?	This	concept	has	been	explored	thus	far	by	 Loughlin	 et	 al.	 (2014)	 and	 Grant	 et	 al.	 (2016)	 in	 populations	 in	 Boston	 and	American	 Indians	 respectively.	 Both	 populations	 had	 used	 PCV7	 in	 their	 routine	immunisation	since	2000,	so	the	herd	immunity	effects	were	only	measured	in	the	additional	6	serotypes	covered	by	PCV13.		
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Loughlin	 et	 al.	 (2014)	 investigated	 the	 PCV13	 coverage	 required	 to	 show	 herd	immunity	 in	 nonimmune	 children	 (children	 either	 unvaccinated	 or	 under	vaccinated)	<5	years	of	age	living	in	Boston,	Massachusetts.	PCV13	was	introduced	into	the	community	in	July	2010,	replacing	PCV7	with	no	catch-up	campaign.	Prior	to	the	study,	herd	 immunity	effects	were	defined	a	priori	as	a	persistent,	50%	or	more	decline	in	carriage	of	the	additional	6	PCV13	types	in	nonimmune	children,	across	 comparable	 study	 intervals	 to	 account	 for	 potential	 seasonal	 variation	 in	carriage.	Vaccine	uptake	for	the	community	was	estimated	between	June	2010	and	July	2012	using	weekly,	aggregate,	stratified	summaries	of	the	number	of	children	having	 received	 none	 or	 any	 number	 of	 PCV13	 doses	 from	 the	 Boston	 Medical	Center,	Primary	Care	Center,	where	the	study	was	held.	However,	during	analysis	of	the	data,	the	definition	of	herd	immunity	effects	was	changed	to	the	time	point	when	 PCV13	 carriage	 prevalence	 in	 the	 immune	 and	 nonimmune	 groups	 was	equivalent.	 Figure	 3	 below	 shows	 that	 this	 carriage	 prevalence	 equivalence	was	achieved	when	community	vaccine	coverage	was	approximately	67%,	lower	than	the	a	priori	definition,	where	 the	decline	was	 seen	 at	 coverage	 at	 approximately	75%	(27).			
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Figure	3:	Comparison	of	the	prevalence	of	PCV13	serotype	carriage	among	immune	and	nonimmune	children,	plotted	with	the	coverage	of	PCV13	in	children	<5	years	of	age	in	the	community	
	Full	line	=	immune;	Dotted	line	=	nonimmune;	Grey	line	=	coverage		In	a	similar	study,	Grant	et	al.	 (2016)	evaluated	the	direct	and	 indirect	 impact	of	PCV13	 in	 American	 Indian	 populations	 in	 the	 US	 relative	 to	 community	 vaccine	coverage.	For	Grant	et	al.	(2016),	the	coverage	associated	with	a	significant	decline	in	PCV13	type	carriage	was	defined	as	when	pre-PCV13	type	carriage	prevalence	no	 longer	 overlapped	 with	 the	 confidence	 intervals	 for	 the	 monthly	 carriage	prevalence	 thereafter.	Monthly	PCV13	coverage	was	estimated	 from	March	2010	through	 March	 2012	 among	 study	 participants	 and	 for	 the	 full	 community	 of	children	<5	years	of	age	using	electronic	health	records	for	vaccination	status	and	the	 US	 Indian	 Health	 Service	 User	 Population	 for	 the	 community	 denominator.	Herd	immunity	for	the	6	additional	serotypes	was	achieved	11	months	after	PCV13	introduction	 when	 community	 vaccine	 coverage	 was	 approximately	 58%,	 as	shown	 in	 Figure	 4	 below.	 In	 addition,	 a	 60%	 reduction	 in	 PCV13-specific	 type	carriage	among	children	occurred	simultaneously	with	an	89%	decline	in	PCV13-specific	type	IPD	rate	among	children	in	the	same	age	group	in	community	during	the	study	period	(28).	Thus	these	data	support	the	existence	of	a	potential	reliable	
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relationship	between	VT	carriage	reduction	and	its	translation	to	VT	IPD	reduction	in	a	community.			
Figure	4:	Three-month	moving	average	of	PCV13-specific	type	carriage	prevalence	among	under-immunized	Navajo	and	White	Mountain	Apache	children	<5	years	and	community	PCV13	uptake	and	coverage	
	Red	line	=	carriage	prevalence;	Histograms	=	PCV13	coverage;	Histogram	bar	outlined	in	black	identifies	the	month	when	significant	reduction	was	achieved	compared	to	the	pre-PCV13	introduction	period		From	 the	 Loughlin	 and	 the	 Grant	 studies,	 the	 prospect	 of	 using	 pneumococcal	carriage	 surveillance	 to	 show	effects	of	herd	 immunity	may	prove	 to	be	a	 viable	option	 for	 LMICs	 considering	 the	 use	 of	 PCV	 in	 their	 NIPs.	 Using	 carriage	surveillance	 bypasses	 the	 need	 for	 robust	 disease	 surveillance	 and	 can	 be	implemented	as	the	vaccine	is	being	introduced	into	the	population	with	little	pre-vaccine	 introduction.	However	both	of	 these	studies	use	community	samples	not	samples	collected	from	children	suffering	from	acute	respiratory	illness	(ARI).		As	 pneumococcal	 carriage	 is	 a	 precursor	 to	 disease,	 it	 is	 assumed	 that	 if	 VT	carriage	declines,	VT	disease	 also	declines.	However	 there	 is	not	 always	 a	direct	correlation	between	carriage	serotypes	and	those	isolated	in	invasive	disease	(29).	Environmental	 factors,	 host	 factors	 and	 bacterial	 virulence	 all	 play	 a	 role	 in	development	of	disease.	What	has	been	shown	is	the	presence	of	higher	carriage	of	pneumococcus	 in	 children	 with	 ARI	 or	 pneumonia	 (30).	 Thus	 those	 that	 suffer	from	respiratory	illness	are	at	a	higher	risk	of	disease	to	begin	with.	The	isolation	of	pneumococcus	from	the	NP	of	children	hospitalised	with	ARI	is	not	indicative	of	an	aetiological	cause	of	their	admission	but	the	lack	of	VTs	in	carriage	would	mean	
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these	types	are	no	longer	circulating	in	the	population	to	cause	disease	(20).	This	in	 conjunction	 with	 their	 admission	 to	 a	 health	 centre	 makes	 them	 an	 ideal	population	to	conduct	surveillance	to	monitor	the	effects	of	PCV	in	the	population	(20).	Explicitly	this	is	because	they	are	at	high	risk	of	disease,	they	come	from	the	population	of	interest	and	they	congregate	in	a	health	facility	for	care.			
3.8.	Laos	and	PCV	Lao	PDR	 is	classified	as	a	 least	developed	country	(LDC)	and	Laotians	 face	many	challenges	when	accessing	health	care,	including	distance,	infrastructure,	cost	and	staffing	shortages.		These	factors	as	well	as	generally	low	levels	of	resources	make	disease	surveillance	very	difficult	even	in	the	most	developed	parts	of	the	country.	Lao	 PDR,	 with	 the	 assistance	 of	 Gavi,	 introduced	 PCV13	 into	 their	 Expanded	Programme	of	Immunization	(EPI)	program	in	October	2013.	The	schedule	was	for	PCV13	vaccination	to	be	given	to	infants	at	6,	10,	14	weeks	and	for	those	up	to	12	months	of	age	that	came	to	the	clinic,	3	doses	were	also	offered.		Prior	 to	 the	 introduction	of	PCV13	 into	 the	NIP,	Lao	PDR	had	no	reliable	disease	surveillance	data	on	IPD	or	pneumonia.	This	included	no	IPD	incidence	estimates	or	pneumonia	 and	no	 routine	data	on	 circulating	 serotypes	 for	 either	disease	or	carriage,	making	it	very	difficult	to	not	only	measure	the	direct	effects	of	PCV13	in	the	population	but	also	the	 level	of	coverage	to	achieve	herd	 immunity.	The	only	study	to	consider	 IPD	 in	Lao	PDR	was	a	hospital-based	study	of	all	patients	with	suspected	 community	 acquired	 septicaemia	 or	meningitis	 from	 January	 2003	 to	April	2009	(31).	Of	the	pneumococcal	culture	positive	samples	from	patients	of	all	ages,	76%	of	serotypes	were	covered	by	PCV13	(31).	The	major	limitations	of	the	Moore	 et	 al.	 (2010)	 study	 were	 the	 low	 culture	 positives	 (0.21%	 and	 5.4%	positivity	for	haemocultures	and	cerebrospinal	fluid	respectively)	in	thousands	of	patients	 as	 part	 of	 larger	 evaluation	 of	 all-cause	 sepsis	 and/or	meningitis.	 Thus	this	 was	 not	 IPD	 surveillance	 and	 highlighted	 the	 issues	 with	 IPD	 surveillance	when	 relying	 on	 culture.	 Using	 carriage	 surveillance	 could	 be	 a	 viable	 option	 to	address	 the	 issues	 surrounding	 the	 paucity	 of	 robust	 disease	 surveillance	 to	evaluate	 the	 performance	 of	 PCV13	 in	 Lao	 PDR.	 Carriage	 surveillance	 could	 be	used	 to	 not	 only	 observe	 the	 direct	 effects	 of	 PCV13	 use	 over	 time	 but	 also	 to	determine	the	point	at	which	herd	immunity	occurs.	
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3.9.	Aims		The	 primary	 aim	 of	 the	 study	 was	 to	 estimate	 the	 PCV13	 coverage	 required	 to	demonstrate	maximal	 indirect	 effects	 of	 PCV13	 (also	 known	 as	 herd	 immunity)	among	 children	 aged	 2-59	 months,	 hospitalised	 with	 ARI	 or	 pneumonia	 from	December	2013	to	June	2016	in	Lao	PDR.			Secondary	aims	were	 to	describe	 the	epidemiology	of	 cases	and	describe	overall	pneumococcal	 carriage,	 VT	 carriage	 and	 NVT	 carriage	 among	 vaccinated	 and	undervaccinated	cases.	
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4.	Methods	
4.1.	Study	Site	Administratively,	Lao	PDR	is	made	up	of	18	provinces,	each	consisting	of	districts	containing	 numerous	 villages,	 with	 some	 more	 densely	 populated	 districts	containing	up	to	70	villages.	In	terms	of	health	care,	villages	are	serviced	by	their	designated	local	health	centre	or	district	hospital.	If	the	level	of	care	needed	is	not	available	 at	 the	 health	 centre/district	 hospital,	 patients	 are	 referred	 on	 to	 the	Provincial	Hospital.	If	the	level	of	care	is	not	available	at	the	provincial	level	then	they	 are	 further	 referred	 onto	 the	 large	 Central	 Hospitals	 located	 in	 Vientiane	Capital.	Patients	can	also	present	directly	at	their	health	facility	of	choice	without	a	referral.	Universal	free	health	care	is	currently	not	available	in	the	country,	but	is	being	 trialled	 in	 a	 few	 provinces.	 Routine	 immunisations	 are	 free	 to	 all	 eligible	children.			The	 study	was	 conducted	 at	 the	Paediatric	Department	 of	Mahosot	Hospital,	 the	oldest	hospital	in	Lao	PDR,	a	tertiary	referral	central	hospital	servicing	all	ages	and	conditions.	The	majority	of	patients	that	seek	care	there	are	from	Vientiane	Capital	as	 the	 hospital	 is	 located	 in	 the	 city	 centre.	 Patients	 seek	 care	 directly	 at	 the	hospital	or	are	referred	from	smaller	district	hospitals	and	health	centres.			
4.2.	Design	PneuCAPTIVE	was	nested	 in	 a	 larger	 study	on	 the	 aetiology	of	ARI	 conducted	at	Mahosot	Hospital,	in	collaboration	with	the	Lao-Oxford-Mahosot-Wellcome	Trust-Research	 Unit	 (LOMWRU).	 PneuCAPTIVE	 was	 a	 prospective	 cohort	 study	 with	patients	 recruited	 from	 all	 wards	 admitting	 children	 (general	 paediatric	 ward,	paediatric	infectious	disease	ward	and	neonatal/paediatric	intensive	care	unit)	at	Mahosot	Hospital	from	December	2013	to	June	2017.	Due	to	submission	dates	for	this	thesis	the	data	presented	are	from	December	2013	to	July	2016	(inclusive).		
4.3.	Study	Participants	Eligible	 cases	 were	 children	 aged	 2-59	 months	 admitted	 to	 Mahosot	 Hospital	during	the	study	period	with	ARI	defined	as	a	history	of	illness	≤14	days	with	fever	
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or	documented	tympanic	fever	(>38°C)	and	one	or	more	of	dyspnoea	(as	described	by	 the	 patient	 and/or	 study	 doctor),	 cough,	 rhinitis	 and	 abnormal	 pulmonary	auscultatory	 examination.	 Cases	 that	 did	 not	 satisfy	 the	 eligibility	 criteria	 were	excluded.		Once	 the	 case	was	 deemed	 eligible,	 study	 staff,	 using	 an	 information	 sheet	 as	 a	guide,	explained	the	study	to	the	parent/guardian	of	the	case	for	informed	consent.	The	 signed	 consent	 form	 was	 kept	 with	 the	 relevant	 case	 report	 form	 (CRF)	(Appendix	A)	for	each	case.	It	was	made	clear	to	the	parent	that	at	any	time,	they	could	 rescind	 consent,	 removing	 their	 child	 from	 the	 study.	 Enrolled	 cases	were	allocated	a	unique	study	identification	number.		
4.4.	Data	and	swab	collection	
4.4.1.	Data	collection	Data	were	 collected	 from	 eligible	 cases	 on	 a	 dedicated	 study	 CRF	 (Appendix	 A).	Data	of	interest	collected	included,	village,	sex,	ethnicity,	vaccination	status,	clinical	signs,	symptoms	and	management.	Other	potential	risk	factors	were	also	collected	and	these	included	if	there	was	a	smoker	present	in	the	house,	how	many	children	lived	in	the	house	under	the	age	of	4	years,	financially	self-sufficient,	practised	hot	bed	after	birth,	breastfed	and	if	the	child	attended	kindergarten/day	care.	
4.4.2.	Nasopharyngeal	swab	(NPS)	sample	collection	Study	doctors,	at	time	of	recruitment,	collected	a	single	NP	sample	(NPS)	from	each	case	using	a	flocked	NP	paediatric	swab.	To	sample	the	nasopharynx,	the	NPS	was	inserted	into	the	child’s	nostril	and	passed	directly	backwards,	parallel	to	the	base	of	 the	NP	 passage	 and	 kept	 in	 place	 for	 5	 seconds	 or	 rotated	 180°,	 as	 shown	 in	Figure	5	below.			
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Figure	5:	Collecting	a	nasopharyngeal	swab	
		The	 swab	 was	 then	 removed	 and	 immersed	 immediately	 into	 a	 1.0ml	 cryovial	containing	 sterile	 skim	 milk-tryptone-glucose-glycerol	 broth	 (STGGB)	 as	 per	standard	 methods	 (32).	 The	 NPS	 was	 kept	 cool	 and	 transported	 to	 LOMWRU	laboratories	within	4	hours	of	collection,	where	it	was	snap	frozen	at	-80°C.			
4.5.	Lab	methods	Nasopharyngeal	samples	were	shipped	in	batches	on	dry	ice	to	the	Pneumococcal	Research	Group	laboratories	in	the	Murdoch	Childrens	Research	Institute	(MCRI),	Melbourne	for	microbiology	and	microarray	analyses.	At	MCRI,	aliquots	of	NPS	had	DNA	 extracted	 and	 the	 DNA	 eluent	 was	 used	 to	 detect	 the	 presence	 of	pneumococcus	 in	 the	samples	using	a	quantitative	PCR	(qPCR)	method	 targeting	the	 lytA	 gene	 (33,	 34).	 Samples	 positive	 for	 lytA	 or	 equivocal	 were	 grown	 on	selective	nutrient	media	to	not	only	increase	the	quantity	of	DNA	present	but	also	to	 check	 if	 those	 equivocal	 have	 pneumococcus	 in	 the	 samples.	 Equivocals	were	defined	as	samples	with	at	least	1	triplicate	within	the	<40	cycling	threshold	(Ct)	limit.	 Culture	 positive	 samples	 subsequently	 underwent	 DNA	 extraction	 and	analysed	using	a	molecular	serotyping	method,	microarray	(34).	The	microarray,	for	 the	 purposes	 of	 this	 study,	 elucidated	 what	 serotypes	 were	 present	 in	 the	sample	in	rank	order	of	the	most	abundant.	Samples	that	were	culture	negative	but	were	 positive	 for	 lytA	 if	 2/3	 triplicates	 gave	 a	 positive	 result	 (<40	 Ct)	 were	classified	as	positive	for	pneumococcal	carriage	(33,	34).		
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4.6.	PCV	vaccination	status	PCV	 vaccination	 status	 was	 determined	 by	 written	 record	 from	 the	 parent-held	mother	child	health	(MCH)	card	or	the	immunisation	register	at	the	health	centre.	If	the	child’s	record	of	vaccination	was	not	found	at	the	health	centre	and	the	MCH	card	 was	 still	 not	 available,	 any	 child	 satisfying	 the	 criteria	 of	 being	 born	 18	months	prior	to	PCV13	introduction	into	their	village,	receiving	their	vaccinations	in	Thailand/Vietnam	or	 their	parents	 reported	 that	 the	 child	had	never	 received	any	 vaccinations,	 were	 considered	 unvaccinated.	 Figure	 6	 below,	 details	 the	decision-making	flowchart	of	each	case’s	PCV	vaccination	status.		When	 the	 date	 of	 PCV	 vaccinations	 was	 not	 legible	 or	 illogical	 the	 following	assumptions	were	made:	
• Date	of	birth	(DOB)	was	crosschecked	with	date	of	hepatitis	B	vaccination	as	this	was	given	at,	or	shortly	after	birth	to	check	if	DOB	was	correct	
• PCV	dates	were	compared	with	oral	polio	vaccine	and	pentavalent	vaccine	dates,	as	these	three	vaccinations	should	have	been	given	at	the	same	time	to	check	if	the	PCV	dates	were	correct	
• If	 PCV	 dates	made	 logical	 sense,	 but	 the	 year	was	 incorrect	 in	 one	 of	 the	dates	 it	 was	 changed	 accordingly.	 For	 example,	 PCV	 doses	 were	 given	approximately	one	month	apart,	so	if	the	first	dose	was	given	in	November	2013,	 the	 second	December	2013	and	 the	 third	 in	 January	2013,	 then	 the	year	of	the	last	dose	was	incorrect	and	logically	January	2014.			
Chapter	2	–	PneCAPTIVE		
	 35	
Figure	6:	Decision	making	flow	chart	of	case's	PCV	vaccination	status	
	MCH=mother	child	health;	DOB=date	of	birth;	PCV=pneumococcal	conjugate	vaccine		
4.7.	Sample	size,	data	management	and	analysis	
4.7.1.	Data	management	Data	 collected	 from	 each	 case	 using	 the	 dedicated	 CRF	were	 first	monitored	 for	correctness	 and	 completeness	 before	 being	 entered	 into	 dedicated	 databases.	Errors	 fixed	on	 the	CRF	had	 the	error	struck	 through	with	a	 line	and	 the	correct	information	noted	above	with	the	initials	of	the	person	making	the	change	and	the	date	 in	 brackets.	 Collected	 data	 were	 double	 data	 entered	 by	 study	 staff	 into	 a	
Chapter	2	–	PneCAPTIVE		
	 36	
Microsoft	Access	database	(Microsoft,	US).	Data	was	cleaned	by	comparing	the	two	entries	and	corrected	in	the	data	entry	database	with	the	discrepancy.	Data	were	extracted	 from	 the	database	 and	 imported	 into	 Stata	14	 IC	 (Statcorp,	US)	where	analysis	was	done.		
4.7.2.	Sample	size	We	expected	there	to	be	a	50%	reduction	in	VT	carriage	in	undervaccinated	cases.	To	 see	 this	 effect	 size,	 400	 cases	were	 estimated	 to	 be	 required	 each	 year	 for	 3	years.	However,	 the	NP	 carriage	 (case)	 population	 sample	 size	was	 restricted	 to	the	 number	 of	 patients	 being	 admitted	 with	 ARI	 or	 pneumonia	 over	 the	 3-year	study	period.	As	we	were	capturing	all	ARI	cases	admitted	to	Mahosot	hospital	in	the	 2-59	 month	 age	 group,	 we	 were	 sampling	 the	 entire	 population	 for	 our	definition,	 thus	we	 could	 not	 improve	 our	 recruitment	methods	 for	 the	 study	 to	attain	the	estimated	annual	400	required.	
4.7.3.	Outcome	variables	
PCV	vaccination	status	The	 number	 of	 PCV13	 doses	 required	 for	 a	 classification	 of	 being	 “vaccinated”	depended	 on	 the	 child’s	 age	 at	 the	 time	 of	 vaccination	 and	 is	 defined	 below	 in	Table	 1	 (35).	 Age	was	 calculated	 by	 the	 child’s	 date	 of	 birth	 and	 the	 time	when	receiving	the	first	dose	of	PCV13.		
	
Table	1:	Classification	of	PCV13	vaccination	status	by	age	and	number	of	doses	
Age	 Vaccinated	 Undervaccinated	0-11	months	of	age	 2	PCV13	doses	 0	or	1	PCV13	dose	≥	12	months	of	age	 1	PCV13	dose	 0	doses	PCV13	PCV13=13-valent	pneumococcal	conjugate	vaccine		
Pneumococcal	Carriage	Pneumococcal	carriage	was	described	as	total	pneumococcal,	VT	and	NVT	carriage.	All	 samples	 positive	 for	 pneumococcus	 by	 qPCR	 were	 counted	 in	 the	 total	pneumococcal	carriage	group.	Samples	with	PCV13	serotypes	(1,	3,	4,	5,	6A,	6B,	7F,	9V,	 14,	 18C,	 19A,	 19F,	 23F)	 were	 classified	 as	 VT	 carriage	 samples.	 Samples	
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positive	for	serotypes	not	contained	in	PCV13	and	non-typeables	were	classified	as	NVT	carriage.	Samples	could	contain	both	VT	and	NVT	types.	
Pneumonia	Definition	 of	 pneumonia	 was	 defined	 according	 to	 the	 2005	 WHO	 Integrated	Management	of	Childhood	Illness	(IMCI)	guidelines.	Using	the	2005	case	definition	for	pneumonia,	the	presence	of	cough	or	difficulty	breathing	and	tachypnoea	(>50	breaths	 per	minute	 for	 children	 aged	 2-11	months;	 >40	 breaths	 per	minute	 for	children	 aged	 12-59	 months)	 plus	 lower	 chest	 wall	 in-drawing	 or	 one	 or	 more	general	danger	signs:	inability	to	drink,	persistent	vomiting,	convulsions,	lethargy,	unconsciousness,	 stridor	when	 calm,	 severe	malnutrition	 (as	 documented	 in	 the	medical	records),	central	cyanosis	or	the	saturation	of	oxygen	<90%	in	room	air.		
Potential	risk	factors	Potential	 risk	 factors	 and	 confounders	 for	 carriage	 rate	 were	 self-reported.	 The	variables	included	in	this	analysis	were	if	there	was	a	smoker	in	the	house,	if	there	were	 children	 <5	 years	 of	 age	 living	 in	 the	 house	 (including	 the	 number),	 if	 the	household	was	financially	self-sufficient,	 if	the	case	was	breastfed	and	if	the	child	attended	kindergarten/day	care.			The	 variables	 were	 yes/no	 dichotomous	 responses,	 except	 for	 the	 number	 of	children	 <5	 years	 of	 age	 living	 in	 the	 house.	 For	 this	 variable,	 the	 presence	 of	children	 <5	 years	 of	 age	was	 analysed	 and	 the	 number	 of	 children	 living	 in	 the	house	 was	 grouped,	 with	 one	 group	 having	 1-2	 and	 the	 other	 greater	 than	 2	children	<5	years	of	age	living	in	the	house.	
4.7.4.	Analysis	In	 general,	 continuous	 variables	 were	 summarised	 using	 the	 number	 of	observations,	minimum	and	maximum,	and	 the	mean	and	standard	deviation	(or	median	 and	 interquartile	 range	 for	 non-parametric	 data).	 Categorical	 variables	were	summarised	using	frequency	counts	and	percentages.			For	 descriptive	 analysis	 of	 the	 cases,	 stratified	 by	 PCV13	vaccinated/undervaccinated,	p-values	using	 the	chi-squared	 test	and/or	95%	CIs	
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were	 calculated	 for	 both	 vaccinated	 and	 undervaccinated	 cases	 to	 determine	 if	there	were	any	significant	differences	between	the	two	groups.		To	observe	the	direct	and	indirect	effects	of	PCV	coverage	and	monthly	VT	carriage	rates	 of	 vaccinated/undervaccinated	 cases	 were	 plotted	 in	 rolling	 7-month	intervals,	overlaid	with	the	monthly	PCV	vaccination	rate	of	all	cases	over	the	time	of	the	study.	Monthly	pneumococcal	carriage	rates	among	cases	was	calculated	by	adding	 the	 number	 of	 cases	 carrying	 a	VT,	 divided	 by	 the	 total	 number	 of	 cases	carrying	any	pneumococcus.	Monthly	vaccination	rate	 in	cases	was	calculated	by	adding	the	number	of	cases	deemed	vaccinated	as	per	the	definition	above,	divided	by	the	total	number	of	cases	enrolled	for	the	month.	Rolling	intervals	were	used	to	smooth	 the	 data	 caused	 by	 the	 small	 numbers	 per	month	 enrolled	 in	 the	 study.	Rolling	intervals	were	calculated	by	plotting	the	average	proportion	of	carriage	or	vaccination	for	the	month	and	the	3	months	before	and	3	months	after	each	month.	Thus	producing	7	month	rolling	intervals	for	each	month	from	December	2013	to	July	 2016.	 For	 both	 monthly	 carriage	 and	 vaccination	 rate	 in	 cases,	 the	 95%	confidence	 intervals	were	 calculated.	 Reported	 carriage	 rates	were	 not	 adjusted	for	potential	confounders	such	as	age	and	seasonality	due	to	time	constraints.		Using	 the	unadjusted	VT	 carriage	 rates,	 it	was	determined	 if	 indirect	 effects	had	occurred	during	the	study.	Maximal	indirect	effects	were	defined	as	the	risk	of	VT	carriage	among	undervaccinated	children	being	equivalent	to	vaccinated	children	2-59	months	of	age,	 i.e.	 a	 risk	 ratio	of	1.	This	 indirect	effect	was	chosen	because	there	 is	 no	 pre-PCV	 data	 available	 to	 calculate	 indirect	 effects	 using	 more	traditional	 methods	 comparing	 post-PCV	 carriage	 rates	 among	 undervaccinated	groups	with	pre-PCV	carriage	rates.			
4.8.	Ethical	considerations	Any	identifying	 information	collected	on	CRFs	were	kept	 in	 locked	filing	cabinets	only	accessible	by	study	staff.	This	was	also	the	case	for	electronic	databases	kept	in	password	protected	drives,	accessible	to	study	staff	only.	In	addition,	letters	of	approvals	 to	 visit	 and	 access	 data	 from	Mahosot	Hospital,	 District	Hospitals	 and	Health	 Centres	 were	 obtained	 from	 both	 the	 director	 of	 Mahosot	 Hospital	 and	LOMWRU	where	the	study	is	based.		
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	Ethical	 approvals	 were	 granted	 by	 5	 ethical	 committees;	 National	 Ethics	Committee	 for	 Health	 Research	 (No.	 057/2013;	 Ministry	 of	 Health,	 Lao	 PDR),	Oxford	 Tropical	 Research	 Ethics	 Committee	 (1050-13;	 LOMWRU),	 The	 Royal	Children’s	 Hospital	 (33177B;	 MCRI),	 Ethics	 Research	 Committee	(2013.30.LAO.2.EPI;	WPRO),	Human	Research	Ethics	Committee	(2015/491;	ANU).			
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5.	Results	As	the	study	is	ongoing,	data	shown	was	until	the	end	of	July	2016.	
5.1.	Characteristics	of	cases	In	 total	800	 cases	were	 recruited	 from	December	2013	until	 July	2016.	Of	 those	800,	1	case	was	ineligible,	6	cases	were	missing	data	and	10	were	outside	of	the	2-59	month	age	limits.	Thus	783	cases	were	included	in	the	final	analysis	(Figure	7).			
Figure	7:	Recruitment	flowchart	of	study	up	to	July	2016	
			From	 December	 2013	 to	 July	 2016,	 approximately	 30	 cases	 were	 enrolled	 each	month	with	a	large	increase	of	cases	during	June-August	2014	(Figure	8).				
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Figure	8:	Case	enrolment	from	Dec	2013	to	July	2016	
	The	demographics	of	cases,	stratified	by	vaccination	status	can	be	seen	in	Table	2	below.	 The	 median	 age	 of	 vaccinated	 cases	 was	 significantly	 younger	 than	undervaccinated	 cases.	 Undervaccinated	 cases	 were	 more	 likely	 to	 be	 from	 the	province,	not	breastfed	and	less	likely	to	attend	kindergarten/day	care.	The	cases	with	 unknown	 vaccination	 status	 were	 a	 mix	 of	 Vientiane	 Capital	 and	 Province	children.	 They	 were	 of	 similar	 age	 to	 the	 vaccinated	 cases	 and	 generally	 the	characteristics	 do	 not	 differ	 greatly	 from	 the	 known	 vaccination	 status	 children,	except	for	the	attendance	at	kindergarten/day	care	and	their	breastfed	status.		
Table	2:	Characteristics	of	ARI	cases	admitted	to	Mahosot	Hospital,	Vientiane	Capital,	Lao	PDR	from	December	2013	to	July	2016,	stratified	by	vaccination	status		
Characteristics	 Total	
(n=783)	
Vaccinated	
(n=331)	
Undervaccinated	
(n=351)	
Unknown	
(n=101)	
p-
value	Median	age	in	months	(IQR)	 14	(8-24)	 12	(8-17)	 21	(8-33)	 10	(7-18)	 <0.001*	Male,	n	(%)	 446	(57)	 197	(60)	 193	(55)	 56	(55)	 0.46	Pneumonia,	n	(%)	 416	(53)	 172	(52)	 188	(54)	 56	(55)	 0.81	VC,	n	(%)	Province,	n	(%)	 646	(83)	137	(17)	 302	(91)	29	(9)	 290	(83)	61	(17)	 54	(53)	46	(47)	 	<0.001*	Smoker	in	the	house,	n	(%)	 307	(39)	 121	(37)	 141	(40)	 45	(45)	 0.06	
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Children	<5yo	living	in	the	house,	n	(%)	1-2	≥3	
765	(98)		724	(92)	41	(5)	
325	(98)		 312	(94)	13	(4)	
342	(97)		 325	(93)	17	(5)	
98	(97)		 87	(86)	11	(11)	
0.56		 0.11	Self-sufficient,	n	(%)	 726	(93)	 306	(92)	 329	(94)	 91	(90)	 0.17	Breastfed,	n	(%)	 461	(59)	 212	(64)	 174	(50)	 75	(74)	 <0.001*	Kindergarten/day	care	attendance,		n	(%)	 149	(19)	 54	(16)	 87	(25)	 8	(8)	 <0.001*	VC	=	Vientiane	Capital		
5.2.	Pneumococcal	carriage	Carriage	samples	were	available	for	all	783	of	cases	included	in	the	final	analysis.	Table	3	below	reports	the	total,	VT,	NVT	carriage	in	cases,	stratified	by	vaccination	status.	The	proportion	of	total	pneumococcal	carriage	was	40%,	with	no	significant	difference	 in	 vaccinated	 and	 undervaccinated	 cases	 (p=0.35).	 Overall	 vaccinated	cases	were	less	likely	to	carry	a	VT	(p<0.001)	and	more	likely	to	carry	a	NVT	than	undervaccinated	 cases	 (p=0.006).	 The	 unknown	 vaccination	 cases	 had	 similar	overall	 carriage,	 but	 when	 comparing	 VT	 and	 NVT,	 the	 proportion	 carried	 was	approximately	equal.			
Table	 3:	 Pneumococcal	 carriage	 in	 ARI	 cases	 admitted	 to	 Mahosot	 Hospital,	 Vientiane	Capital,	Lao	PDR	from	December	2013	to	July	2016,	stratified	by	vaccination	status	
Pneumococcal	
Carriage	 Total	(n=783)	 Vaccinated	(n=331)	 Undervaccinated	(n=351)	 Unknown	(n=101)	 p-value	Total,	n	(%)*	 313	(40)	 126	(38)	 150	(43)	 37	(37)	 0.35	VT,	n	(%)**		 141	(18)	 45	(14)	 78	(22)	 18	(18)	 0.001*	NVT,	n	(%)**	 153	(20)	 78	(24)	 59	(17)	 16	(16)	 0.006*	VT	=	Vaccine	type;	NVT	=	non-vaccine	type	*42	pneumococcal	carriage	positive	samples	did	not	have	a	serotype	or	non-typeable	identified	**Samples	can	contain	multiple	serotypes;	both	VT	and	NVT		
	5.3.	Carriage	of	VTs	and	PCV13	coverage	Figure	 9	 shows	 the	 proportion	 of	 children	 carrying	 a	 VT,	 stratified	 by	 their	vaccination	 status,	 overlaid	 with	 the	 vaccination	 rate	 of	 cases	 during	 the	 study	period.	 In	 vaccinated	 cases,	 VT	 carriage	 declined,	 whilst	 VT	 carriage	 remained	relatively	unchanged	in	undervaccinated	cases.		
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Figure	9:	PCV13	vaccine	serotype	carriage	in	vaccinated	and	undervaccinated	cases,	by	case	PCV13	vaccination	status,	using	7-month	rolling	intervals	
Vaccinated	 Undervaccinated	
	 	The	 red	 line	 is	 the	 vaccination	 rate;	 blue	 lines	 are	 vaccine	 type	 (VT)	 carriage.	 The	 shaded	 areas	 are	 the	 95%	CI	 surrounding	 carriage	 and	vaccination	rate	
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Using	the	unadjusted	VT	carriage	rates	 in	vaccinated	and	unvaccinated	cases,	the	risk	 ratio	 of	 VT	 carriage	 between	 the	 two	 groups	 was	 estimated.	 The	 indirect	effects	have	not	yet	been	seen	as	the	risk	ratio	of	VT	carriage	in	the	two	groups	is	not	equivalent,	i.e.	does	not	equal	1.		
Figure	10:	Rate	ratio	of	risk	of	VT	carriage	in	vaccinated	and	undervaccinated	cases*	
	*July	2016	data	not	included	in	risk	ratio	analysis	
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6.	Discussion	This	 is	 the	 first	 study	 to	 assess	 herd	 immunity	 using	 carriage	 surveillance.	 The	observed	 magnitude	 of	 indirect	 effects	 due	 to	 PCV	 is	 dependent	 on	 a	 range	 of	factors	 such	 as	 the	 immunisation	 strategy,	 coverage	 rate,	 the	 pneumococcal	population	epidemiology	and	 the	quality	of	 surveillance	methods	 to	detect	 these	effects	 (36).	 This	 study	 established	 robust	 surveillance	 at	 Mahosot	 Hospital,	allowing	for	indirect	effects	to	be	observed	in	this	population.			As	per	WHO	recommendations,	 Lao	PDR	uses	 a	3+0	 schedule.	This	 schedule	has	been	 shown	 to	have	 indirect	 effects	on	VT	 IPD	when	 introduced	nationally	 (37),	supporting	 WHO	 recommendations	 for	 the	 advocacy	 of	 these	 lower	 dose	schedules.	 However,	 immunisation	 coverage	 and	 the	 inclusion	 of	 a	 catch-up	campaign	play	larger	roles	in	terms	of	producing	indirect	effects.	Loo	et	al.	(2014	found	 only	 2	 studies	 of	 21	 that	 showed	 no	 evidence	 of	 VT	 IPD	 reductions	 in	unimmunised	 groups	 in	 their	 systematic	 analysis	 of	 indirect	 effects	 of	 dosing	schedules	on	pneumococcal	disease	and	colonisation.	Both	of	 these	studies	came	from	countries	that	did	not	employ	catch-up	campaigns	and	had	vaccine	coverage	levels	 that	 may	 have	 been	 inadequate	 to	 demonstrate	 indirect	 effects	 (37).	 The	method	 by	which	 a	 catch-up	 campaign	 speeds	 up	 the	 process	 of	 indirect	 effects	due	 to	 PCV	 is	 through	 reduction	 of	 NP	 carriage	 of	 VTs	 in	 toddlers	 who	 are	 the	major	reservoir	for	VT	transmission	to	unvaccinated	and	undervaccinated	groups.	Even	though	Lao	PDR	did	 include	a	catch-up	campaign,	allowing	for	PCV13	to	be	given	to	children	up	to	12months	of	age,	this	was	a	passive	system	and	relied	on	children	being	brought	 to	 the	health	 centre	who	had	previously	 completed	 their	vaccinations.	 Thus	 uptake	 would	 have	 been	 minimal	 in	 this	 older	 age	 group,	allowing	 for	 continual	 circulation	 of	 VTs	 in	 the	 community.	 The	 data	 presented	here	 are	 only	 up	 to	 2.5	 years	 post-PCV	 introduction.	 If	 VT	 carriage	 was	 to	 be	interrupted	 in	 the	 community	 it	 would	 require	 vaccination	 of	 5	 birth	 cohorts,	taking	at	least	4	years	to	achieve,	delaying	indirect	effects,	which	would	have	been	created	rapidly	by	an	effective	catch-up	campaign.		The	vaccination	rate	in	cases	increased	over	time	to	reach	70%	by	July	2016.	Based	on	 the	 studies	 by	 Grant	 et	 al.	 (2016)	 and	 Loughlin	 et	 al.	 (2014),	 the	 coverage	
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required	 to	 see	 herd	 immunity	 effects	 based	 on	 VT	 carriage	 in	 the	 <5	 year	 old	population	sat	at	approximately	60-70%	(27,	28).	With	 the	case	vaccination	rate	reaching	 the	60-70%	mark,	herd	 immunity	was	not	expected	as	yet	because	 this	was	the	case	PCV13	vaccination	rate.	The	case	vaccination	rate	is	not	an	accurate	representation	 of	 the	 true	 PCV13	 coverage	 in	 the	 population.	 Firstly,	 the	vaccination	rate	is	based	on	cases	that	have	been	admitted	to	hospital	and	as	cases	are	young,	they	are	not	representative	of	the	community	coverage	for	total	<5	year	olds.	 Secondly,	 even	 though	PCV13	was	 introduced	 into	 routine	 immunisation	 in	October	 2013,	 roll	 out	 of	 PCV13	 has	 been	 gradual,	 with	 some	 of	 the	 further	provinces	not	administering	PCV13	until	 as	 late	as	2015	(pers.	 comm.	Provincial	Health	centre	staff).	This	anecdotal	evidence	is	supported	by	the	undervaccinated	cases	significantly	more	likely	to	come	from	the	provinces.	This	means	that	in	the	wider	community,	PCV13	has	only	been	in	use	for	over	a	year,	contributing	to	the	lack	 of	 herd	 immunity	 effects.	 Thus	 the	 vaccination	 rate	 in	 cases	 is	 likely	 an	overestimation	of	the	true	coverage	in	the	community.			Mature	 PCV	 programmes	 see	 a	 greater	 impact	 of	 PCV	 than	 new	 adopters	 (13).		Previous	studies	by	Loughlin	et	al.	(2014)	and	Grant	et	al.	(2016)	were	undertaken	in	settings	where	PCV7	had	been	in	use	for	many	years,	so	therefore	the	coverage	they	 estimated	 for	 PCV	 herd	 immunity	was	 based	 on	 the	 additional	 6	 serotypes	included	 in	 PCV13,	 not	 all	 PCV13	 VTs.	 As	 the	 case	 vaccination	 rate	 is	 likely	 an	overestimation	 of	 the	 true	 community	 coverage,	 other	 methods	 of	 vaccine	coverage	 were	 considered.	 A	 contact	 serosurvey	 was	 conducted	 and	simultaneously	 data	 was	 collected	 from	 immunisation	 registers	 held	 at	 health	centres	 and	 district	 hospitals	 around	 the	 country.	 For	 the	 contact	 serosurvey,	contacts	 of	 cases	 were	 identified	 and	 their	 vaccination	 status	 was	 determined	either	using	MCH	cards	or	health	centre	immunisation	registry	data.	In	addition	a	subset	of	contacts	12-59	months	of	age	had	a	blood	sample	collected	to	determine	their	PCV	vaccination	status.	For	the	immunisation	registry	data,	each	village	keeps	a	record	of	vaccination	at	their	assigned	health	centre	or	district	hospital.	This	data	is	 kept	 in	 a	 line	 list	 format,	 allowing	 each	 child	 to	 be	 counted	 individually.	Amalgamated	with	population	data	for	each,	village,	the	monthly	vaccination	rate	for	 each	 village	 could	 be	 estimated.	 Immunisation	 registry	 data	 was	 collected	dependent	on	the	village	the	case	resided	in.	The	theory	behind	both	methods	was	
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that	 carriage	 was	 affected	 most	 by	 children	 they	 have	 contact	 with.	 Based	 on	preliminary	 data	 from	 the	 contact	 serosurvey	 (data	 not	 shown),	 the	 vaccine	coverage	rate	did	not	correspond	to	 the	preliminary	data	(data	not	shown)	 from	the	 health	 centre	 immunisation	 registry.	 Therefore,	 it	 was	 decided	 the	 contact	serosurvey	did	not	provide	an	accurate	estimate	of	community	coverage	and	was	suspended.	 Data	 collection	 and	 analysis	 will	 be	 pursued	 for	 the	 health	 centre	immunisation	 registries	 as	 the	 primary	 method	 for	 estimating	 community	coverage	in	the	final	analysis.			Vaccinated	 cases	 had	 significantly	 lower	 carriage	 of	 VTs	 than	 undervaccinated	cases,	 but	 total	 pneumococcal	 carriage	 rates	 did	 not	 change	 for	 both	 groups.	Pneumococcal	carriage	rates	are	affected	by	age,	seasonality,	risk	 factors	and	the	presence	of	NVTs.	Carriage	rates	are	associated	with	age,	with	peak	carriage	rates	in	toddlers	and	wane	over	time	(38-40).	As	cases	of	ARI	admitted	to	hospital	are	in	younger	age	groups,	most	of	 these	will	be	vaccinated	 in	comparison	 to	 the	older	children	in	the	early	years	of	PCV	introduction.	Over	time,	the	percentage	of	older	children	 entering	 the	 surveillance	 who	 are	 vaccinated	 will	 increase	 as	 multiple	birth	 cohorts	 are	PCV13	vaccinated.	 In	 addition,	 the	decline	 in	VT	 in	 early	 years	post	 PCV	 may	 purely	 be	 due	 to	 the	 fact	 older	 children	 have	 less	 carriage	 and	subsequently	less	likely	to	carry	VTs.	Therefore	carriage	rates	need	to	be	adjusted	for	age.	Carriage	is	also	affected	by	season	with	winter	in	temperate	climates	and	dry	 season	 in	 tropical	 climates	 seeing	 peaks	 in	 pneumococcal	 carriage	 (41,	 42).	However,	risk	factors,	such	as	age	and	seasonality	were	not	accounted	for	in	these	results.	 For	 the	 final	 analysis	 risk	 factors	will	 be	 identified	 and	 accounted	 for	 in	both	 carriage	 and	 vaccination	 rates	 in	 cases.	 In	 addition	 to	 age,	 season	 and	PCV	coverage,	 pneumococcal	 carriage	 is	 also	 influenced	 by	 many	 factors	 such	 as	exclusive	 breast-feeding,	 crowding,	 socio-demographic	 information,	 caregiver	education	level,	smokers	in	household	and	kindergarten	attendance	to	name	a	few.	However,	 as	 total	 pneumococcal	 carriage	 did	 not	 change	 over	 the	 study	 period,	these	risk	factors	may	not	have	changed	over	time	and	if	not	accounted	for	will	not	significantly	 change	 the	 results.	 Nonetheless	 potential	 confounders	 will	 be	assessed	 in	 the	 final	 analysis,	 but	 due	 to	 time	 constraints	 it	was	 not	 possible	 to	include	these	adjustments	in	these	results.			
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Replacement	 carriage,	 or	 serotype	 replacement	 has	 been	 seen	 in	 all	 populations	using	 PCVs	 (43).	 Serotype	 replacement	 is	 the	 increase	 of	 NVTs	 among	asymptomatic	carriers	following	reductions	in	VTs	and	to	a	lesser	extent	invasive	disease	 caused	by	NVTs	 (43).	The	potential	 reasons	behind	 this	 increase	 in	NVT	carriage	 after	 use	 of	 PCV	 in	 a	 population	 could	 be	 due	 to	 the	 phenomenon	 of	unmasking,	where	 the	reduction	of	VTs	has	made	 it	easier	 to	detect	NVTs	or	 the	acquisition	 of	 NVTs	 after	 VTs	 are	 removed	 from	 the	 nasopharynx	 (43).	Surveillance	of	NVTs	is	 important	for	a	number	of	reasons,	namely	monitoring	of	NVT	 IPD,	 increasing	 understanding	 of	 serotype	 composition	 in	 a	 population	 and	design	 of	 next	 generation	 PCVs.	 In	 a	 systematic	 review	 and	 meta-analysis	 by	Balsells	 et	 al.	 (2017),	 prior	 to	 the	 introduction	 of	 higher	 valency	 PCVs	 in	 North	America	 and	 Europe,	 approximately	 half	 of	 childhood	 IPD	 cases	 were	 due	 to	serotypes	 not	 incorporated	 in	 current	 PCV	 formulations	 (44).	 Asia,	 where	 the	largest	 burden	of	 disease	 lies	 also	has	 a	 great	diversity	 of	 serotypes	 (18),	which	has	repercussions	in	how	effective	current	formulation	PCVs	will	be.	Development	of	 next	 generation	 PCVs	 will	 require	 more	 data	 from	 LMICs	 regarding	 NVTs	 to	create	vaccine	formulations	that	will	afford	greater	protection.			In	conclusion,	less	than	3	years	after	PCV13	introduction,	herd	immunity	effects	of	PCV13	based	on	NP	carriage	surveillance	in	ARI	cases	has	not	yet	been	observed	in	Lao	PDR.	This	is	not	unexpected,	as	PCV13	coverage	in	the	community	of	Lao	PDR	is	 likely	 too	 low	 to	 protect	 the	 undervaccinated	 population.	 This	 is	 because	 the	data	are	only	up	 to	2.5	years	post-PCV	 introduction.	However	direct	effects	have	manifested	in	vaccinated	cases,	shown	by	the	reduction	in	VTs,	with	no	change	in	total	pneumococcal	 carriage	 rates	 for	 all	 cases.	The	data	presented	has	not	been	adjusted	for	confounders.	Data	on	potential	confounders	have	been	collected	and	will	 be	 included	 in	 the	 final	 analysis.	 The	 data	 presented	 here	 shows	 the	applicability	of	NP	surveillance	in	ARI	cases	as	a	method	to	determine	when	a	PCV	program	has	 achieved	herd	 immunity	 effects	 for	 their	population.	This	 is	 crucial	for	 LMICs	 like	 Lao	 PDR,	 who	 are	 unable	 to	 rely	 on	 typical	 methods	 of	 PCV	evaluation.	 The	method	presented	 here	 shows	 that	 a	 robust	 surveillance	 system	can	be	established	quickly	in	a	LMIC	setting.	These	data	will	strengthen	the	use	of	this	method	in	other	LMICs	in	the	region	considering	using	PCV	in	their	population.	Lao	PDR	 is	expected	 to	 transition	 to	a	domestic	 funding	model	 for	 their	NIP	and	
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data	 such	 as	 this	will	 provide	 evidence	 to	 both	Ministry	 of	 Health	 policymakers	and	external	funders	of	the	effectiveness	of	PCV13	in	the	program	and	support	its	continual	use	in	the	program.		
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7.	Recommendations:	
• Continuation	of	NP	carriage	surveillance	should	continue	to	determine	the	coverage	required	to	see	indirect	effects.	The	primary	aim	of	the	study	has	not	 been	 achieved	 as	 yet.	 Once	 indirect	 effects	 have	 been	 observed,	 the	corresponding	 coverage	 will	 set	 a	 minimum	 benchmark	 for	 NIP	 Laos	 to	reach	in	order	to	get	the	maximal	benefit	from	PCV	for	their	population.	
• Estimation	of	coverage	was	part	of	 the	primary	aim	for	 this	study.	During	the	time	of	the	study,	PCV13	coverage	was	not	able	to	be	included	in	the	EPI	coverage	 survey.	 In	 addition	 to	 calculating	 vaccination	 rates	 in	 cases,	vaccine	 coverage	 was	 also	 assessed	 using	 a	 contact	 serosurvey	 and	 raw	data	 collected	 from	 the	 village	 immunisation	 registers	 held	 at	 health	centres	and	district	hospitals	throughout	the	country.	Based	on	preliminary	analysis,	 the	 contact	 serosurvey	 was	 not	 a	 good	 measure	 to	 estimate	vaccine	 coverage.	 Therefore,	 it	 is	 recommended	 to	 continue	 collection	 of	immunisation	data	from	health	centres	and	district	hospitals	and	to	use	this	method	to	estimate	vaccine	coverage.			
• Surveillance	of	serotype	carriage	should	continue	to	monitor	 the	situation	with	NVTs.	Not	all	serotypes	cause	disease	but	the	elimination	of	VTs	from	carriage	creates	an	opportunity	 for	other	serotypes	 to	occupy	 the	vacated	space	 and	 potentially	 cause	 IPD.	 These	 replacement	 serotypes	 are	important,	as	 it	will	advise	 the	 future	PCV	 formulations	or	 the	design	of	a	vaccine	that	targets	a	shared	antigen	irrespective	of	serotype.		
• There	should	be	consideration	given	to	methods	to	assess	changes	in	IPD	in	adults.	The	greatest	impact	of	PCV	is	in	the	unvaccinated	adult	population.	Generally,	indirect	effects	in	adults	are	estimated	using	surveillance	of	IPD	and	CAP	pre-	 and	post-vaccine	 introduction.	For	Laos	 this	 is	not	possible,	without	 surveillance	 in	 place	 prior	 to	 vaccine	 introduction.	 A	 possible	method	 could	 be	 a	 case-control	 study	 with	 the	 vaccination	 status	 of	children	 living	 with	 adult	 IPD	 cases	 being	 investigated.	 This	 would	 be	difficult	as	 the	vaccine	has	now	been	 in	use	since	October	2013,	with	PCV	effects	confounding	the	results.	In	addition,	pneumococcal	carriage	analysis	is	conducted	in	Melbourne	and	timely	reporting	of	IPD	serotype	would	not	
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be	possible.	In	the	current	set	up,	assessment	of	IPD	in	adults	would	not	be	feasible.	
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1.	Prologue	
1.1.	Role	A/Prof	 Fiona	 Russell	 was	 contracted	 by	 the	 World	 Health	 Organization	 (WHO)	Western	Pacific	Regional	Office	(WPRO)	to	conduct	an	evaluation	of	rotavirus	(RV)	vaccine	introduction	in	Kiribati.	This	was	to	support	the	introduction	of	RV	vaccine	into	the	Kiribati	national	expanded	program	of	immunisation	(EPI)	schedule.	The	terms	of	 reference	 for	 this	work	was	 to	 establish	 post-marketing	 surveillance	 of	intussusception	 (IS)	 and	 also	 a	 establish	 burden	 measurement	 of	 acute	gastroenteritis	(AGE)	that	could	be	used	to	evaluate	the	impact	of	RV	vaccine	in	the	community.		With	the	assistance	and	guidance	of	A/Prof	Russell,	my	role	was	to	complete	the	terms	of	reference	set	by	WHO	WPRO	for	evaluating	RV	vaccine	introduction	into	Kiribati.	The	evaluation	consisted	of	2	parts:	1)	determining	baseline	data	for	AGE,	IS	 and	 severe	 acute	malnutrition	 (SAM)	 and	 2)	 designing	 and	 establishing	 an	 IS	surveillance	 system	 as	 part	 of	 RV	 vaccine	 post-marketing	 surveillance	 of	 IS.	 To	achieve	this	I	was	responsible	for:	
• Drafting	of	a	protocol	 to	detail	our	methods	 for	 the	evaluation	before	our	site	visit	
• Preparing	 all	 data	 collection	 instruments,	 adapted	 from	 WHO	 generic	protocols	for	RV	vaccine	introduction	(included	in	Appendix	A	and	C)	
• Liaising	with	Ministry	of	Health	and	Medical	Services	(MHMS)	staff	to	find	and	access	the	required	data	
• Where	available,	reviewing	and	cleaning	electronic	hospital	admission	data	
• Going	 through	 hospital	 admission	 books	 where	 electronic	 data	 were	 not	available	
• Cleaning	and	subsequently	analysing	the	data	for	reporting	
• Presentation	 of	 preliminary	 results	 and	 methods	 of	 continual	 IS	surveillance	to	MHMS	and	Tungaru	Central	Hospital	(TCH)	paediatric	staff	
• Preparation	 of	 WHO	 reports	 (mission	 and	 findings	 report	 included	 in	appendices	D	and	E)		
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Specifically	 for	 IS	 surveillance,	 I	 was	 responsible	 for	 writing	 the	 standard	operating	 procedure	 (SOP),	 training	 the	 local	 coordinator	 and	 acting	 as	 the	external	monitor	to	support	and	monitor	the	surveillance.	 I	plan	to	return	in	 late	2017	 to	 complete	 the	 evaluation	 and	 collect	 any	missing	data	 from	 the	previous	site	visit.	With	the	approval	 from	WPRO	and	MHMS,	a	manuscript	describing	the	baseline	AGE	and	SAM	incidence	prior	to	RV	vaccine	introduction	was	prepared	for	submission	to	Western	Pacific	Surveillance	and	Response	Journal	(WPSAR).			In	 addition	 during	my	 time	 on	 site,	 I	 assisted	 in	 a	 limited	 capacity	with	 an	 AGE	outbreak	and	subsequently	acute	respiratory	infection	outbreak	in	Tarawa.	During	these	 outbreaks	 I	 acted	 in	 an	 informal	 capacity	 to	 help	 staff	 at	 TCH	 with	 case	reporting	 and	 I	 also	 liaised	with	 the	different	departments	 (statistics,	 laboratory	and	 environmental	 unit)	 involved	 to	 check	 on	 the	 progress	 of	 the	 outbreak	investigation.	 	This	experience	was	my	first	opportunity	to	apply	classroom	skills	in	 outbreak	 investigation	 to	 a	 real	 life	 setting.	 After	 effective	 public	 health	interventions	promoting	hygiene	practises	in	the	community	the	outbreaks	ceased	after	a	few	days	with	a	limited	number	of	cases.		
1.2	Lessons	learnt	This	was	my	first	experience	working	in	a	consultancy	role	for	WHO	and	through	this	 I	 was	 exposed	 to	 processes	 and	 aims	 that	 are	 different	 to	 my	 skills	 and	experience	 in	 research.	 From	a	data	perspective	 I	 learnt	 about	 the	 limitations	of	administrative	data,	both	population	and	hospital	records.	For	population	data,	 it	can	be	difficult	to	get	accurate	summary	data	and	these	data	are	not	necessarily	in	a	 format	 that	 is	 flexible	 for	 reporting	 (for	 example	 the	 age	 groups	 are	 not	exclusive).	 For	 hospital	 records,	 incomplete	 coding,	 variability	 in	 text	 variables,	etc.	need	to	be	considered.	For	example,	with	diagnoses	it	was	important	to	collect	both	the	code	and	the	written	diagnosis	to	ensure	cases	were	not	missed	as	there	were	occasionally	mismatches	between	what	condition	the	patient	was	coded	for	and	the	true	diagnoses.	Data	received	was	often	in	a	format	requiring	cleaning	and	checking,	with	careful	documentation	of	the	process	followed	crucial,	as	I	often	had	to	 revisit	 the	 data	 for	 additional	 analyses.	 In	 addition,	 I	 learnt	 the	 benefits	 of	receiving	 the	 data	 in	 an	 electronic	 format	 for	 ease	 downstream	 of	 cleaning	 and	analysis.	This	became	obvious	when	I	had	to	reanalyse	 the	data	 for	SAM	and	did	
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not	 have	 the	most	 recent	 data	 available	 as	we	 had	 collected	 it	 by	 hand	 for	 AGE	only.	I	also	learnt	the	importance	of	establishing	a	case	definition	that	matched	the	aims	of	the	project.	Because	RV	testing	is	not	available	in	Kiribati,	AGE	was	used	as	a	proxy	to	evaluate	the	impact	of	RV	vaccine	in	the	population.	This	meant	it	was	important	 to	 exclude	 any	 diagnoses	 that	 were	 indicative	 of	 a	 bacterial	 cause	 or	chronic	 conditions.	 Thus	 the	 case	 definition	 excluded	 any	 diagnoses	 of	 bacterial	diarrhoea,	bloody	diarrhoea,	blood	in	the	stool	or	chronic	gastrointestinal	disease.			I	 learnt	how	to	liaise	with	different	stakeholders,	both	within	the	hospital	system	and	 other	 Non-government	 organisations	 (NGOs)	 working	 in	 the	 same	 area.	Dependent	on	the	situation,	different	methods	of	presentation/conversation	had	to	be	employed	to	get	the	message	across.	I	found	speaking	to	people	face	to	face	was	the	best	form	of	communication	as	there	was	less	room	for	confusion	and	potential	disagreement.	I	also	had	to	mindful	of	other	NGO’s	working	in	the	same	area	and	relied	heavily	on	A/Prof	Russell’s	advice	on	the	content	of	my	conversations	and	who	I	should	include	in	these	discussions.			The	 key	 area	 of	 development	 for	 me	 was	 the	 design,	 implementation	 and	subsequent	monitoring	of	a	surveillance	system.	I	was	able	to	apply	my	theoretical	understanding	of	public	health	surveillance	to	this	project.	Firstly	I	had	to	speak	to	the	 relevant	 stakeholders	 (MHMS,	 Paediatric	 Department	 of	 TCH,	 Kiribati	 WHO	Country	 Office)	 to	 understand	 how	 cases	 presented	 and	 subsequently	 treated.	Using	this	knowledge	I	had	to	adapt	generic	protocols	and	data	collection	tools	to	the	specific	situation	at	TCH.	I	had	to	train	the	local	coordinator,	a	senior	paediatric	nurse	in	the	SOPs	and	ensure	that	I	had	explained	the	process	properly	so	she	felt	confident	 acting	 in	 her	 role.	 Even	 though	 there	was	 no	 formal	 evaluation	 of	 the	surveillance	system,	it	was	useful	to	apply	the	surveillance	framework	to	identify	strengths	and	weaknesses	of	the	system,	attempting	to	pre-empt	issues.			Separate	 to	 the	 evaluation,	 the	 outbreak	 investigation	 happening	 on	 site	while	 I	was	 there	 gave	 me	 a	 taste	 of	 the	 importance	 of	 process	 and	 establishing	communication	lines	during	an	outbreak	response.		
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1.3	Public	Health	implications	and	impact	Rotavirus	is	the	most	common	cause	of	AGE	in	infants	and	children.	The	use	of	RV	vaccines	has	reduced	the	burden	of	RV	infection	in	both	developed	and	developing	countries.	The	presence	of	 a	 large	burden	of	malnutrition	 in	 the	population	may	lead	 to	 decreased	 RV	 vaccine	 effectiveness.	 Nonetheless,	 through	 the	 use	 of	 RV	vaccines	in	Kiribati,	there	will	still	be	a	large	number	of	children	protected	from	RV	infection	altogether	or	who	experience	reduced	severity	of	disease.			Intussusception	is	a	rare	severe	adverse	event	associated	with	RV	use.	As	part	of	the	 post-marketing	 safety	 of	 RV	 vaccine	 use	 in	 any	 naïve	 population,	 WHO	recommends	 IS	 surveillance	 to	 be	 done.	 The	 importance	 of	 establishing	 and	monitoring	changes	in	IS	in	a	population	pre-	and	post-RV	vaccination	introduction	is	 to	 provide	 evidence	 that	 the	 vaccine	 is	 safe.	 From	 the	 work	 detailed	 in	 this	chapter,	the	epidemiology	of	IS	will	be	described	in	Kiribati,	which	is	important	not	only	to	add	to	the	body	of	evidence	on	IS	globally	but	also	to	establish	a	baseline	pre-RV	 vaccine	 introduction.	Monitoring	 for	 IS	 incidence	 is	 important	 to	 ensure	both	vaccine	 safety	and	public	 faith	 in	 the	vaccine.	Through	 the	 review	we	were	able	to	build	capacity	and	understanding	of	AGE	and	IS	in	the	staff	working	at	TCH	by	 informing	 them	of	 the	background	of	AGE/IS,	what	RV	vaccines	are,	 the	 risks	associated	with	RV	vaccine	use	and	showing	them	the	epidemiology	of	AGE	and	IS	at	 TCH	 prior	 to	 RV	 vaccine	 introduction	 and	 how	 it	 will	 help	 reduce	 the	 AGE	burden	in	their	community.			The	data	presented	 in	 this	chapter	provides	a	baseline	measure	and	surveillance	system	 that	 Kiribati	 health	 policy	makers	 and	 advocates	 can	 use	 to	monitor	 the	safety	 of	 RV	 use	 in	 their	 population.	 It	 is	 hoped	 that	 the	 data	 will	 provide	reassuring	 information	 for	 MHMS	 with	 regards	 to	 the	 safety	 of	 RV	 vaccine	 and	show	that	the	benefits	of	RV	vaccine	outweigh	the	risks.	This	would	give	them	the	confidence	 to	 keep	 the	 vaccine	 in	 the	 national	 schedule,	 protecting	 their	population	from	RV	disease,	thereby	reducing	mortality,	morbidity	and	strains	on	the	health	systems	of	Kiribati.			
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2.	Abstract	
Background	 and	 Aims:	 Rotavirus	 (RV)	 is	 the	 most	 common	 cause	 of	 acute	gastroenteritis	(AGE)	in	infants	and	children	globally.	To	address	the	high	burden	of	AGE	in	Kiribati,	the	Ministry	of	Health	and	Medical	Services	(MHMS)	introduced	RV	vaccine	 in	August	2015.	As	part	of	RV	vaccine	 introduction,	 the	World	Health	Organization	 (WHO)	 recommends	 post-marketing	 safety	 surveillance	 of	intussusception	(IS).	IS	is	a	rare,	but	severe,	adverse	event	shown	to	be	associated	with	RV	vaccine	use.	Thus	 to	 support	 the	 introduction	of	RV	vaccine,	baseline	 IS	incidence	 and	 epidemiology	 was	 determined	 and	 active	 surveillance	 of	 IS	 was	established	 to	 ascertain	 if	 there	 was	 a	 temporal	 relationship	 of	 IS	 cases	 to	 RV	vaccine	as	part	of	recommended	post-marketing	safety	monitoring.	
	
Methods:	 To	 determine	 baseline	 IS	 incidence	 and	 epidemiology,	 data	 were	collected	 for	children	<2	years	admitted	 to	Tungaru	Central	Hospital	 (TCH)	 from	June	2010	 to	April	2015.	Eligibility	 criteria	 for	 IS	 cases	was	 children	≤24months	with	 a	 discharge	 diagnosis	 of	 IS	 or	 bowel	 obstruction.	 To	 ensure	 no	 cases	were	missed,	deaths	associated	with	dysentery	or	bloody	diarrhoea	were	also	searched	for	as	a	common	symptom	of	IS	is	red	currant	stools.	Medical	records	of	potential	IS	 cases	 were	 reviewed	 and	 IS	 was	 confirmed	 if	 they	 satisfied	 Level	 1	 of	 the	Brighton	 clinical	 case	 definition.	 In	 addition,	 confirmed	 cases	 had	 sex,	 age,	residence,	date	of	admission,	date	of	discharge,	discharge	diagnosis,	management	and	 outcome	 (alive/dead),	 extracted	 from	 the	 medical	 records,	 to	 describe	 the	epidemiology	of	cases	during	the	study	period.	The	2010	Census	data	for	Tarawa	was	used	as	the	denominator	to	calculate	IS	incidence.	To	establish	IS	surveillance	post-RV	 vaccine	 introduction	 in	 August	 2015,	 cases	with	 diagnoses	 indicative	 of	bowel	 obstruction	 and	 admitted	 to	 TCH,	 were	 eligible	 for	 inclusion.	 A	 temporal	relationship	to	RV	vaccine	was	determined	by	an	IS	event	occurring	1-7	days	after	the	 first	dose	of	RV	vaccine	or	 likely	 related	8-21	days	after	 the	 first	dose	of	RV	vaccine	or	1-7	days	after	the	second	dose	of	RV	vaccine.	
	
Results:	There	were	2	 IS	cases	over	 the	5-year	pre-RV	vaccine	review	period	and	the	annual	 IS	 incidence	was	20	per	100,000	children	 (95%	CI	2-73)	<1	year	old.	Both	 cases	 were	 female,	 aged	 5	 months	 old	 and	 required	 surgical	 intervention,	
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with	no	deaths.	It	is	estimated	that	one	additional	case	of	IS	may	occur	every	5-17	years.	The	IS	surveillance	system	drew	on	existing	staff	and	processes	at	TCH.	The	case	definition	used	followed	WHO	guidelines	and	a	local	coordinator	was	trained	to	identify	and	subsequently	report	any	potential	IS	cases	in	the	system.	Since	the	introduction	of	RV	vaccine	in	August	2015	there	has	been	no	reported	IS	cases.		
	
Summary	and	conclusions:		The	incidence	rate	of	IS	in	Kiribati	is	low	in	comparison	to	countries	in	the	Asia-Pacific	and	the	global	average.	However	the	epidemiology	of	cases	is	typical	of	what	is	seen	in	other	parts	of	the	world.	There	were	no	deaths	from	IS	found	in	the	review.	Intussusception	is	a	rare	event	and	for	at	least	50%	of	the	 population,	 surgery	 is	 available	 if	 a	 case	 occurs.	 The	 establishment	 of	 the	 IS	surveillance	 system,	 taps	 into	 existing	 systems	 and	 has	 minimal	 reporting	requirements,	 making	 it	 easy	 for	 staff	 responsible	 to	 report	 IS	 cases	 after	 the	introduction	 of	 RV	 vaccine.	 Thirty	months	 since	 the	 introduction	 of	 RV	 vaccine,	there	 have	 been	 no	 reported	 IS	 cases.	 As	 IS	 is	 a	 rare	 condition	 and	Kiribati	 is	 a	small	country,	Kiribati	would	be	better	suited	to	rely	on	data	from	other	countries	in	the	region	regarding	RV	vaccine	safety.		
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3.	Introduction	
3.1.	Epidemiology	of	intussusception	(IS)	Intussusception	occurs	when	one	segment	of	the	bowel	becomes	in-folded	within	a	more	distal	segment,	causing	bowel	obstruction	(1,	2).			
Figure	1:	Pictorial	of	anatomy	of	intussusception	(2)	
		If	the	resulting	obstruction	is	not	relieved,	the	blood	supply	to	the	bowel	becomes	impaired	and,	if	left	untreated,	this	condition	is	likely	to	be	fatal.	Clinical	symptoms	include	 vomiting,	 abdominal	 pain,	 red	 currant	 jelly	 stools	 and	 lethargy	 (1).	Diagnosis	 can	 be	 determined	 using	 radiography,	 ultrasonography,	 but	 most	commonly	 contrast	 enema.	 The	 condition	 can	 be	 treated	 using	 surgical	 or	 non-surgical	methods	(1).			Naturally	 occurring	 IS	 is	 the	most	 common	 cause	 of	 bowel	 obstruction	 in	 young	children	worldwide	 (3).	 Based	 on	 a	 comprehensive	 global	 review	 by	 Jiang	 et	 al.	(2013)	of	available	IS	studies	in	children,	peak	incidence	was	seen	among	those	4-7	months	of	age	at	97-126	per	100,000	 infant	years,	with	no	obvious	patterns	of	seasonality.	 The	 male	 to	 female	 ratio	 is	 3:1.	 Of	 those	 that	 present	 to	 hospital,	mortality	post-presentation	was	highest	in	Africa	(9.4%)	in	comparison	to	all	other	regions	where	it	was	<1%	(3).			Intussusception	 is	 a	 rare	 event.	 	 In	 the	 Jiang	 et	 al.	 (2013)	 review,	 the	 mean	incidence	was	74	per	100,000	infant	years	(range	9-328	per	100,00	infant	years),	
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but	 as	 shown	 in	 the	 range,	 there	 were	 large	 differences	 between	 studies.	Summarising	82	original	articles	by	region,	Figure	2,	taken	from	Jiang	et	al.	(2013)	shows	the	incidence	for	children	<1	years	of	age,	country,	source	of	data	(national,	regional,	hospital)	and	if	the	rates	had	been	stratified	by	month	of	age.	There	were	many	countries	in	the	world	without	reports	on	IS	epidemiology	for	their	country,	Kiribati	 included.	 Also,	 there	was	much	 heterogeneity	 both	 between	 and	within	regions	 in	 terms	 of	 methods	 for	 IS	 diagnosis,	 treatment	 of	 IS	 and	 sample	 sizes	included	 in	 each	 of	 the	 studies.	 These	 factors,	 in	 addition	 to	 potential	environmental	and	genetic	factors	unique	to	each	country/region	may	explain	the	large	discrepancies	of	IS	incidence	between	countries	and	regions.		
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Figure	2:	Intussusception	incidence	among	children	<1	year	of	age	by	region.	Taken	from	Jiang	et	al.	(2013)(3).	
		
3.2.	IS	and	Rotavirus	(RV)	vaccine	In	 2009,	 WHO	 recommended	 that	 all	 infants	 be	 routinely	 immunised	 with	 RV	vaccine	 to	 prevent	RV	disease	 (4).	 The	 currently	 licensed	RV	 vaccines	 (Rotarix®,	GlaxoSmithKline	and	RotaTeq®,	Merck)	have	been	shown	to	be	safe	and	effective	against	RV	AGE,	with	reductions	of	up	to	71%	of	RV-hospitalisations	in	children	<5	years	of	age	(5).	In	addition,	reductions	in	all-cause	AGE	admissions	for	children	<2	years	of	age	of	17-50%	has	also	been	shown	(6).		
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	However,	 the	 first	 licensed	 RV	 vaccine,	 RotaShield®,	 was	 withdrawn	 from	 use	after	an	increase	of	IS	was	observed	in	infants	following	vaccination.	RotaShield®	was	a	 live-attenuated,	oral	 vaccine	 consisting	of	 three	 rhesus-human	 reassortant	strains	 was	 given	 in	 a	 3-dose	 regimen	 (7).	 From	 early	 pre-licensure	 trials	 the	vaccine	was	shown	to	be	highly	efficacious	for	the	prevention	of	severe	diarrhoea	and	 hospitalisation	 due	 to	 RV	 infection	 (8,	 9)	 but	 there	 were	 indications	 of	 a	possible	 association	 of	 RotaShield®	 and	 IS,	 with	 a	 non-significant	 increase	 in	vaccine	 recipients	 in	 comparison	 to	 controls	 (10).	 Nine	 months	 after	 the	introduction	of	RotaShield®	in	the	US	in	1998,	there	were	15	cases	of	IS	reported	to	a	passive	surveillance	system	and	the	vaccination	program	was	suspended	(11).	By	 September	 1999,	 additional	 cases	 were	 reported	 in	 vaccine	 recipients	 and	evidence	supporting	a	temporal	link	was	developing,	leading	to	the	vaccine	being	completely	withdrawal	from	the	market	in	October	1999	(12).	The	estimated	risk	of	 IS	 was	 calculated	 to	 be	 1/10,000	 children	 vaccinated,	 with	 cases	 clustering	mostly	within	3-14	days	 after	 the	 first	 dose,	with	highest	 risk	 in	 those	 receiving	their	first	dose	after	3	months	of	age	(13,	14).			Currently	 there	 are	 two	 licenced	 RV	 vaccines	 in	 the	market,	 RotaTeq®	 (Merck)	and	 Rotarix®	 (GlaxoSmithKline).	 Both	 licenced	 vaccines	 use	 a	 different	formulation	 to	 RotaShield®,	 with	 RotaTeq®	 a	 live	 oral	 vaccine,	 containing	 five	human-bovine	 reassortant	 RV	 strains	 (15)	 and	 Rotarix®	 a	 live	 oral	 vaccine,	containing	a	single	human	RV	strain	(16).	Due	to	the	experience	with	RotaShield®,	both	 vaccines	 had	 to	 be	 shown	 to	 not	 only	 be	 efficacious	 against	 RV	 but	 also	 to	demonstrate	safety	with	IS	as	an	outcome.	 In	a	double-blind,	randomised	control	trial	 (DBRCT)	 of	 over	 63,000	 Latin	 American	 infants	 randomised	 to	 receive	RotaTeq®	or	placebo,	there	were	25	cases	of	definitive	IS	(16).	During	the	entire	safety	 surveillance	 period	 of	 100	 days	 after	 dose	 1,	 IS	 occurred	 in	 9	 vaccine	recipients	and	16	placebo	recipients	(difference	in	risk	-2.23	per	100,000;	95%	CI	-5.70-0.94;	 p=0.16)	 (16).	 Thus	 within	 the	 trial	 setting,	 the	 vaccine	 was	 not	associated	with	an	increased	risk	of	IS	during	the	31	day	period	after	either	dose	of	vaccine	in	comparison	to	placebo	(16).	For	Rotarix®,	in	a	DBRCT	of	60,000	infants	from	11	 countries,	 randomised	 to	 receive	Rotarix®	 or	 placebo,	 IS	 occurred	 in	 6	vaccine	recipients	and	5	placebo	recipients	within	the	42	day	period	after	any	dose	
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of	vaccine	(multiplicity-adjusted,	relative	risk	1.6;	95%	CI	0.4-6.2)	(15).	Therefore	like	RotaTeq®,	Rotarix®	in	this	trial	setting,	was	not	found	to	have	a	significantly	increased	risk	of	IS	in	vaccine	recipients	at	any	time	during	the	study	period	(15).				From	 pre-licensure	 data,	 both	 vaccines	 were	 highly	 efficacious	 against	 many	different	 types	 of	 RV	 genotypes,	 making	 them	 highly	 appealing	 to	 all	 countries	with	 a	 high	 burden	 of	 RV	 disease.	 Vaccine	 efficacy	 of	 84.7%	 and	 98%	 against	severe	RV	gastroenteritis	was	observed	 for	RotaTeq®	and	Rotarix®	respectively	(15,	16).	Thus	both	RV	vaccines	were	shown	to	not	only	be	efficacious	against	RV	disease	 but	 also	 demonstrated	 safety	 with	 IS	 as	 an	 outcome,	 leading	 to	 their	successful	licensure.			
3.3.	Post-marketing	surveillance	of	IS	From	the	pre-licensure	RCTs,	there	was	no	association	found	between	RV	vaccine	use	and	 IS,	but	 increased	 risks	of	 IS	were	 seen	 in	post-marketing	 surveillance	 in	Mexican,	Brazilian,	Australian	and	United	States	(US)	 infants	(17-19).	Using	case-series	and	case-control	methods,	an	increased	risk	of	IS	1-7	days	after	first	dose	RV	vaccine	was	reported	in	vaccinated	Mexican	and	Brazilian	infants	of	1	per	51,000	and	1	per	68,000	respectively	 (17).	 In	Australia,	using	self-controlled	case-series	and	 case-control	methods	 found	 a	 small	 increased	 risk	 of	 IS	 of	 5.6	 per	 100,000	vaccinated	 infants	 in	 the	 first	 1-7	 days	 after	 the	 first	 dose	 of	 RV	 vaccine	 and	 a	smaller	 increased	 risk	 1-7	 days	 after	 the	 second	 dose	 RV	 vaccine	 (18).	 For	 US	infants,	 approximately	 1.5	 excess	 cases	 of	 IS	 per	 100,000	 recipients	 of	 the	 first	dose	of	RV	vaccine	was	observed	using	both	a	self-controlled	risk-interval	design	and	a	cohort	design	(19).			Taking	 into	 consideration	 the	 small	 increased	 risk	 of	 IS	 from	 post-marketing	surveillance,	studies	have	assessed	the	risk	of	IS	versus	the	benefit	of	RV	vaccine	use.	 For	 the	 US,	 the	 summary	 benefit-risk	 ratios	 for	 RV-associated	 deaths	 and	hospitalisations	 were	 71:1	 and	 1093:1	 respectively	 to	 IS	 (20).	 The	 estimated	benefit-risk	ratios	for	England	were	similar	for	RV-associated	deaths	but	lower	for	hospitalisation	 at	 375:1	 (21).	 Benefit-risk	 ratio	 modelling	 in	 Japan	 had	 similar	levels	 to	 England	 for	 hospitalisation	 but	 a	 much	 higher	 ratio	 for	 RV-associated	deaths	at	366:1	(22).	Even	though	the	benefits	of	RV	vaccine	in	preventing	deaths	
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and	 hospitalisations	 of	 AGE	 outweigh	 the	 risk	 of	 IS,	 WHO	 recommends	 post-marketing	 surveillance	 should	 be	 conducted	 for	 severe	 adverse	 events,	 with	 a	focus	on	 IS	whenever	RV	vaccines	are	 introduced	 into	new	populations	 (4).	This	has	 been	 supported	 by	 WHO	 with	 standardised	 guidelines	 on	 how	 to	 conduct	surveillance	 and	 data	 collection	 forms	 to	 collect	 pre-	 and	 post-RV	 vaccine	introduction	in	a	given	population	(1).		Post-marketing	surveillance	of	RV	vaccine	can	be	done	actively,	passively	or	using	a	combination	of	both	methods.	In	an	active	system,	the	options	include	an	active	search	for	adverse	reactions	or	active	follow	up	of	vaccine	recipients	for	a	defined	period	of	time.	The	benefits	of	an	active	system	are	that	data	are	collected	in	real-time,	 collected	 data	 are	 the	 most	 accurate	 and	 specific	 research	 questions	regarding	vaccine	effectiveness	or	potential	adverse	events	can	be	addressed	(7).	The	 disadvantages	 of	 an	 active	 system	 are	 that	 it	 is	 more	 labour	 intensive	 and	costly.	Passive	systems	are	reliant	on	reporting	 from	stakeholders	 in	 the	system.	The	 benefits	 of	 a	 passive	 system	 are	 the	 use	 of	 existing	 resources.	 The	disadvantages	 of	 a	 passive	 system	 are	 the	 reliance	 on	 reporting,	 which	encompasses,	 under-reporting	 of	 adverse	 events,	 incomplete	 data,	 limited	 or	 no	follow	 up,	 unable	 to	 ascertain	 definitive	 diagnoses	 and	 inaccurate/lack	 of	numerator/denominator	 data	 to	 be	 able	 to	 establish	 causality	 or	 incidence	 (7).	Monitoring	 for	 a	 rare	 severe	 adverse	 event	 like	 IS	 can	 be	 achieved	 through	 a	combination	of	both	active	and	passive	systems.	This	minimises	the	disadvantages	in	both	systems.			
3.4.	RV	vaccine	and	Kiribati	Acute	gastroenteritis	is	a	substantial	burden	in	Kiribati,	with	diarrhoea	estimated	to	cause	10.7%	of	all	<5	year	old	deaths	(23).	In	2002,	11%	of	all	hospitalisations	in	 children	 <4	 years	 old	were	 due	 to	 AGE	 (24).	 	 To	 address	 this	 high	 burden	 of	disease,	Kiribati	introduced	RV	vaccine,	Rotarix®	(GlaxoSmithKline)	into	their	EPI	schedule	 in	 August	 2015.	 For	 Kiribati	 the	 baseline	 IS	 incidence	 was	 unknown.	Thus,	Kiribati	needed	to	determine	the	IS	epidemiology	for	their	population	prior	to	 RV	 vaccine	 introduction	 and	 subsequently	 establish	 IS	 surveillance	 post-RV	vaccine	introduction,	instilling	confidence	in	the	use	of	RV	vaccine.		
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3.5.	Aims	The	aim	of	the	study	were	to:	
• Describe	the	baseline	epidemiology	of	IS	
• Determine	 a	 baseline	 incidence	 of	 IS	 pre-RV	 vaccine	 introduction	 in	children	≤2years	of	age	living	on	Tarawa	
• Establish	 an	 IS	 surveillance	 system	 to	 capture	 and	 record	 all	 IS	 cases	 in	children	living	on	Tarawa,	≤2years	of	age	post-RV	vaccine	introduction		
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4.	Methods	
4.1.	Context	Kiribati	 is	 a	 country	 of	 33	 atolls	 and	 low-lying	 reefs	 widely	 scattered	 along	 the	Equator	 in	 the	 central	 Pacific	 Ocean	 (24).	 Kiribati	 has	 a	 population	 of	approximately	100,000,	with	11,000	of	those	being	children	<5	years	of	age	(24).	The	 island	 of	 Tarawa	 is	 home	 to	 approximately	 60%	 of	 the	 total	 population	 of	Kiribati.	 The	 national	 economy	 depends	 primarily	 on	 I-Kiribati	 people	 working	abroad,	fishing	licence	fees,	exports	of	sea	products	and	foreign	aid	(24).	Kiribati	is	vulnerable	 both	 internally	 due	 to	 depletion	 of	 limited	 natural	 resources	 and	externally	 to	 the	effects	of	 climate	 change	on	 rising	 sea	 levels	 and	unpredictable	weather	 (24).	 Kiribati	 has	 the	 lowest	 level	 of	 development	 in	 the	 Pacific	 region	when	accounting	for	mortality,	morbidity	and	living	conditions	per	capita	GDP	and	also	is	considered	a	least	developed	country	globally	(24).			Each	 village	 in	 Kiribati	 has	 a	 health	 centre	 staffed	 by	 nurses	who	 provide	 basic	primary	health	care,	administer	vaccinations	and	run	health	promotion	activities.	Patients	who	 require	 further	 care	 are	 either	 referred	 or	 seek	 care	 at	 1	 of	 the	 2	hospitals	on	Tarawa:	one	in	Betio	and	the	other,	Tungaru	Central	Hospital	(TCH),	in	Bikenibeu.	TCH	is	the	main	hospital	for	Tarawa	and	also	the	only	facility	that	can	provide	management	for	severe	cases	of	disease	and	provide	surgery.	TCH	is	also	the	referral	hospital	 for	 the	outer	 islands.	The	majority	of	 families	on	Tarawa	do	seek	health	care	at	TCH.	However	it	is	not	uncommon	for	children	to	die	at	home	with	no	autopsy	or	death	reporting	available,	especially	for	children	who	reside	on	the	outer	islands	where	access	to	health	care	is	a	major	issue.			
4.2.	Determining	baseline	IS	incidence	
4.2.1.	IS	case	definition	We	used	the	standard	WHO	case	definition	for	IS	which	ranks	level	of	certainty	by	incorporating	various	criteria	and	can	be	found	in	Box	1.	This	case	definition	was	developed	by	the	Brighton	Collaboration	Intussusception	Working	Group	to	assist	with	 the	 surveillance	 of	 IS	 post-RV	 vaccine	 introduction,	 and	 includes	 a	 case	
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definition	for	IS	based	solely	on	clinical	criteria	(7).	Using	a	clinical	case	definition	bypassed	 the	 need	 for	 access	 to	 radiological,	 ultrasound	 or	 surgical	 diagnoses,	especially	 in	 regions	where	 these	 facilities	or	expertise	may	not	be	available	 (7).	The	definition	was	suitable	for	use	in	a	wide	range	of	settings	and	provided	a	set	of	standardised	clinical	criteria	validated	in	developed	and	developing	countries	(7).	Quoting	 from	 WHO	 post-marketing	 safety	 surveillance;	 ‘The	 definition	 divides	clinical	events	into	a	classification	according	to	the	level	of	evidence	for	diagnostic	certainty,	with	level	1	diagnostic	certainty	defined	as	a	confirmed	or	definite	case	of	 intussusception”	 (7).	 	However,	WHO	also	recommends	capturing	all	 clinically	suspected	 events,	 regardless	 of	 satisfaction	 of	 the	 Brighton	 Collaboration	 case	definition	(7).			Potential	IS	cases	were	those	aged	≤24	months	old,	and	had	a	discharge	diagnosis	of	IS	or	bowel	obstruction.	In	these	cases	the	medical	records	of	each	potential	case	were	 reviewed	 and	 determined	 to	 be	 a	 Level	 1-3	 case	 of	 IS	 as	 per	 the	 Brighton	clinical	case	definition	by	a	paediatrician	(7,	25).			
Box	1:	Brighton	clinical	case	definition	of	intussusception	
	
4.2.2.	IS	data	collection	Hospital	admission	books	(June	2010-April	2015)	and	electronic	medical	records	were	reviewed	for	potential	IS	cases	in	children	<2years	of	age.	For	the	electronic	data,	 the	 search	 terms	 ‘IS’	 and	 ‘bowel	 obstruction’	 were	 used	 to	 find	 potential	
• Level	1	-	diagnosis	of	IS	by	surgical,	radiological	or	autopsy	criteria;	
• Level	 2	 -	 presence	 of	 2	 major	 clinical	 criteria	 or	 1	 major	 and	 3	 minor	criteria;		
• Level	3	-	presence	of	4	or	more	minor	clinical	criteria		Major	 criteria	 were,	 evidence	 of	 intestinal	 obstruction,	 features	 of	 intestinal	invagination	and	evidence	of	intestinal	vascular	compromise	or	venous	congestion.	Minor	criteria	were	age	<1	year,	male,	abdominal	pain,	vomiting,	 lethargy,	pallor,	hypovolemic	shock	and	plain	abdominal	radiograph	showing	an	abnormal	but	non-specific	bowel	gas	pattern.			
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cases.	 Using	 the	 same	 search	 terms,	 hospital	 admission	 books	 were	 manually	searched	for	the	time	periods	electronic	data	was	not	available.	Data	from	January	2014	and	February	2014	were	 incomplete	 from	both	sources.	Both	sources	were	in	a	line	list	format,	inclusive	of	unique	hospital	number.	In	addition,	following	on	from	 concerns	 of	 the	 paediatric	 staff	 of	 potential	 cases	 being	 missed	 with	 the	above	inclusion	criteria,	deaths	caused	by	dysentery	or	had	reported	blood	in	the	stool	were	also	reviewed	as	potential	IS	cases.	To	cross-check	the	list	of	potential	cases	found	was	complete,	we	also	asked	the	paediatricians	and	paediatric	surgeon	if	there	were	any	potential	cases	we	had	missed.		All	potential	IS	cases	had	their	medical	records	reviewed	and	data	were	recorded	on	 a	 dedicated	 data	 collection	 form	 (Appendix	 A).	 Variables	 collected	 from	 the	hospital	 records	 were	 sex,	 age,	 residence,	 date	 of	 admission,	 date	 of	 discharge,	discharge	 diagnosis,	 management	 and	 outcome.	 Based	 on	 clinical	 symptoms	and/or	results	from	investigations,	cases	were	classified	as	a	level	1,	2,	3	using	the	Brighton	 clinical	 case	 definition	 by	 a	 paediatrician.	 All	 completed	 forms	 were	placed	in	a	folder	held	at	the	WHO	country	office.			
4.2.3.	Study	population	For	incidence	calculations,	the	TCH	catchment	population	was	defined	as	children	<2	 years	 residing	 on	 Tarawa.	 Potential	 cases	 residing	 outside	 of	 Tarawa	 were	excluded	after	all	cases	were	identified.	Hence,	only	hospitalised	IS	cases	residing	on	Tarawa	were	included	in	the	population-based	analysis.	Denominator	data	for	rates	were	obtained	from	the	most	recent	census,	which	occurred	in	2010.	The	age	groups	 in	 the	2010	 census	 relevant	 for	 this	 review	were	<12	months	 and	12-23	months.	A	2.2%	growth	 rate	was	 applied	per	 annum	 to	 the	2010	 census	data	 to	calculate	the	2011-2015	<2	years	population.	
4.2.4.	Estimation	of	potential	IS	cases	attributable	to	RV	vaccine		Based	on	data	from	post-licensure	surveillance	conducted	in	Mexico,	Brazil,	US	and	Australia,	 the	 increased	 risk	 of	 IS	 post-RV	 vaccination	 was	 1	 per	 51,000,	 1	 per	68,000,	 1.5	 per	 100,000	 and	 5.6	 per	 100,000,	 respectively	 (17-19).	 Using	 the	population	to	be	vaccinated	(3000	infants	per	year)	in	Kiribati	and	the	estimated	risk	 (2-7	 per	 100,000	 vaccinated)	 from	 these	 data,	 an	 estimated	 number	 of	
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additional	IS	cases	per	year	potentially	attributable	to	RV	vaccination	for	Tarawa	was	calculated.		
4.3.	Establishing	IS	surveillance	
4.3.1.	System	objectives	The	objective	of	the	IS	surveillance	system	is	to	capture	and	record	all	IS	cases	in	children	≤2years	of	age	living	on	Tarawa	post-RV	vaccine	introduction.	
4.3.2.	Engaging	stakeholders	The	Ministry	of	Health	and	Medical	Services	in	Kiribati	asked	WHO	to	assist	with	the	 evaluation	 and	 IS	 surveillance	 for	 RV	 vaccine	 introduction.	 Thus	MHMS	was	engaged	 in	 the	 process	 from	 the	 outset.	 We	 had	 a	 series	 of	 meetings	 with	 the	paediatricians	 and	 a	 TCH	 surgeon	 to	 explain	 the	 purpose	 and	 goals	 of	 our	 visit.	During	these	meetings	we	discussed	their	clinical	experience	and	management	of	IS	cases	and	the	number	of	IS	cases	seen	each	year.	In	addition	the	meetings	were	to	 explain	 the	 purpose	 of	 conducting	 IS	 surveillance	 to	 not	 only	 increase	awareness	 of	 IS	 in	 the	 hospital	 but	 also	 to	 identify	 a	 suitable	 staff	member	who	could	conduct	the	surveillance.	
4.3.3.	Flow	of	information	into	the	system	Based	on	discussions	with	the	paediatric	staff	at	TCH,	the	flow	of	potential	IS	cases	into	TCH	was	mapped.	Figure	3	 is	a	 flowchart	of	how	potential	cases	go	 through	the	 system,	providing	 the	 foundation	 for	 the	 IS	 surveillance	 system	 to	piggyback	onto.			
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Figure	3:	Flow	of	potential	IS	cases	into	Tungaru	Central	Hospital	(TCH)	and	subsequent	treatment	and	outcome	options	
		
4.3.4.	Available/required	resources	We	 considered	 the	 following	 resources	 that	 would	 be	 required	 for	 system	operation:	data	collection	tools,	method	of	data	storage,	a	local	coordinator	and	a	SOP	 for	 them	 to	 follow.	 Through	discussions	with	 paediatric	 staff,	WHO	 country	office	 and	 MHMS	 we	 considered	 whether	 employing	 a	 local	 coordinator	 from	outside	the	hospital	was	feasible.	However,	the	paediatric	staff	suggested	it	would	be	best	to	ask	a	senior	member	of	staff	to	act	in	this	capacity	as	they	would	be	on	site	and	also	already	knew	the	protocols	at	TCH.			
4.3.5.	Attributes	As	 part	 of	 my	 MAE,	 I	 undertook	 a	 review	 of	 the	 surveillance	 attributes	 of	 the	planned	system	as	per	the	Center	for	Disease	Control	(CDC)	Updated	Guidelines	for	Evaluating	Public	Health	Surveillance	Systems	(26).	The	attributes	assessed	were:		
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− Simplicity	(simple	structure	and	ease	of	operation)	
− Flexibility	 (ability	 to	 adapt	 to	 changing	 information	 needs	 or	 operating	conditions	with	little	additional	time,	personnel,	or	allocated	funds)	
− Data	quality	(completeness	and	validity	of	the	data)	
− Acceptability	(willingness	of	persons	and	organisations)		Sensitivity	(proportion	of	cases	of	a	health-related	event	detected)		
− Positive	value	predictive	(PVP)	(proportion	of	reported	cases	that	actually	have	the	health-related	event)	
− Representativeness	(accurately	describes	the	occurrence	of	a	health-related	event	over	time	and	its	distribution	in	the	population	by	place	and	person)		
− Timeliness	(speed	between	steps	in	the	system)	
− Stability	 (ability	 to	 collect,	 manage,	 and	 provide	 data	 properly	 without	failure	and	to	be	operational	when	it	is	needed)		
− Usefulness	 (contribution	 to	 prevention	 and	 control	 of	 adverse	 health	events,	 inclusive	 of	 an	 improved	 understanding	 of	 the	 public	 health	implications	of	such	events)		
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5.	Results	
5.1.	Baseline	IS	incidence	There	were	2	IS	cases	over	the	5-year	period	pre-RV	vaccine	 introduction	(Table	1).	Both	cases	were	female,	aged	5	months	old	and	required	surgical	intervention.	Case	 1	 fully	 recovered	 with	 no	 sequelae	 and	 Case	 2	 recovered	 with	 sequelae,	requiring	further	surgery	for	intestinal	adhesions.	The	annual	incidence	of	IS	was	20	 per	 100,000	 (95%	 CI	 2-73)	 children	 <1	 years.	 In	 addition,	 no	 deaths	 from	dysentery	or	reported	blood	in	stool	met	the	Brighton	IS	classification.		Approximately	3000	infants	will	be	vaccinated	in	Kiribati	each	year.	The	estimated	increased	 risk	 of	 IS	 due	 to	 rotavirus	 vaccine	 is	 2-7	 cases	 per	 100,000	 infants	vaccinated.	 Therefore,	 based	 on	 the	 risk	 calculated	 by	 previous	 studies	 (17,	 18),	there	may	be	one	additional	case	of	 IS	every	5-17	years	 in	Kiribati,	 following	the	introduction	of	RV	vaccine.			
Table	 1:	 Characteristics	 of	 intussusception	 cases	 <2	 years	 admitted	 to	 Tungaru	 Central	Hospital	(TCH),	June	2010-April	2015	
Characteristics	 Case	1	 Case	2	
Age	 5	months	 5	months	Sex	 Female	 Female	Residence		 Bikenibeu	 Betio	Year	of	admission	 2014	 2011	Management	 Surgery	 Surgery	LOS	 3	days	 28	days	Outcome	 Fully	recovered	 Recovered	with	sequelae		
5.2.	IS	Surveillance	
5.2.1.	Results	of	stakeholder	engagement	Informal	 feedback	 from	 paediatric	 and	 nursing	 staff	 indicated	 the	 meetings	 we	held	 to	 discuss	 the	 planned	 IS	 surveillance	were	well	 received.	 A	major	 concern	identified	 from	 these	meetings	was	 that	 this	 surveillance	 system	would	 not	 add	substantially	to	their	workload.	As	a	result	of	this	and	other	discussions	with	the	
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paediatric	 staff,	WHO	 country	 office	 and	MHMS,	we	 decided	 it	would	 be	 best	 to	identify	an	existing	staff	member	to	act	as	the	local	coordinator	for	the	system.	The	local	 coordinator	 would	 absorb	 the	 IS	 surveillance	 role	 into	 their	 pre-existing	duties.		Concerns	were	raised	by	medical	staff	of	the	possibility	of	missed	IS	cases	due	to	misdiagnosis	 of	 IS	 as	 dysentery.	 Thus	we	 also	 included	 a	 review	of	 any	 cases	 of	death	with	 dysentery	 or	 reported	 blood	 in	 stool	 of	 children	 in	 our	 age	 group	 to	ensure	 these	 were	 not	 misdiagnosed	 and	 subsequently	 missed	 in	 our	 system.	Discussions	with	 paediatric	 staff	 at	 TCH	 also	 informed	 our	 understanding	 of	 the	data,	 in	 that	 we	 became	 aware	 that	 surgical	 intervention	 is	 available	 but	ultrasound	reduction	and	air/liquid	enema	are	not	available	and	autopsies	are	not	performed.	
5.2.2.	Case	definition	The	case	definition	used	for	IS	was	the	same	as	the	one	used	for	review	from	WHO	guidelines.			Causality	 of	 IS	 to	RV	 vaccine	will	 be	 established	 by	 reviewing	 the	 time	 of	 the	 IS	event	and	date	of	RV	vaccination.	As	definitive	causality	cannot	be	established	for	individual	cases,	the	causality	assignment,	based	on	post-marketing	surveillance	of	RV	 vaccines	 as	 discussed	 in	 the	 introduction	 (17,	 18),	 is	 divided	 into	 three	categories:		
• Potentially	vaccine	related	–	1-7	days	after	the	first	dose	of	RV	vaccine	
• Likely	related	–	8-21	days	after	the	first	dose	of	RV	vaccine	or	1-7	days	after	the	second	dose	of	RV	vaccine	
• Unrelated	to	vaccine	–	21	days	after	any	dose	of	RV	vaccine	
5.2.3.	Flow	of	information	into	system	Prior	 to	 the	visit	 to	Kiribati,	WHO,	A/Prof	Russell	 and	MHMS	had	decided	 the	 IS	surveillance	 system	would	 be	 set	 up	 at	 TCH.	 This	was	 because	 IS	 is	 severe	 and	requires	hospital	and	surgical	treatment,	thus	cases	would	present	here.	TCH	was	chosen	to	host	the	surveillance	system	as	it	is	the	only	tertiary	health	facility	with	the	resources	to	treat	and	manage	IS	cases	in	country.			
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Based	on	the	understanding	how	cases	 flowed	through	the	TCH	system,	Figure	4	outlines	 the	 steps	 of	 when	 a	 case	 is	 identified	 by	 the	 system.	 Briefly,	 once	paediatric	staff	identified	a	case,	the	local	surveillance	coordinator	would	either	be	notified	 by	 paediatric	 staff	 (nurses,	 paediatrician	 and/or	 paediatric	 surgeon)	 or	would	 identify	 the	 case	 themselves	 during	 their	 time	 on	 the	 ward.	 The	 local	coordinator	 would	 complete	 a	 case	 investigation	 form	 (Appendix	 C)	 using	 the	medical	 records	 for	 the	 case	 and	 determine	 if	 the	 case	 fits	 the	 Level	 1-3	 case	definition.	 For	 those	 satisfying	 the	 Level	 1	 case	 definition,	 the	 local	 coordinator	would	 speak	 to	 the	 treating	 paediatrician/surgeon	 for	 the	 details	 regarding	 the	management	and	clinical	outcome	of	the	case.	The	local	coordinator	would	contact	the	 clinic	 where	 the	 case	 received	 his	 or	 her	 vaccinations	 to	 determine	 their	vaccination	status,	as	there	are	no	parent-held	record	for	immunisation	status.	The	batch	and	expiry	date	of	the	rotavirus	vaccine	would	be	recorded	from	the	MHMS	pharmacy	 records,	 who	 distribute	 the	 vaccines	 to	 the	 health	 centres.	 With	 this	information,	the	local	coordinator	in	consultation	with	paediatric	staff,	WHO	staff,	MHMS	and	external	monitors,	would	decide	if	the	IS	event	is	potentially,	likely	or	not	related	to	the	vaccine	based	on	timing	as	detailed	previously.	After	completion	of	the	form	and	attachment	of	a	copy	of	the	relevant	medical	record,	data	would	be	entered	by	the	local	coordinator	into	the	Epidata	version	3.1	(EpiData,	Denmark)	database	kept	on	the	WHO	country	office	computer,	with	completed	paperwork	of	completed	cases	would	be	stored	in	a	secure	location	at	MHMS.			
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Figure	4:	Outline	of	investigation	of	potential	intussusception	cases	by	local	surveillance	coordinator	
		In	addition,	as	the	external	monitors,	we	would	contact	the	local	coordinator	on	a	regular	basis	(quarterly	by	email)	to	monitor	the	performance	of	the	surveillance	system,	 respond	 to	 an	 increase	 in	 cases	 and	 check	 relevant	 forms	 are	 being	completed	 and	 stored	 appropriately.	 Suspected	 cases	 identified	 from	 the	surveillance	 system	 and	 hospital	 records	 post-RV	 vaccine	 introduction	 will	 be	reviewed	 by	 us	 on	 a	 subsequent	 annual	 visit	 within	 the	 3	 year	 time	 period	 to	ensure	all	suspected	cases	were	captured	for	data	quality	purposes.	
5.2.4.	Resources	required	to	operate	the	system	We	adapted	existing	WHO	IS	data	collection	 tools	 from	the	WHO	post-marketing	surveillance	of	RV	vaccine	safety(7),	for	the	situation	in	Tarawa.	These	same	tools	were	adapted	and	used	successfully	in	Fiji	by	A/Prof	Russell	and	thus	adapted	for	use	in	Tarawa.	We	designed	and	tested	a	simple	Epidata	database	for	data	entry	of	
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collection	 forms.	We	wrote	an	SOP	 for	use	as	both	 training	 tool	and	surveillance	protocol	 for	 the	 local	 coordinator	 to	 follow.	 Due	 to	 the	 small	 number	 of	 cases,	paper	 records	 and	 photocopies	 of	 the	 relevant	 medical	 records	 will	 be	 kept	 at	MHMS.		The	 deputy	 nurse	 of	 the	 paediatric	 ward	 was	 assigned	 to	 coordinate	 the	 IS	surveillance	 system	 and	 as	 the	 designated	 local	 IS	 surveillance	 coordinator.	 The	local	coordinator	was	trained	in	the	IS	surveillance	SOP	(Appendix	B)	to	undertake	the	surveillance	at	TCH.			External	monitors	 are	 scheduled	 to	 return	within	 2	 years	 after	 establishment	 of	the	 system	 to	 review	 the	 data	 collected	 in	 the	 system.	 In	 the	 interim,	 external	monitors	were	in	regular	contact	with	the	local	coordinator	to	monitor	cases,	help	with	the	review	of	suspected	cases	remotely	and	also	provide	support	to	the	local	coordinator.	 The	 review	 post-RV	 vaccine	 introduction	 will	 be	 done	 to	 not	 only	ensure	no	cases	have	been	missed	but	also	to	ensure	children	who	have	died	and	have	 a	 discharge	 diagnosis	 of	 dysentery	 or	 bloody	 diarrhoea	 were	 correctly	classified	(see	sensitivity	below).		
5.2.5.	Results	of	the	system	so	far	Rotavirus	 vaccine	was	 introduced	 into	 Kiribati	 in	 August	 2015.	 As	 of	 December	2016,	there	have	been	no	cases	of	IS	reported	by	the	local	coordinator	and	public	health	nurses	in	TCH	and	Kiribati	respectively.		
5.2.6.	Attributes	of	the	IS	surveillance	system	
Simplicity	The	surveillance	system	is	expected	to	be	simple	as	it	was	designed	to	complement	the	current	treatment	and	diagnosis	for	suspected	IS,	with	TCH	as	the	only	sentinel	site	and	using	existing	staff	in	the	paediatric	ward.	The	rarity	of	IS	pre-	and	post-RV	vaccine	introduction	is	not	expected	to	add	many	additional	cases	therefore	the	additional	 workload	 created	 by	 the	 system	 will	 be	 minimal.	 In	 addition,	 the	investigation	form	is	short	and	the	relevant	medical	records	are	easily	accessible	from	the	hospital.	The	data	from	cases	will	only	need	to	be	analysed	when	I	come	
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for	the	next	review.	Thus	there	is	no	onus	on	the	staff	at	the	hospital	to	analyse	or	disseminate	the	data	on	IS	incidence.	
Flexibility	The	system	is	expected	to	be	 flexible	as	 there	are	very	 limited	components	to	 its	function.	External	monitors	 can	 change	 forms	quickly	with	 advice	 from	 the	 local	coordinator	without	affecting	existing	reporting	or	collection	methods.	This	is	also	true	 of	 inclusion	 of	 other	 adverse	 events	 such	 as	 fever,	 vomiting,	 nausea.	Intussusception	 is	 not	 an	 infectious	 disease	 and	 the	 presentation	 and	 number	cases	 suffering	 from	 IS	will	 not	 change,	 thus	 the	 case	 definition	will	 remain	 the	same	throughout	the	surveillance	period	and	thereafter.	The	main	concern	for	the	systems	 flexibility	would	be	changing	of	associated	health	personnel.	 If	 this	does	happen,	 the	 external	monitor	 will	 liaise	 with	 the	 relevant	 staff	 in	WHO	 country	office	to	identify	suitable	health	personnel	to	take	over.		
Data	quality	To	 address	 the	 issue	 of	 data	 completeness,	 the	 local	 coordinator	will	 photocopy	the	relevant	medical	records	held	either	at	the	bedside	of	the	child	(if	they	haven’t	yet	 been	 discharged)	 or	 from	 the	 medical	 records	 department	 located	 at	 the	hospital.	 The	 local	 coordinator	 will	 also	 have	 access	 to	 the	 treating	paediatrician/surgeon	and	can	discuss	specific	case	issues	and	confirm	a	potential	temporal	relationship	between	the	IS	event	and	RV	vaccination	with	them.	For	RV	vaccination	 status,	 it	 is	 expected	 the	 case’s	 vaccination	 history	 can	 be	 located	 at	their	relevant	clinic.	Also	the	RV	vaccine	batch	and	expiry	will	be	easily	accessible	from	the	MHMS	pharmacy	located	at	the	hospital,	eliminating	the	need	to	travel	for	this	 information.	At	 the	 subsequent	 site	 visit,	 the	 external	monitor	will	 check	 all	the	 completed	 forms	 for	 completeness	 and	 if	 there	 is	 uncertainty,	 consult	 the	photocopied	medical	records	for	the	case.	
Acceptability	The	request	for	the	establishment	of	IS	surveillance	post-RV	vaccine	introduction	was	 made	 by	 MHMS	 to	 WHO,	 to	 ensure	 RV	 vaccine	 was	 safe	 to	 use	 in	 their	population.	 The	 system	 was	 designed	 in	 consultation	 with	 the	 heads	 of	 the	paediatric	 division	 at	 TCH	 to	 ensure	 the	 establishment	 of	 the	 system	would	 not	increase	their	workload	and	create	a	barrier	to	the	function	of	the	system.	Based	
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on	the	informal	feedback	from	paediatric	staff,	they	were	happy	to	be	engaged	in	the	process	and	subsequent	design	of	 the	system,	especially	as	we	adopted	what	they	had	deemed	to	be	the	best	options	in	terms	of	how	the	system	would	fit	into	their	daily	tasks	and	responsibilities.		
Sensitivity	This	system	is	expected	to	be	highly	sensitive	at	both	the	level	of	case	presentation	and	case	diagnosis.	As	IS	is	a	severe	disease	and	causes	great	distress	in	the	child,	all	cases	will	seek	health	care	and	also	require	admission	to	TCH.			A	 standard	 form	 for	 definitive	 diagnosis	 of	 IS	 was	 used	 as	 part	 of	 the	 case	investigation	 form	 to	 provide	 a	 standardised	 method	 (7)	 for	 diagnosis	 of	 IS	 in	infants	 and	 children.	 The	 use	 of	 a	 standardised	 case	 definition	will	 improve	 the	quality	and	comparability	of	vaccine	safety	data	collected.	For	Kiribati,	only	a	level	1	 case	definition	was	 is	 available	 as	 they	do	not	 have	 the	 facilities	 to	 satisfy	 the	radiological	criteria	and	do	not	conduct	autopsies.			The	key	limitation	of	the	system	is	missing	of	cases	either	presenting	with	clinical	symptoms	that	can	be	mistaken	for	other	common	causes	such	as	dysentery.	The	symptoms	of	IS	are	also	very	distinct	with	the	distress	in	the	child	and	the	passing	of	red	currant	jelly	stools.	The	passing	of	red	currant	jelly	stools	could	be	mistaken	for	bloody	diarrhoea,	 leading	to	a	misdiagnosis	of	dysentery.	From	the	IS	review,	there	 were	 no	 cases	missed	 by	 the	medical	 record	 search	 and	 discussions	 with	clinicians.	In	addition,	during	our	review	of	records	prior	to	implementation	of	the	system	there	were	no	deaths	from	dysentery	fitting	the	case	definition.	However	to	ensure	 that	 all	 potential	 cases	 of	 IS	 have	 been	 included	 post-RV	 vaccine	introduction,	 the	 external	monitor	will	 review	 all	 hospital	 discharge	 records	 for	any	 diagnoses	 of	 IS	 or	 bowel	 obstruction	 and	 deaths	 by	 dysentery	 and	 bloody	diarrhoea	during	the	site	visit	in	2017.		
Predictive	value	positive	(PVP)	Definitive	 diagnosis	 of	 IS	 for	 Kiribati	 is	 only	 possible	 by	 surgical	 methods	 and	previously	established	clinical	signs	and	symptoms.	Even	though	the	incidence	of	IS	 is	 low	 in	 the	 population,	 PVP	 will	 be	 high	 due	 to	 the	 methods	 of	 definitive	diagnosis,	 unless	 cases	 die	 before	 surgery.	 However,	 even	 the	 lower	 levels	 of	
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classification	 have	 been	 shown	 to	 be	 highly	 specific	 (>87%)	 (25).	 To	 ensure	reported	 cases	 are	 true	 cases,	 hospital	 records	will	 be	 reviewed	and	assessed	 to	ensure	they	fit	the	criteria.	The	case	definition	used	for	the	surveillance	system	is	based	 on	 studies	 done	 in	 both	 developed	 and	 developing	 country	 settings	 and	agreed	 upon	 by	 the	 Brighton	 Collaboration,	 a	 global	 network	 of	 vaccine	 safety	experts.	In	addition,	the	tools	used	for	classifying	cases	have	been	used	and	tested	in	many	 countries	 that	 have	 introduced	RV	 vaccine	 into	 their	 population	This	 is	especially	important	in	the	first	year	of	vaccine	introduction,	as	there	may	be	a	risk	of	over	reporting	of	cases	due	to	the	 increased	awareness	of	 the	disease.	 If	cases	are	reported	as	IS	but	this	is	not	supported	by	surgical	findings	or	clinical	criteria	then	they	will	be	omitted	from	the	reported	counts.	
Representativeness	The	system	is	representative	for	Tarawa.	TCH	is	the	only	hospital	 in	Kiribati	that	can	 provide	 the	 required	 care	 and	management	 to	 treat	 cases	 and	 is	 located	 on	Tarawa.	Thus	all	cases	of	IS	from	Tarawa	will	be	captured	here.	In	addition,	as	TCH	is	the	referral	hospital	for	Kiribati,	children	from	the	outer	islands	suffering	from	IS	will	be	referred	to	TCH	for	care.	With	the	combination	of	Tarawa	being	home	to	at	least	50%	of	the	population	and	the	referral	hospital	in	Kiribati	for	all	IS	cases,	the	results	from	the	system	can	be	extrapolated	to	the	larger	Kiribati	population.			
Timeliness	For	 this	 condition,	 timeliness	 is	 not	 an	 essential	 attribute	 of	 the	 system.	Intussusception	 is	 a	 rare	 event	 that	 is	 non-communicable	 and	 not	 prone	 to	outbreaks,	 thus	 if	 a	 case	 does	 occur	 delays	 in	 reporting	 would	 not	 lead	 to	additional	morbidity	 or	mortality.	 It	 is	 however	 expected	 the	 reporting	 of	 cases	will	occur	rapidly	as	 the	 local	 coordinator	 is	based	 in	 the	paediatric	ward	where	potential	 cases	 would	 be	 admitted	 and	 has	 daily	 interactions	 with	 the	 treating	paediatrician.	 Rotavirus	 vaccination	 status	 may	 have	 more	 of	 a	 lag	 time,	 as	 it	requires	 liaising	with	health	 centre	 staff.	 Fortunately	WHO	country	office	 is	very	active	in	the	community	and	the	local	coordinator	would	notify	staff	shortly	after	the	event,	as	she	 is	required	to	submit	 the	paperwork	to	the	WHO	country	office	for	storage,	data	entry	and	a	response	if	deemed	necessary.		
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Stability	The	system	is	likely	to	be	stable	as	it	is	reliant	on	resources	already	in	place	for	IS	diagnosis	and	management.	The	greatest	risk	for	stability	will	be	if	key	paediatric	staff	leave	TCH.	This	is	unlikely	as	TCH	is	the	only	tertiary	hospital	in	Kiribati	and	there	are	no	other	options	in	terms	of	facilities	to	practice.	The	other	main	risk	is	as	 IS	 is	 a	 rare	 event,	 interest	 may	 wane,	 so	 regular	 contact	 between	 the	 local	coordinator	and	external	monitor	will	be	 important	to	ensure	potential	cases	are	being	 identified	 throughout	 the	 surveillance	 period.	 The	 supported	 surveillance	will	 continue	 for	3	years	post-RV	 introduction.	Three	years	post	RV	 introduction	will	give	immunisation	policy	makers	a	good	indication	of	the	risk	associated	with	RV	 use	 and	 IS	 in	 the	 Kiribati	 population.	 After	 3	 years,	 there	 will	 be	 enough	evidence	on	the	safety	of	the	vaccine	to	warrant	IS	surveillance	cessation.	
Usefulness	The	purpose	of	the	IS	surveillance	system	is	to	detect	potential	cases	of	IS	post-RV	vaccine	introduction	to	show	the	vaccine	is	safe.	This	is	to	determine	if	there	is	a	temporal	relationship	between	the	IS	event	and	RV	vaccine	administration	in	the	case.	The	system	will	serve	 this	purpose	and	more	 importantly	provide	evidence	there	are	not	excess	cases	of	 IS	occurring	post-RV	vaccine	 introduction.	This	will	help	to	provide	MHMS	with	the	data	required	to	show	the	public	and	policymakers	the	vaccine	is	safe.	
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6.	Discussion	The	annual	incidence	of	IS	(20/100,000	(95%	CI	2-73)	in	children	<1	year	found	in	this	review	was	similar	to	the	IS	incidence	reported	in	Oceania	(27-101/100,000).	Reasons	 for	 the	discrepancy	between	 countries	 include	under	 reporting	of	 cases	due	 to	 health	 seeking	 behaviour,	 inability	 to	 confirm	 the	 diagnosis	 and	 weak	reporting	 systems.	 Other	 factors	 may	 include	 environmental	 or	 genetic	 factors,	which	may	vary	by	population,	highlighting	the	need	to	establish	baseline	IS	data	to	 assess	 any	 potential	 vaccine-associated	 risk	 (3).	 However,	 for	 Kiribati	 we	believe	 that	 the	 incidence	we	 have	 calculated	 is	 accurate	 considering	 Tarawa	 is	home	to	more	than	half	the	population	of	Kiribati.	In	addition,	TCH	is	accessible	to	all	inhabitants	of	Tarawa	for	treatment	and	the	severity	of	IS	would	force	people	to	seek	treatment.	Thus	few,	if	any,	cases	would	be	missed	by	TCH.			The	key	limitations	with	the	IS	review	were	the	small	numbers	of	IS	cases	in	the	5	years	preceding	RV	vaccine	introduction.	During	the	review	period,	only	two	cases	were	 identified	 making	 it	 difficult	 to	 draw	 many	 conclusions	 on	 the	 baseline	epidemiology	 of	 IS	 in	 Kiribati.	 The	 age	 of	 IS	 cases	 in	 this	 review	 reflected	 the	naturally	 occurring	peak	 found	globally	 of	 4-7	months	of	 age	 (3).	 The	 sex	of	 the	cases	differed	from	what	is	seen	elsewhere	with	a	male	predominance	in	published	reports,	with	both	cases	being	female.	For	the	study	period,	no	cases	were	missed,	cross-checked	by	review	of	 the	medical	 records,	discussions	with	paediatric	staff	and	also	review	of	cases	that	had	died	of	dysentery,	bacterial	diarrhoea	or	bloody	diarrhoea.	The	latter	cases	of	dysentery	were	reviewed	following	concerns	of	staff	they	could	be	misdiagnosed	IS	cases.			The	purpose	of	the	surveillance	system	is	to	support	the	introduction	of	RV	vaccine	into	Kiribati	and	show	the	vaccine	is	safe	for	use	in	the	population.	The	strengths	of	the	IS	surveillance	system	lie	in	the	simplicity,	acceptability,	sensitivity	and	PVP	of	the	system.	The	system	relies	heavily	on	the	paediatric	staff	at	TCH,	therefore	it	was	 very	 important	 they	 were	 engaged,	 happy	 with	 the	 design	 and	 minimal	additions	 to	 their	workload.	This	was	achieved	 through	discussions	with	 the	key	staff	and	presentation	of	the	system	to	all	the	paediatric	staff	at	the	end	of	our	visit.	Due	to	the	nature	of	IS	and	the	available	resources	at	TCH,	this	meant	the	system	
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had	 both	 high	 sensitivity	 and	 specificity	 to	 detect	 and	 diagnose	 cases.	Intussusception	 is	a	severe	condition	and	parents	would	always	bring	 their	child	into	TCH	care	if	 it	occurred.	At	TCH,	the	only	treatment	available	 is	surgery.	This	means	 all	 potential	 cases	 would	 have	 a	 definitive	 diagnosis	 of	 IS,	 a	 level	 1	classification	with	near	100%	specificity.			The	 weaknesses	 of	 the	 system	 are	 in	 the	 stability	 and	 data	 quality	 attributes.	Because	the	system	relies	on	TCH	paediatric	staff,	if	there	are	changes	to	key	staff	members	 this	will	 undermine	 the	 system.	However,	 there	 are	 two	elements	 that	will	protect	the	system	from	instability;	one	being	TCH	is	the	only	tertiary	health	facility	 in	 the	 country	 and	 the	 surveillance	 is	 only	 being	 conducted	 for	 a	 short	period	of	 time.	The	key	staff	 involved	are	 the	paediatricians,	paediatric	 surgeons	and	the	senior	paediatric	nursing	staff.	Being	the	only	tertiary	health	facility	in	the	country	means	 this	 is	 the	 only	 health	 facility	 that	 can	 house	 these	 staff	 and	 the	likelihood	of	them	moving	to	a	different	health	facility	is	not	possible,	especially	in	the	short-term.	 In	 terms	of	data	quality,	 the	 forms	are	simple	but	data	regarding	RV	vaccination	for	potential	cases	will	need	to	be	sought	from	an	outside	source.	Thus	far	there	have	been	no	indications	this	will	be	an	issue,	but	in	practice	it	still	remains	to	be	seen.			To	 ensure	 the	 system	 is	working,	 a	 post-RV	 vaccine	 introduction	 review	will	 be	conducted.	The	same	methodology	and	case	definition	will	be	used	to	determine	if	there	 have	 been	 any	 IS	 cases	missed.	 It	 will	 also	 be	 important	 to	meet	 with	 all	stakeholders	to	discuss	how	the	system	is	functioning	and	if	there	were	any	issues	that	may	 inhibit	 the	 system	 from	capturing	potential	 cases	based	on	 the	original	design.	A	key	concern	in	the	design	is	the	potential	of	missed	cases	from	the	outer	islands	that	do	not	seek	care	in	time.	Whilst	TCH	is	the	referral	point	for	Kiribati,	it	is	possible	cases	from	the	outer	islands	may	not	be	able	to	seek	care	in	time	and	so	cases	may	be	missed	this	way.	This	shouldn’t	be	an	issue	in	terms	of	determining	vaccine	safety	as	the	baseline	IS	data	is	from	the	same	population	but	the	system	as	a	whole	may	potentially	miss	cases	this	way.			As	 IS	 is	 a	 rare	 adverse	 event,	 the	 ability	 to	 detect	 the	 expected	 additional	 case	related	 to	 use	 of	 RV	 vaccine	will	 be	 a	 problem	 if	 it	 does	 occur.	 The	 surveillance	
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system	 is	expected	 to	detect	cases	of	 IS	post-RV	vaccine	 introduction,	but	due	 to	the	small	numbers,	the	additional	case(s)	will	greatly	increase	the	incidence	of	IS	cases.	Thus	because	the	numbers	are	so	small,	an	IS	incidence	rate	post-RV	vaccine	introduction	will	not	be	calculated.	As	the	population	of	Tarawas	is	small	and	IS	is	rare,	one	additional	case	occurring	by	chance	would	 increase	 the	 IS	 incidence	by	50%.	 Temporality	 of	 the	 IS	 case	 to	 RV	 vaccine	 receipt	will	 provide	 the	 greatest	source	 of	 evidence	 as	 to	 a	 concern	 in	 Rotarix®	 safety	 in	 this	 population.	 A	 risk	assessment	approach	could	be	used,	where	timing	of	IS	cases,	location	of	IS	cases	and	 changes	 to	 access	 to	 care	would	 be	 considered	 to	 determine	 if	 the	 IS	 cases	were	potentially	related	to	vaccine	or	by	chance.	However,	in	this	setting	it	will	be	very	difficult	to	determine	causality.	This	is	because	as	the	numbers	are	so	small,	the	 same	 assessments	 post-marketing	 in	 the	 US,	 Mexico	 and	 Australia	 will	 be	impossible	to	achieve	in	Kiribati.			An	evaluation	of	the	surveillance	system	will	be	done	in	late	2017,	when	we	return	to	 complete	 the	 AGE	 evaluation.	 WHO	 recommends	 IS	 surveillance	 for	 3	 years	post-RV	vaccine	introduction.	If	there	were	issues	with	vaccine	safety,	these	would	be	 seen	 within	 these	 3	 years.	 The	 data	 collected	 during	 this	 3-year	 period	 will	provide	enough	evidence	to	reassure	MHMS	of	the	vaccine’s	safety.	There	would	be	no	 need	 to	 continue	 this	 surveillance	 beyond	 the	 recommended	 time	 period.	 In	addition,	based	on	the	review,	IS	cases	received	appropriate	surgical	care,	with	no	deaths.	 This	means	 if	 a	 vaccine-related	 case	were	 to	 occur	 the	 appropriate	 care	would	be	available	with	a	favourable	outcome.				Intussusception	is	a	rare	but	potentially	fatal	event	and	use	of	RV	vaccine	has	been	shown	to	increase	the	risk	of	IS	occurring.	In	Kiribati,	if	there	are	additional	cases	related	 to	 vaccination,	 effective	 treatment	 is	 available	 for	 at	 least	 50%	 of	 the	population.	The	establishment	of	a	simple	but	robust	IS	surveillance	system	post-RV	vaccine	 introduction	will	provide	the	data	needed	to	show	RV	vaccine	 is	safe.	To	 support	 this,	 a	 check	 of	 the	 data	 quality	 will	 be	 done	 by	 external	 monitors	within	 the	3	year	 time	period	of	RV	vaccine	 introduction	 to	 instil	 the	 confidence	that	the	system	did	not	detect	any	IS	cases	post-RV	vaccine	introduction.		
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7.	Recommendations		
• For	 the	next	visit,	 the	external	monitor	should	 investigate	admissions	and	the	referral	process	of	Betio	Hospital	 for	cases	of	AGE	and	SAM.	This	 is	 to	ensure	children	were	referred	onto	TCH.	This	is	to	ensure	the	AGE	and	SAM	incidences	calculated	from	the	initial	site	visit	accurately	reflect	the	burden	of	disease	 in	 the	population.	 If	 there	are	a	 substantial	number	of	 children	admitted	 and	 treated	 at	 Betio	 Hospital,	 the	 same	 review	 process	 done	 at	TCH	 previously	 should	 be	 conducted	 and	 the	 incidence	 calculations	adjusted	 to	 reflect	 these	 additional	 cases	 both	 pre	 and	 post-RV	 vaccine	introduction.		
• On	the	post-RV	vaccine	introduction	review,	to	ensure	maximal	usefulness,	it	is	imperative	that	the	external	monitor	conducts	the	following	activities:		
o Meet	 with	 the	 local	 coordinator	 to	 discuss	 the	 operation	 of	 the	surveillance	 system.	 This	 is	 to	 identify	 if	 there	 are	 issues	 or	problems	with	the	surveillance	system		
o Discuss	the	operation	of	the	surveillance	system	with	paediatric	staff	to	check	 if	 the	system	 is	 still	 acceptable	and	capturing	all	potential	cases.		
o Check	 the	medical	 records	 of	 IS	 cases	 detected	 by	 the	 surveillance	system	to	ensure	data	is	complete	and	accurate	during	their	next	site	visit.		
o Review	 medical	 records	 of	 fatal	 cases	 of	 dysentery	 or	 bloody	diarrhoea,	to	ensure	these	are	not	missed	IS	cases.	
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1.	Prologue	
1.1.	Role	Over	 the	past	 couple	of	 years,	 there	have	been	 a	number	of	 vaccine-preventable	disease	(VPD)	outbreaks	in	rural	People’s	Democratic	Republic	of	Laos	(Lao	PDR).	This	has	led	health	authorities	to	have	an	increased	interest	in	VPD	immunity,	and	consequently	 Dr	 Anonh	 Xeuatvongsa	 head	 of	 the	 National	 Immunization	Programme	(NIP)	Lao	PDR,	requested	a	serosurvey	of	Haemophilus	influenzae	type	b	 (Hib)	 antibodies	 to	 assess	 the	 immunity	 to	 Hib	 in	 the	 population.	 As	 our	PneuCAPTIVE	study	 (detailed	 in	Chapter	2)	was	already	collecting	 immunisation	data	and	sera	from	children	living	in	Vientiane	Capital	in	a	contact	serosurvey	for	pneumococcus,	 we	 were	 also	 able	 to	 use	 the	 same	 sera	 for	 detection	 of	 Hib	antibodies.			The	Hib	serosurvey	detailed	 in	 this	chapter	was	 the	work	required	 to	satisfy	 the	epidemiological	component	of	my	Masters	of	Philosophy	in	Applied	Epidemiology	(MAE).	 My	 responsibilities	 on	 the	 project	 included	 the	 design	 of	 the	 study,	preparation	of	the	documents	and	forms	needed,	overseeing	the	day-to-day	work	for	 the	contact	serosurvey,	 setting	priorities	 for	 the	project,	participation	 in	 field	work	when	 required,	maintenance	 of	 the	 study	 databases,	 training	 of	 local	 staff	and	regular	reporting	 to	 investigators.	From	this	work,	 I	will	prepare	a	report	 to	present	to	NIP	and	if	permitted,	a	manuscript	to	be	published	in	a	peer-reviewed	journal	post-MAE.			
1.2.	Lessons	learnt	The	 lessons	 I	 learnt	 on	 this	 study	 were	 broad,	 ranging	 from	 epidemiological	concepts	to	logistical	skills.	One	of	the	first	lessons	I	learnt	through	this	work	was	in	regards	to	sampling	methodology.	I	learnt	about	the	different	sampling	methods	and	the	limitations	of	each,	in	particular	the	commonly	used	Expanded	Programme	of	Immunization	(EPI)	survey	method.	The	EPI	survey	method	was	important	for	me	to	understand	because	this	was	the	survey	method	used	in	Lao	PDR	to	estimate	vaccine	coverage	 in	 the	country.	Following	on	 from	sampling	 I	came	to	a	greater	understanding	of	the	concepts	of	internal	and	external	validity.			
	 	 Chapter	4	–	Hib	Serosurvey	
	
	 159	
As	 the	design	of	 the	 study	used	 convenience	 sampling,	 I	 learnt	 about	 the	 impact	this	 had	 on	 statistical	 considerations	 for	 the	 results.	 I	 learnt	 how	 to	 calculate	sample	sizes	of	varying	precision	for	different	levels	of	clustering.	In	addition,	I	had	to	 consider	 the	 potential	 effect	 measurement	 bias	 played	 in	 my	 results	 due	 to	cross-reactivity	of	other	bacteria	to	the	Hib	assay.				
1.3.	Public	Health	implications	and	impact	Since	 the	 development	 and	 widespread	 use	 of	 Hib	 vaccines,	 incidence	 of	 Hib	disease	has	significantly	decreased.	However,	in	more	recent	times,	some	countries	have	 seen	an	 increase	 in	Hib	 incidence	and	also	breakthrough	disease.	This	data	contributes	to	the	knowledge	of	Hib	in	the	region.	This	is	the	first	Hib	serosurvey	done	in	the	region	and	provides	an	example	of	the	situation	in	Southeast	Asia	and	supports	the	recommendation	for	continued	surveillance	of	Hib	disease	to	ensure	there	is	no	increase	post-Hib	vaccine	introduction.			Based	 on	 recent	 serosurveys	 for	 hepatitis	 B	 (HepB)	 and	 measles	 conducted	 in	various	Lao	PDR,	coupled	with	VPD	outbreaks,	there	are	concerns	between	what	is	recorded	either	on	the	mother-child	health	(MCH)	card	or	immunisation	registers	and	the	serological	 immunity	in	the	population.	This	has	flowed	into	Hib	disease,	where	there	are	concerns	children	in	the	wider	population	are	not	protected.	The	results	from	this	study	attempt	to	address	these	questions	by	describing	both	the	vaccination	status	by	written	record	and	serological	immunity	in	the	same	sample	population.	Currently	 there	 is	no	booster	dose	 in	 the	 schedule	 and	based	on	 the	results	 for	 this	work	 there	 is	no	recommendation	 to	add	a	booster	dose	 into	 the	schedule.	 However,	 the	 written	 record	 vaccine	 coverage	 from	 this	 study	 was	similar	 to	 the	 NIP	 estimates	 for	 Vientiane	 Capital.	 However	 these	 estimates	 are	lower	than	both	the	regional	and	global	estimates	of	DTP-Hib-HepB	vaccine,	giving	NIP	further	impetus	to	continue	improving	vaccine	coverage	through	both	old	and	alternative	vaccination	efforts.			
1.4.	Acknowledgements	I	would	 like	 to	 thank	A/Prof	Fiona	Russell,	Dr	Stephanie	Davis	and	Anne	Balloch	for	their	support,	expertise	and	patience	with	me	for	this	project.	My	gratitude	to	Dr	Anonh	Xeuatvongsa	for	always	supporting	our	work	with	NIP.	My	thanks	to	Dr	
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Cattram	Nguyen	for	helping	me	understand	the	statistical	intricacies	of	my	study.	Special	 thanks	 to	 the	PneuCAPTIVE	 team	 in	Vientiane	who	were	 responsible	 for	conducting	the	fieldwork	and	to	Dr	Ruth	Lim	who	provided	the	training	needed	for	blood	collection.	Finally,	thanks	to	all	participants	and	their	families,	who	without	their	support	we	could	not	do	this	study.	
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2.	Abstract	
Background/aims:	People’s	Democratic	Republic	of	Laos	(Lao	PDR)	has	suffered	in	recent	 times	 from	outbreaks	of	 vaccine-preventable	disease	 (VPD),	 leading	 to	an	increase	in	concerns	the	population	was	not	protected	from	other	VPDs	such	as	H.	
influenzae	type	b	(Hib).	The	aim	of	the	study	in	Vientiane	Capital	was	to	report	the	vaccination	 coverage	by	written	 record	 in	 children	<5	 years	 of	 age	 and	describe	evidence	of	serological	protection	to	Hib	from	these	same	children.			
Methods:	 A	 convenience	 sample	 of	 children	 <5	 years	 of	 age	 living	 in	 Vientiane	Capital	was	used	to	determine	coverage	by	written	record	for	Hib	vaccine	(given	as	part	 of	DTPw-Hib-HepB	 vaccine).	 A	 subset	 of	 these	 children	 aged	 12-59	months	had	 a	 blood	 sample	 taken	 to	 test	 for	 IgG	 antibody	 levels	 to	 Hib	 capsular	polysaccharide,	polyribosylribitol	phosphate	(PRP).	Vaccination	status	was	defined	as	children	having	received	3	doses	of	Hib	vaccine.	Written	record	was	defined	as	either	 the	 parent-held	 mother	 child	 handbook	 (MCH)	 containing	 the	 record	 of	vaccination	 or	 via	 immunisation	 registers	 held	 at	 the	 child’s	 health	 centre.	Evidence	of	serological	protection	was	defined	as	short	and	long-term	with	cut-offs	being	 ≥0.15μg/ml	 and	 ≥1.0μg/ml,	 respectively.	 Chi-squared	 tests	 and	 95%	confidence	intervals	were	used	to	compare	groups.			
Results:	In	total,	559	and	262	participants	were	included	in	the	analysis	for	written	record	 vaccination	 coverage	 and	 serological	 evidence	 of	 Hib	 protection,	respectively.	 Overall,	 62%	 of	 children	 were	 Hib	 vaccinated	 based	 on	 written	record,	 with	 the	 highest	 coverage	 (74%)	 in	 children	 12-23	 months	 old.	Unvaccinated	 children	were	more	 likely	 to	 be	 from	 an	 ethnic	minority	 than	 Lao	Loum	 (p<0.001)	 and	 seek	 care	 from	 a	 local	 health	 centre	 rather	 than	 a	 tertiary	hospital	(p<0.001).	Vaccinated	children	were	more	likely	to	seek	care	at	a	tertiary	hospital	(p<0.001)	rather	than	a	local	health	centre.	Of	those	with	a	blood	sample	all	 had	 serological	 evidence	 of	 short-term	 immunity	 and	 60%	 had	 serological	evidence	of	long-term	immunity,	with	no	significant	difference	between	age	groups	for	 evidence	 of	 long-term	 immunity	 (p=0.492).	 Of	 the	 children	 with	 serological	results	 available,	 34%	 were	 unvaccinated	 by	 written	 record.	 All	 unvaccinated	
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children	by	written	 record	had	 serological	 evidence	of	 short-term	 immunity	 and	23%	had	evidence	of	long-term	immunity.		
Summary	 and	 Conclusions:	 Vaccination	 coverage	 in	 this	 population	 by	 written	record	was	similar	to	the	reported	coverage	for	Vientiane	Capital	by	the	National	Immunization	Programme	(NIP).	However,	the	Hib	vaccine	(given	as	part	of	DTPw-Hib-HepB	 vaccine)	 coverage	 estimates	 by	 written	 record	 in	 Lao	 PDR	 are	 lower	than	both	regional	and	global	estimates.	All	children	with	serological	results	have	evidence	of	short-term	protection	to	Hib	irrespective	of	written	vaccination	status.	In	 addition,	 a	 large	 proportion	 of	 unvaccinated	 children	 showed	 serological	evidence	of	 long-term	immunity	to	Hib.	Possible	reasons	for	this	discrepancy	are	recording	errors,	cross-reactivity	of	other	pathogens	with	the	Hib	assay	or	ongoing	exposure	to	Hib	 in	the	population	creating	an	environment	of	natural	protection.	Based	 on	 these	 data,	 changes	 to	 the	 current	 immunisation	 schedule	 cannot	 be	recommended	 without	 adequate	 Hib	 disease	 data.	 H.	 influenzae	 type	 b	 disease	surveillance	 is	 recommended	 to	 continue	 to	 monitor	 for	 any	 changes.
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3.	Introduction	
3.1.	Haemophilus	influenzae	type	b	(Hib)	
H.	 influenzae	 is	 a	 Gram-negative	 coccobacillus,	 of	 both	 capsulated	 and	 non-encapsulated	types.	H.	influenzae	 type	b	(Hib)	 is	 the	most	pathogenic,	accounting	for	>90%	of	systemic	infections.	H.	influenzae	type	b	primarily	causes	pneumonia	and	meningitis	 almost	 exclusively	 in	 children	 <5	 years	 of	 age.	 In	 2000,	 Hib	was	estimated	 to	 have	 caused	 approximately	 2-3million	 cases	 of	 serious	 disease	 and	386,000	 deaths	 in	 young	 children	 worldwide,	 with	 peak	 incidence	 in	 those	younger	than	6	months	of	age.	Transmission	occurs	through	infectious	respiratory	droplets	(1).			The	 best	method	 of	 Hib	 disease	 prevention	 is	 through	 the	 use	 of	 Hib	 conjugate	vaccines.	 H.	 influenzae	 type	 b	 vaccines	 have	 been	 available	 since	 the	 1980s,	however	widespread	vaccination	did	not	occur	until	 the	2000s.	With	widespread	routine	vaccination,	Hib	meningitis	has	largely	been	eliminated	from	high-income	countries	 (HICs)	 and	 low-	 and	 middle-income	 countries	 (LMICs)	 that	 have	introduced	 Hib	 vaccines	 into	 their	 population	 (1).	 Hib	 vaccine	 is	 available	 in	 a	monovalent	 form	 or	 in	 combination	 vaccines	 containing	 diphtheria	 (DTP),	reducing	the	number	of	injections	needed	to	cover	infants	from	common	childhood	diseases	(2).			
3.2.	Monitoring	of	vaccine	coverage	Vaccination	coverage	is	defined	as	the	number	of	persons	in	a	defined	population	vaccinated	 against	 a	 certain	 disease	 over	 the	 total	 target	 population	 (3).	 The	purpose	of	monitoring	vaccine	coverage	in	a	population	is	to	ensure	the	population	remains	 protected	 from	 disease,	 through	 both	 the	 identification	 of	 gaps	 and	maintenance	 of	 herd	 immunity.	 Monitoring	 of	 vaccine	 coverage	 in	 a	 national	program	helps	identify	areas	of	low	coverage,	where	the	population	is	susceptible.	This	is	important	as	there	is	a	need	to	design	and	implement	custom	interventions	to	 ensure	 the	 susceptible	 population	 are	 protected.	 Herd	 immunity	 effects	 are	where	 unvaccinated	 populations	 are	 also	 protected	 from	 disease	 and	 when	considered,	the	maximum	value	a	vaccine	has	in	a	vaccination	program	is	realised.	In	addition	to	these	functional	purposes,	reporting	of	vaccination	coverage	acts	as	
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a	 good	 indicator	 for	 setting	 targets	 for	 health	 programs	 at	 local,	 national	 and	international	levels	(3).		In	general,	 the	determination	of	vaccine	coverage	 is	 reliant	on	record	and	recall-based	 sources	 of	 data	 such	 as	 administrative	 data,	 surveys,	 immunisation	registries	 and	 parent	 recall.	 Each	 of	 these	 sources	 of	 data	 have	 pros	 and	 cons,	which	are	summarised	in	Figure	1,	from	a	review	by	Lopalco	and	Santisteve,	2014	(3).		
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Figure	1:	Strengths	and	weaknesses	of	different	methodologies	for	assessing	vaccination	coverage.	Taken	from	Lopalco	and	Santisteve	et	al.	(2014)(3).	
		In	general,	the	major	issue	with	these	methods	is	the	reliability	of	the	numerator	and/or	 denominator	 data	 and	 the	method	 of	 data	 collection.	 This	 is	 particularly	noticeable	 in	LMIC	settings	where	 these	data	may	either	not	exist	or	be	severely	over/underestimated	for	a	range	of	reasons.	In	addition,	these	methods	may	not	be	ideal	 for	 the	 assessment	 of	 long-term	 protection	 in	 a	 population,	 due	 to	waning	antibody	 levels	 over	 time	 and	 changes	 in	 the	 biology	 of	 the	 pathogens	 that	may	affect	the	protection	afforded	by	these	vaccines	in	the	population.			
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	Administrative	 data,	 when	 collected	 and	 reported	 correctly,	 gives	 a	 robust	estimate	 of	 vaccine	 coverage	 and	 is	 the	 primary	 source	 for	 vaccine	 coverage	estimates	 in	 HICs.	 However,	 use	 of	 administrative	 data	 in	 LMICs	 is	 particularly	problematic,	 with	 concerns	 surrounding	 the	 reliability	 of	 the	 numerator	 and	denominator	data.	For	denominator	data,	accurate	estimates	of	the	population	are	difficult	 to	 obtain	 due	 to	 the	 lack	 of	 clear	 administrative	 boundaries	 to	 count	population	numbers,	registries	of	births,	deaths	and	migration.	Numerator	data	are	affected	by	accurate	record	keeping,	missing	data,	differences	in	reporting	(i.e.	only	the	 number	 of	 doses	 given	 and	 not	 the	 actual	 number	 of	 children	 vaccinated	 in	their	 population)	 and	 also	 the	 logistics	 of	 getting	 this	 data	 to	 the	 relevant	administrative	bodies	to	be	included	in	the	coverage	estimates.			Due	to	the	 issues	surrounding	the	reliability	of	administrative	data,	surveys	have	been	used	in	LMICs	to	provide	an	additional	source	of	vaccine	coverage	estimates.	One	 well-known	 example	 is	 the	 Expanded	 Programme	 of	 Immunization	 (EPI)	coverage	 surveys,	 which	 use	 a	 cluster	 survey	 design.	 The	 World	 Health	Organization	(WHO)	and	the	United	Nations	Childrens	Fund	(UNICEF)	developed	the	EPI	survey	method	in	response	to	a	need	for	a	rapid	and	cost-effective	method	to	 assess	 the	 immunisation	 coverage	 at	 a	 national	 level	 (4).	 In	 brief,	 after	 the	selection	 of	 30	 clusters,	 7	 households	 are	 randomly	 selected	within	 each	 cluster	and	 children	 12-23	months	 are	 surveyed	 (4).	 This	 method	 theoretically	 gives	 a	total	 sample	 size	 of	 210	 children	 12-23	 months	 of	 age,	 providing	 an	 estimate	within	 10%	 of	 the	 population	 immunisation	 rate	 (4).	 However	 this	 method	 is	prone	 to	 selection	 bias	 and	 applicability	 to	 measure	 other	 health	 outcomes	 is	limited	 (5).	 The	 selection	 of	 households	 is	 a	major	 factor	 to	 the	 introduction	 of	selection	 bias	 into	 the	 results.	 In	 many	 LMIC	 settings,	 there	 are	 no	 up	 to	 date	household	 lists,	 making	 it	 difficult	 to	 choose	 a	 representative	 sample.	 Thus	 the	training	 of	 surveyors	 and	 supervisors	 is	 important	 to	 ensure	 households	 are	chosen	at	random.			Another	method	to	determine	the	immunity	in	a	population	is	through	the	use	of	serosurveys.	The	benefits	of	using	serosurveys	are	that	they	provide	an	objective	measure	 of	 the	 actual	 level	 of	 immunity	 in	 a	 population.	 This	 is	 important	 for	
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identification	of	factors	that	may	predict	low	coverage	and	also	waning	immunity	in	a	population	(3).	Serosurveys	rely	on	the	collection	of	samples,	most	commonly	blood	or	related	fluids,	to	test	for	the	prevalence	of	antibodies	in	individuals	from	a	population	 (6).	 Serosurveys	 can	 include	 serum	 collected	 for	 other	 purposes	 or	specifically	 to	 address	 a	 research	 question.	 The	 key	 limitations	 are	 the	 potential	high	 costs	 associated	 with	 conducting	 a	 serosurvey,	 selection	 process	 and	 if	 a	reliable	 correlate	 of	 protection	 exists.	 Serosureys	 can	be	prone	 to	 selection	bias,	especially	if	they	rely	on	serum	collected	for	a	different	purpose.	If	there	is	no	clear	correlate	of	protection,	they	cannot	distinguish	between	vaccination	and	naturally	acquired	 immunity	 (3).	 In	LMIC	 settings,	 specimen	collection,	 reliable	 laboratory	assays	and	appropriate	statistical	analysis	have	been	a	hindrance	to	their	use	(6).	However,	serosurveys	can	be	very	useful	 to	help	design	and	monitor	vaccination	programs	(6).			
3.3.	Serological	evidence	of	Hib	immunity	Hib	 immunity	 is	 determined	 by	 measuring	 antibody	 production	 against	 a	component	 of	 its	 capsule,	 a	 repeating	 polymer	 of	 ribosyl	 and	 ribitol	 phosphate	(polyribosyl-ribitol-phosphate,	 PRP),	 which	 is	 essential	 for	 its	 pathogenicity	 but	also	 the	 immunogenic	 component	of	Hib	 conjugate	vaccines	 (7).	Through	animal	studies,	 studies	 of	 passive	 immunisation,	 analysis	 of	 natural	 immunity	 and	 early	Hib	 polysaccharide	 vaccine	 efficacy	 trials,	 short-term	 and	 long-term	 protection	anti-PRP	 antibody	 thresholds	 of	 ≥0.15μg/ml	 and	 ≥1.0μg/ml,	 respectively,	 were	established	 (7).	 A	month	 after	 a	 primary	 series	 of	Hib	 vaccine,	 >95%	of	 vaccine	recipients	 had	 both	 short	 and	 long-term	 immunity	 (8-11)	 as	 determined	 by	 the	antibody	cutoffs	detailed	above.			However	 persistence	 of	 immunity	 is	 a	 concern,	 as	 documented	 in	 the	 United	Kingdom	 (UK).	 In	 1992,	 Hib	 vaccine	 was	 introduced	 into	 the	 UK	 routine	 infant	immunisation	schedule	as	a	3-dose	regimen,	given	at	2,	3	and	4	months	of	age,	and	no	booster	(12).	Simultaneously,	a	catch-up	campaign	was	also	introduced	to	give	a	single	dose	to	children	6	months	to	4	years	of	age	to	reduce	Hib	disease	rapidly	(12).	At	first,	the	incidence	of	disease	rapidly	decreased	in	children	<5	years	of	age	from	22.9	 in	1990	 to	0.65	per	100,000	 in	1998	 (13).	By	2000,	 not	 only	had	Hib	disease	 incidence	 increased	 (14),	 but	 there	were	 also	 reports	 of	 vaccine	 failures	
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(15),	even	with	maintenance	of	high	vaccine	coverage	(13).	Potential	reasons	 for	this	 included	 lower	 vaccine	 effectiveness	 in	 infants	 compared	 to	 older	 children	vaccinated	 in	 the	 catch-up	 campaign	 (13),	 loss	 of	 natural	 boosting	 to	Hib	due	 to	reduced	Hib	carriage	exposure	 in	 the	community	 (16),	waning	of	herd	 immunity	(17)	 and	 use	 of	 lower	 efficacy	 combination	 vaccines	 (acelluar	 pertussis	formulation	 rather	 than	 whole-cell)	 (18-20).	 Thus	 it	 was	 unknown	 whether	protection	 persisted.	 Serosurveys	 were	 employed	 to	 investigate	 long-term	persistence	 of	 antibody	 and	 immunological	 memory	 in	 older	 children	 who	 had	received	infant	Hib	vaccination.			In	studies	conducted	 in	HICs,	Hib	antibody	 levels	were	measured	 in	children	2-5	years	of	age,	who	in	infancy	had	been	fully	Hib	vaccinated.	Approximately	75%	of	these	 children	 had	Hib	 antibody	 levels	 ≥0.15μg/ml	 and	 approximately	 40%	 had	Hib	antibody	levels	≥1.0μg/ml	(12,	19,	21-23).		Specifically	in	the	UK,	children	who	received	 vaccine	 in	 infancy	 had	 lower	 antibody	 concentrations	 than	 those	 who	received	vaccine	during	a	 catch-up	campaign	 (17).	 In	English	adults,	median	Hib	antibody	concentrations	fell	from	1.29μg/ml	to	0.7μg/ml	from	1991	to	1994,	with	no	 significant	 change	 in	 antibody	 concentrations	 up	 to	 2003	 (24).	 The	 outcome	from	these	studies	suggested	a	decline	in	natural	boosting	due	to	less	exposure	to	Hib	and	also	supported	 the	proposal	 for	an	additional	booster	 to	be	 included	 for	older	children.		The	long-term	persistence	of	Hib	immunity	in	LMICs	is	unclear.	Studies	conducted	in	children	<6	years	of	age,	in	LMICs	found	that	antibody	levels	for	both	the	short	and	 long-term	protection	were	 slightly	higher	 than	 those	 in	HICs,	 approximately	92%	 and	 78%,	 respectively	 (20,	 25,	 26).	 The	 children	 included	 in	 these	 studies	were	not	all	fully	vaccinated,	with	approximately	15%	overall	being	unvaccinated.	Looking	 at	 specific	 LMICs,	 the	 experience	 of	 long-term	 protection	 against	 Hib	disease	post-Hib	vaccine	introduction	is	mixed.	In	a	longitudinal	surveillance	study	based	 in	 Kenya	 investigating	 the	 effect	 of	 Hib	 vaccine	 on	 disease,	 carriage	 and	population	 immunity,	79%	of	 children	4-35	months	of	age	had	evidence	of	 long-term	 protective	 antibodies,	 8	 years	 after	 Hib	 vaccine	 introduction	 into	 the	community	 (27).	 In	 the	 Kenyan	 setting,	 this	 level	 of	 seroprotection	 kept	 Hib	disease	under	control	with	no	need	for	a	booster	dose,	but	continued	surveillance	
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was	 recommended	 (27).	 In	 contrast,	using	 the	 same	 infant	 schedule	as	Kenya	 (3	doses	 with	 no	 booster),	 the	 Gambia	 has	 seen	 a	 gradual	 increase	 in	 Hib	 disease	incidence	in	children	2-59	months	of	age	in	the	post-Hib	vaccine	era	(28).	Seventy	per	 cent	 of	 children	 5-6	 years	 of	 age	 had	 evidence	 of	 long-term	 protective	antibodies	in	the	Gambia	(28).	However,	there	is	no	recommendation	to	introduce	a	 booster	 dose	 as	 questions	 remain	 of	 necessity,	 age	 and	 also	what	 factors	may	influence	 resurgence	 of	 Hib	 disease	 in	 LMIC	 settings.	 Regardless,	 ongoing	surveillance	 is	 important	 in	 order	 to	 detect	 changes	 in	Hib	disease	 after	 vaccine	introduction	and	is	recommended	by	all	studies.			
3.4.	Vaccine	preventable	disease	outbreaks	(VPD)	–	situation	in	Lao	PDR	In	the	past	a	small	number	of	serosurveys	have	been	conducted	in	Lao	PDR,	with	the	 focus	 on	VPD,	 namely	 diphtheria	 and	hepatitis	 B	 (HepB).	 Black	 et	 al.	 (2014)	conducted	 a	 cross-sectional	 serosurvey	 in	 Lao	 PDR	 of	 HepB	 serology	 in	 the	population.	From	their	results,	Black	et	al.	(2014)	found	vaccination	coverage	was	suboptimal	(65.6%)	even	in	the	urban	populations	with	best	access	to	care	(29).	In	addition,	only	17%	of	pre-school	children	with	3	documented	HepB	vaccinations	were	 serologically	 protected	 (black	 2014).	 However	 it	 is	 well	 documented	 with	HepB	 vaccination,	 immunological	 memory	 persists	 even	 though	 circulating	antibody	 may	 be	 low	 (30).	 Thus	 circulating	 antibodies	 is	 not	 an	 accurate	representation	of	true	immunological	protection	against	HepB	in	the	population.				Nanthavong	et	al.	(2015)	investigated	diphtheria	immunity	in	rural	Lao	PDR	where	there	had	been	diphtheria	outbreaks	in	the	past.	Using	a	cluster	sampling	design,	Nanthavong	et	al.	(2015)	reported	only	83.6%	of	children	with	written	evidence	of	receiving	 3	 doses	 of	 diphtheria	 containing	 vaccine	 had	 protective	 levels	 of	diphtheria	 antibodies	 (31).	 Both	 of	 these	 studies	 highlight	 the	 discrepancy	between	the	documented	vaccination	coverage	versus	the	serological	immunity	in	the	population.	However	as	evidenced	with	HepB,	low	levels	of	antibody	does	not	necessarily	mean	absence	of	protection.			Since	 2015,	 in	 Lao	 PDR	 there	 have	 been	 multiple	 outbreaks	 of	 VPDs	 including	measles,	 diphtheria	 and	 polio.	 This	 has	 raised	 concerns	 in	 regards	 to	 the	documented	coverage	versus	 the	serological	 immunity	 in	 the	population,	 leading	
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to	a	request	by	National	Immunization	Programme	(NIP)	to	investigate.	Thus	far,	there	has	been	a	measles	serosurvey	conducted	with	the	results	pending.	To	add	to	this,	an	assessment	was	requested	by	NIP	to	investigate	the	immunity	of	Hib	in	the	population	as	a	proxy	for	DTPw-Hib-HepB	vaccine	coverage.			
3.5.	Aims	and	objectives	The	 aims	 of	 this	 study	 were	 to	 determine	 in	 children	 <5years	 of	 age	 living	 in	Vientiane	Capital:	1. The	percentage	of	children	vaccinated	with	Hib	vaccine,	based	on	written	immunisation	records;	2. The	percentage	of	children	aged	12-59	months	with	serological	evidence	of	Hib	protection;	and	3. What	percentage	of	 the	unvaccinated	children	have	serological	evidence	of	Hib	protection.		 To	achieve	the	study	aims,	the	following	objectives	from	a	convenient	sample	of	children	<5	years	of	age	living	in	Vientiane	Capital,	Lao	PDR	were	to	calculate	the:	
• Coverage	of	Hib	 vaccine	 from	written	 immunisation	 record	 (parent-held	card	or	health	centre	immunisation	register),	by	age	group	and	sex;	
• Serological	 evidence	 of	 Hib	 short-term	 (≥0.15ug/ml)	 and	 long	 term	(≥1.0ug/ml)	 immunity	 by	 measuring	 the	 IgG	 antibody	 levels	 to	 Hib	capsular	PRP,	by	age	group	and	sex;	and	
• Percentage	of	unvaccinated	children	that	have	serological	evidence	of	Hib	short-term	immunity	(≥0.15ug/ml)	and	long	term	immunity	(≥1.0ug/ml)	by	measuring	the	IgG	antibody	levels	to	Hib	capsular	PRP,	by	age	group.	
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4.	Methods	
4.1.	Context	Lao	PDR	is	classified	as	a	least	developed	country	(LDC)	globally	and	is	made	up	of	18	 provinces,	 each	 consisting	 of	 districts	 containing	 numerous	 villages.	 Eighty	percent	 of	 the	 population	 lives	 in	 a	 rural	 setting,	 whilst	 20%	 live	 in	 an	 urban	setting,	 predominantly	 in	 Vientiane	 Capital.	 Vientiane	 Capital	 is	 located	 on	 the	banks	 of	 the	Mekong	River	 overlooking	Thailand.	 Vientiane	 Capital	 consists	 of	 9	districts	 and	 has	 a	 population	 of	 approximately	 820,940,	 with	 a	 <5	 year	 old	population	of	approximately	98,000	and	under	5	mortality	rate	of	86	per	1000	live	births	(32).			Pentavac	 (Serum	 Institute	 of	 India	 and	 Quinvaxem,	 Berna	 Biotech,	 Korea)	containing	diphtheria,	HepB,	 tetanus,	 pertussis	 and	Hib,	was	 introduced	 into	 the	Lao	PDR	NIP	in	2009,	replacing	DTP-HepB	vaccine.	This	vaccine	is	administered	at	6,	10	and	14	weeks	of	age	along	with	13-valent	pneumococcal	 conjugate	vaccine	and	oral	polio	vaccine.	According	to	NIP	data,	2016	coverage	of	 the	third	dose	of	DTPw-Hib-HepB	 vaccine	 in	 children	 12-23	 months	 is	 approximately	 77%	 in	Vientiane	Capital.			Five	 major	 central	 hospitals,	 9	 district	 hospitals	 and	 approximately	 30	 health	centres	 service	 Vientiane	 Capital.	 Parents/caregivers	 can	 access	 routine	immunisation	services	at	any	one	of	these	health	facilities	free	of	charge	for	their	children.	In	addition	to	DTPw-Hib-HepB	vaccine,	vaccines	included	in	the	NIP	are	birth	dose	HepB,	BCG,	oral	polio	vaccine,	pneumococcal	conjugate	vaccine,	measles	and	 rubella.	 Generally,	 routine	 immunisation	 is	 a	 passive	program	with	mothers	bringing	 their	 children	 to	 the	 clinic,	 however	 limited	 outreach	 programs	 do	operate,	depending	on	 the	health	centre	and	 their	available	resources.	During	an	outbreak	 situation,	 district	 hospitals	 and	 health	 centres	 are	 required	 to	 conduct	supplementary	 immunisation	 activities	 (SIAs)	 as	 requested	 by	 NIP,	 a	 recent	example	being	the	polio	campaigns	for	the	polio	outbreak	in	Lao	PDR	in	2015	(see	chapter	5).			
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4.2.	Recruitment	and	data	collection	A	convenience	sample	of	children	<5	years	of	age	living	in	Vientiane	Capital	were	recruited	 from	 contacts	 of	 children	 hospitalised	with	 acute	 respiratory	 infection	(refer	to	Chapter	2	for	details	regarding	the	recruitment	of	these	cases)	as	part	of	another	ongoing	study.				After	consent	had	been	sought	from	cases	to	conduct	the	contact	serosurvey,	a	list	of	 all	 contacts	were	 identified	 from	 the	 case’s	 parent/guardian	 and	 listed	 in	 the	screening	 book,	 with	 each	 contact	 given	 a	 unique	 study	 identification	 number.	Parents	of	contacts	were	contacted	either	by	phone	or	in	person	and	had	the	study	explained	to	them	with	the	use	of	an	information	sheet	(Appendix	A).		Consent	was	 obtained	 from	parents	 in	 two	 stages.	 First	 they	were	 asked	 to	 give	consent	 to	 be	 part	 of	 the	 written	 record	 survey,	 which	 included	 viewing	 and	recording	 their	 child’s	 vaccination	 status	 from	 their	 MCH	 card	 or	 to	 find	 their	record	at	the	health	centre.	The	second	stage	of	consent	was	for	the	serosurvey.	If	the	 child	 was	 >12	 months	 old,	 parents	 were	 asked	 to	 give	 consent	 for	 a	 blood	sample	 to	 be	 taken.	 If	 consent	 was	 given	 for	 the	 blood	 sample,	 up	 to	 1ml	 was	collected,	 using	 aseptic	 technique	 by	 finger	 prick.	 Blood	 samples	 were	 then	transported	to	the	LOMWRU	laboratory	in	a	cool	box	on	the	day	of	collection.		For	 both	 the	 written	 record	 and	 serosurvey,	 basic	 demographic	 data	 were	collected	on	a	dedicated	data	collection	form	(Appendix	B).	Data	collected	included	date	of	birth/age,	sex,	ethnicity	and	where	they	seek	medical	care	for	their	child.			
4.3.	Laboratory	methods	Blood	collected	 in	serum	tubes	were	centrifuged	 to	separate	 the	serum	 from	the	other	blood	 components	by	 laboratory	 technicians	 at	 the	LOMWRU	 laboratories.	The	 serum	was	 then	 aliquotted	 into	microtubes	 for	 storage	 at	 -80C	 in	 ultra	 low	temperature	 (ULT)	 freezers	 on	 site.	 Serum	 samples	 stored	 in	 the	 LOMWRU	laboratory	were	shipped	in	batches	on	dry	ice	to	the	immunology	group	at	MCRI	in	Melbourne,	Australia	for	serological	testing.	Each	shipment	of	serum	samples	had	a	sample	 list	 included	 to	 ensure	 the	 receiving	 laboratory	 could	 account	 for	 all	
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samples	 in	the	shipment.	Once	all	serum	samples	had	arrived	at	the	 immunology	lab	they	were	stored	in	ULT	freezers	until	they	were	processed.			
4.4.	Outcomes	measures	
4.4.1.	Written	record	Using	 either	 the	 MCH	 card	 or	 health	 centre	 immunisation	 registry,	 participants	that	had	received	3	doses	of	vaccine	were	considered	fully	vaccinated.	Participants	receiving	2	doses	or	less	were	considered	undervaccinated.		
4.4.2.	Serological	evidence	of	Hib	antibody	protection	For	determining	Hib	antibody	levels	in	serum	samples,	ELISAs	measuring	IgG	anti-PRP	 levels	were	 performed	with	 samples	 containing	 ≥0.15μg/ml	 and	 ≥1.0μg/ml	considered	evidence	of	short	and	long-term	immunity,	respectively.			
4.5.	Statistical	consideration	Continuous	variables	such	as	age	were	summarised	using	median	and	interquartile	range.	 Discrete	 variables	 including	 sex,	 ethnicity	 and	 health	 seeking	 behaviours,	were	 summarised	 using	 frequency	 counts	 and	 percentages.	 P-values	 were	calculated	 using	 chi-squared	 tests.	Ninety-five	 percent	 confidence	 intervals	were	reported	 for	 proportion	 calculations	 of	 written	 record	 coverage	 and	 antibody	levels.		All	statistical	tests	were	considered	significant	at	the	0.05%	level.	
4.5.1.	Written	record	coverage	Using	 the	 estimated	 national	 coverage	 (77%)	 and	 considering	 the	 effect	 of	clustering	 due	 to	 the	 sample	 collection	 method,	 the	 required	 sample	 size	 was	calculated	for	this	study.	As	the	size	of	the	clusters	were	not	the	same,	sample	size	was	calculated	with	the	following	formula:			 	 Overall	sample	size	=	nI	*	k*(1-ICC)/(k-	nI	*ICC)		Where:	nI	was	the	sample	size	under	individual	randomisation		 	 k	was	the	number	of	clusters		 	 ICC	was	the	intra-cluster	correlation		
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Thus	 for	 the	primary	aim	of	vaccine	coverage	by	written	record,	prevalence	was	estimated	 in	 the	 sample	 to	be	within	5	of	 the	estimated	coverage	of	77%.	 In	 the	sample	 there	were	168	clusters,	with	cluster	size	ranging	 from	1-20.	Taking	 into	consideration	the	effect	of	 the	 ICC	the	sample	size	required	 for	 the	 following	 ICC	values	are	shown	in	Table	1:		
Table	 1:	Written	 record	 of	 vaccination	 sample	 size	 calculations	with	 differing	 levels	 of	intra-cluster	 correlation	 (ICC)	 at	 5%	 precision,	 95%	 confidence	 in	 comparison	 to	nationally	reported	vaccination	coverage	of	77%	in	the	12-23month	age	group	ICC	value	 0.01	 0.02	 0.03	 0.05	 0.1	Sample	size	(5%	precision)	 274.7	 276.5	 278.4	 282.3	 293.4		
4.5.2.	Evidence	of	serological	protection	Based	 on	 the	 literature,	 the	 proportion	 of	 vaccinated	 children	 2-5	 years	 of	 age	showing	evidence	for	short	and	long-term	immunity	ranged	77-100%	and	19-83%,	respectively	 (19-23,	 25).	 However,	 because	 the	 children	 in	 this	 study	 received	their	 last	 vaccinations	 at	 14	weeks	 of	 age,	 only	 evidence	 of	 long-term	 immunity	was	relevant	for	the	purposes	of	sample	size	calculations.			In	 the	 sample	 there	 were	 49	 clusters	 ranging	 in	 size	 from	 1-10.	 Taking	 into	consideration	the	effect	of	the	ICC,	the	sample	size	required	for	the	following	ICC	values	are	shown	in	Table	2	for	long-term	immunity:		
Table	 2:	 Evidence	 of	 long-term	 antibodies	 to	 H.	 influenzae	 type	 b	 (Hib)	 sample	 size	calculations	with	differing	levels	of	intra-cluster	(ICC)	at	5%	precision,	95%	confidence	in	comparison	to	the	range	19-83%	reported	in	the	literature	ICC	value	 0.01	 0.02	 0.03	 0.05	 0.1	Sample	size	(5%	confidence)	 224.8-246.6	 233.3-257.1	 242.7-268.9	 264.8-297.0	 350.5-413.1		
4.6.	Ethical	consideration	Ethics	 approval	 was	 gained	 from	 the	 Royal	 Children’s	 Hospital	 (RCH)	 Human	Research	 Ethics	 Committee	 (33177B;	 MCRI),	 Oxford	 Tropical	 Research	 Ethics	Committee	 (1050-13;	 LOMWRU),	 WPRO	 Ethics	 Research	 Committee	(2013.30.LAO.2.EPI)	and	the	Human	Research	Ethics	Committee	(2016/770;	ANU).	
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5.	Results	From	the	1st	of	May	2015	until	the	28th	of	February	2017,	there	were	935	contacts	screened	for	both	written	record	and	serological	evidence	for	Hib	vaccination.	For	the	written	record	and	serological	evidence	a	total	of	559	and	262	were	included	in	 the	 study,	 respectively.	 The	 flowchart	 for	 the	 inclusion	 of	 contacts	 for	 both	surveys	can	be	seen	in	Figure	2.			
Figure	 2:	 Flowchart	 of	 participant	 recruitment	 into	 the	 written	 record	 and	 serological	evidence	survey,	from	May	2015	to	February	2017	
Written	record	survey	 Serological	survey	
	
	Children	 were	 ineligible	 for	 the	 written	 record	 if	 they	 were	 >59	 months	 of	 age.	 Children	 were	ineligible	for	the	serological	survey	if	they	were	<12	months	of	age	or	>59	months	of	age.			The	 characteristics	 of	 contacts,	 stratified	 by	 Hib	 vaccination	 status	 based	 on	written	 record	 is	 shown	 in	 Table	 3.	 Undervaccinated	 contacts	were	 significantly	more	 likely	 to	be	of	 an	ethnicity	other	 than	Lao	Loum.	Regarding	health	 seeking	behaviour,	 vaccinated	 contacts	 were	 significantly	 more	 likely	 to	 visit	 a	 tertiary	hospital	for	care,	whilst	undervaccinated	contacts	were	significantly	more	likely	to	seek	 care	 at	 their	 local	 health	 centre.	 Contacts	with	 unknown	 vaccination	 status	were	 older,	 but	 this	 was	 not	 statistically	 significantly.	 However,	 contacts	 with	unknown	 vaccination	 status	 were	 significantly	 more	 likely	 to	 seek	 care	 at	 a	pharmacy.	
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Table	 3:	 Characteristics	 of	 contacts,	 stratified	 by	 vaccination	 status	 as	 determined	 by	written	record	(n=624)	
	
Characteristics	
Total	
(n=624)	
Vaccinated	
(n=348)	
Undervaccinated	
(n=211)	
Unknown	
(n=65)	
p-value	
Median	age	in	months,	(IQR)	 24	(IQR	11-37)	 22	(IQR	11-33)	 28	(IQR	11-43)	 32	(IQR	24-41)	 0.32	Male,	n	(%)	 340	(54)	 183	(53)	 119	(56)	 38	(58)	 0.54	Ethnicity,	n	(%)	Lao	Loum	Other	 	534	(86)	90	(14)	 	316	(91)	32	(9)	 	166	(79)	45	(21)	 	52	(80)	13	(20)	 		<0.001*	Healthcare,	n	(%)	Tertiary	hospital	Local	Health	Centre	Private	Clinic	Pharmacy	
	490	(79)	164	(26)	367(59)	327	(52)	
	304	(87)	68	(20)	206	(59)	167	(48)	
	140	(66)	73	(35)	122	(58)	115	(55)	
	46	(71)	23	(35)	39	(60)	45	(69)	
	<0.001*	<0.001*	0.93	0.005*			
5.1.	Hib	vaccination	coverage	The	 total	 coverage	 of	 Hib	 vaccine	 (given	 as	 part	 of	 DTPw-Hib-HepB	 vaccine)	 by	written	record	was	62%	(348/559).	Vaccination	status	was	unknown	for	65	cases.	Contacts	 12-23	 months	 of	 age	 had	 significantly	 higher	 coverage	 than	 other	 age	groups	at	74%	(p<0.001).	Coverage	of	different	age	groups	can	be	seen	in	Figure	3.			
Figure	 3:	 Hib	 vaccine	 (given	 as	 part	 of	 DTPw-Hib-HepB	 vaccine)	 coverage	 by	 written	record	in	participants	by	age	group	(bars	indicate	95%	CIs)	
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5.2.	Serological	evidence	Of	the	553	contacts	eligible	for	the	serosurvey,	322	provided	consent.	Of	those,	262	blood	 samples	were	 included	 in	 the	 final	 analysis	 (Figure	 2).	 All	 contacts	 tested	had	serological	evidence	of	short-term	protection.	Sixty	percent	(95%	CI	54-66%)	of	contacts	tested	had	serological	evidence	of	long-term	protection.	There	was	no	significant	difference	between	 age	 groups	 (p=0.492)	 (Figure	4)	 or	 sex	 (p=0.482)	for	long-term	seroprotective	levels.			
Figure	 4:	 Proportion	 of	 samples	with	 short-	 and	 long-term	 antibodies	 for	H.	 influenzae	type	b	(Hib)	by	age	(bars	indicate	95%	CI)	
	Samples	with	antibodies	>0.15ug/ml	are	positive	for	short-term	immunity.	Samples	with	antibodies	>1.0ug/ml	are	positive	for	long-term	immunity.		
5.3.	Unvaccinated	contacts	Of	the	262	contacts	with	a	blood	sample	tested,	34%	were	unvaccinated	based	on	the	written	record.	Of	 those	unvaccinated	by	written	record	with	a	blood	sample	available,	 all	 had	 serological	 evidence	 of	 short-term	 protection	 and	 61%	 had	serological	evidence	of	long-term	protection.		
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6.	Discussion	The	 written	 coverage	 of	 Hib	 vaccine	 reported	 from	 this	 study	 is	 similar	 to	 the	latest	 coverage	 estimates	 for	 Vientiane	 Capital	 (77%)	 from	 NIP.	 However	 the	nationally	 reported	 coverage	 estimates	 for	Lao	PDR	are	 lower	 (86%)	 than	 those	reported	globally	for	Hib	vaccine	(given	as	part	of	DTPw-Hib-HepB	vaccine)	third	dose	(33).	In	addition,	the	nationally	reported	coverage	estimates	in	comparison	to	the	region	(94%)	are	even	lower	(33).	The	nationally	reported	coverage	estimates	for	 Lao	 PDR	 could	 be	 an	 underestimation	 of	 the	 true	 coverage	 due	 to	 the	limitations	of	the	surveying	methods	and	use	of	administrative	data.	The	WHO	EPI	survey	method	 is	used	by	many	LMICs,	 inclusive	of	Lao	PDR	 to	estimate	vaccine	coverage	in	their	respective	countries.	As	highlighted	in	the	 introduction,	 the	EPI	method	is	prone	to	selection	bias	caused	by	out-dated	household	lists,	presence	of	transient	 populations,	 particularly	 in	 the	 rural	 area	 and	 general	 logistical	 issues,	where	 the	population	 is	 spread	over	 large	areas	of	difficult	 terrain.	These	are	all	problems	common	for	Lao	PDR	when	conducting	EPI	surveys.			All	 children	 in	 the	 study	 showed	 evidence	 of	 short-term	 immunity	 and	 60%	showed	evidence	of	long-term	immunity	irrespective	of	written	record	vaccination	status.	 Of	 particular	 interest	 are	 the	 high	 antibody	 levels	 in	 children	marked	 as	unvaccinated.	 A	 community	 serosurvey	 in	 Mali	 prior	 to	 the	 introduction	 of	 Hib	vaccine	 found	 1.5%	 of	 6-7	 month	 old	 infants	 had	 Hib	 antibodies	 ≥0.15	 μg/ml	suggesting	 naturally	 acquired	 Hib	 antibody	 levels	 infants	 in	 this	 population	 and	age	 group	 are	 low	 (26).	 Therefore	 in	 this	 study	 in	 Lao	 PDR,	we	would	 expect	 a	negligible	proportion	of	 unvaccinated	 children	 to	have	Hib	 seroprotective	 levels.	Possible	 reasons	 for	 the	high	 levels	of	Hib	 immunity	are	 recording	errors,	 cross-reactivity	of	other	pathogens	with	the	Hib	assay	or	ongoing	exposure	to	Hib	in	the	population	(19,	34).	It	 is	possible,	unvaccinated	children	by	written	record	did	in	fact	receive	vaccination	but	did	not	have	it	recorded	either	in	their	MCH	card	or	in	the	health	centre	registries	by	staff.	Irrespective	of	the	administrative	data	issues,	the	 level	 of	 vaccine	 coverage	 reported	 may	 protect	 the	 population	 from	 Hib	disease	but	may	not	be	 sufficient	 to	eliminate	Hib	 carriage.	This	 is	 supported	by	our	 colleagues	 in	 Lao	 PDR	 conducting	 an	 aetiological	 study	 of	 acute	 respiratory	infection	(ARI)	in	hospitalised	children	(unpublished	data,	pers.	Comm.	A.	Dubot-
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Peres	 &	 H.	 Nguyen)	 who	 found	 Hib	 in	 their	 carriage	 samples.	 This	 provides	opportunities	for	natural	boosting	of	Hib	in	the	population,	maintaining	high	levels	of	circulating	Hib	antibody.	There	is	also	uncertainty	as	to	the	specificity	of	the	Hib	assay,	 which	 may	 also	 explain	 the	 high	 level	 of	 short	 and	 long-term	 immunity	observed	in	the	unvaccinated	children.	Exposure	to	organisms	such	as	E.	coli	that	share	 common	 antigenic	 structures	with	 the	Hib	 capsule,	 create	 antibodies	with	the	 capabilities	 to	 cross-react	 with	 assays	 that	 target	 Hib	 antibodies	 (34,	 35),	thereby	reducing	the	specificity	of	this	assay	to	detect	Hib	antibodies.	This	brings	into	 question	 the	 use	 of	 this	 Hib	 assay	 as	 a	 measure	 of	 Hib	 protection	 in	 the	community;	 is	 the	 high	 proportions	 of	 children	 with	 evidence	 of	 serological	immunity	through	natural	exposure,	vaccination	or	via	cross-reactivity	with	other	organisms?	 The	 most	 likely	 explanation	 for	 the	 discrepancy	 between	 written	record	and	serological	evidence	is	a	combination	of	all	these	factors.	Therefore	it	is	unknown	if	measuring	circulating	Hib	antibody	is	a	good	correlate	of	protection.			In	 comparison	 to	 other	 studies	 both	 from	 HICs	 and	 LMICs,	 the	 proportion	 of	children	 in	 this	 Lao	PDR	 study	with	 serological	 evidence	 of	 short	 and	 long-term	immunity	are	higher	 than	countries	 from	both	 these	settings.	The	discrepancy	of	serological	evidence	of	Hib	immunity	between	HICs	and	LMICs	are	most	likely	due	to	 vaccine	 coverage	 levels	 and	 length	of	 time	 since	 vaccine	 introduction.	 Studies	from	 the	 UK,	 Kenya	 and	 the	 Gambia,	 report	 high	 vaccine	 coverage	 levels	 post-vaccine	 introduction	(13,	27,	28),	with	 the	UK	having	 introduced	the	Hib	vaccine	into	their	schedule	the	earliest.	With	the	maintenance	of	higher	levels	of	coverage	for	 an	 extended	 length	 of	 time,	 this	 has	 meant	 Hib	 carriage	 has	 been	 all	 but	eliminated	along	with	Hib	disease,	reducing	the	opportunities	for	natural	boosting	in	 the	population	 (19).	Coupled	with	 the	effect	of	waning	antibody	 in	vaccinated	children	 and	 less	 immunogenic	 combination	 vaccine	 formulations,	 the	 levels	 of	circulating	Hib	antibody	in	the	older	age	groups	of	the	population	is	reduced	(19).	This	 has	 meant,	 as	 seen	 in	 the	 UK,	 increases	 in	 Hib	 disease	 incidence.	 Thus	 in	response	 additional	 doses	 of	 vaccine	 have	 been	 or	 are	 being	 considered	 to	 be	added	into	the	routine	immunisation	schedules.	The	identification	of	this	change	in	Hib	 disease	 epidemiology	 has	 been	 attributed	 to	 robust	 disease	 surveillance,	highlighting	 the	 importance	 of	 post-vaccine	 introduction	 surveillance	 to	monitor	
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the	effectiveness	of	the	vaccine.	In	all	studies	investigating	the	issue	of	Hib	disease	protection,	surveillance	is	a	key	recommendation.		The	key	limitation	to	the	study	is	the	use	of	a	convenience	sampling	method.	This	was	 because	 participants	 were	 chosen	 based	 on	 exposure	 to	 cases	 admitted	 to	Mahosot	Hospital	with	ARI	as	part	of	an	ongoing	study	(Chapter	2).	Convenience	sampling	is	non-probablistic	and	is	affected	by	selection	bias	therefore	the	external	validity	 needs	 to	 be	 considered	 when	 discussing	 the	 results.	 The	 use	 of	 a	 non-probalistic	 population	 is	 likely	 to	 diminish	 the	 results	 from	being	 generalised	 to	the	actual	population,	as	not	all	people	in	the	population	have	an	equal	chance	to	be	selected.	In	addition,	because	the	participants	were	contacts	of	cases,	clustering	was	 a	 concern.	 Clustering	 reduces	 the	 overall	 number	 of	 the	 sample,	 as	participants	 from	 the	 same	 cluster	 are	 likely	 to	 have	 similar	 characteristics.	 To	address	this	issue,	the	effect	of	clustering	was	taken	into	account	when	calculating	the	sample	size	as	detailed	 in	the	methods.	The	number	of	participants	exceeded	the	calculated	sample	size,	thus	the	results	are	reliable	for	this	sample	population.	Another	factor	to	consider	for	these	data	are	the	participants	are	all	from	Vientiane	Capital	and	not	representative	of	Lao	PDR	as	a	whole.	Vientiane	Capital	is	weighted	towards	 an	 urban	 population,	 when	 the	 actual	 distribution	 of	 the	 country	 as	 a	whole	is	primarily	rural/remote.	In	addition,	access	to	health	services	is	easier	in	the	 capital,	 leading	 to	 an	 overestimation	 of	 vaccine	 coverage	 if	 extended	 to	 the	whole	 country.	 Nevertheless,	 the	 Hib	 coverage	 calculated	 in	 this	 survey	 were	similar	to	the	official	rates	suggesting	our	data	are	representative	of	Hib	coverage	in	Vientiane	Capital.			The	 coverage	 levels	 reported	 by	 NIP	 for	 Vientiane	 Capital	 and	 our	 data	may	 be	enough	 to	 allow	 for	 protection	 against	Hib	 disease	 but	 not	 eliminate	 carriage	 of	Hib,	 providing	 opportunities	 for	 natural	 boosting	 to	 occur.	 In	 addition,	 the	discrepancy	 between	 written	 record	 and	 serological	 evidence	 may	 also	 be	attributed	to	recording	errors,	with	vaccinated	children	not	being	marked	as	such.	We	cannot	say	 from	these	results	 if	a	booster	dose	 is	 required,	especially	as	 it	 is	not	supported	with	Hib	disease	data.	Continuation	of	surveillance	is	recommended	to	monitor	 the	post-vaccine	 situation	 in	Lao	PDR	 to	 identify	 increases	 in	disease	and	potential	breakthrough	disease	attributed	to	vaccine	failures	not	only	for	Hib	
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but	 other	 VPDs.	 The	 prevention	 of	 VPDs	 in	 Lao	 PDR	 is	 through	 the	 increased	uptake	 of	 vaccines,	 subsequently	 increasing	 vaccine	 coverage	 in	 the	 population.	Improvements	 in	 vaccine	 coverage	 are	 the	 major	 focus	 area	 for	 NIP	 and	development	of	new	methods	to	improve	the	protection	in	the	population	need	to	be	considered.		
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7.	Recommendations	
• Given	 the	 levels	 of	 Hib	 vaccine	 found	 in	 the	 study	were	 lower	 than	 both	regional	 and	 global	 estimates,	 ongoing	 efforts	 by	 NIP	 and	WHO	 to	 boost	vaccination	 rates	 should	 be	 supported.	 These	 may	 include	 outreach	programs,	 both	 education	 and	 mobile	 vaccination	 units.	 Considering	 the	resources	available,	the	education	component	could	be	supported	by	village	health	 volunteers	 and	 for	 the	 mobile	 vaccination	 units,	 these	 could	 be	deployed	on	dedicated	days.		
• Hib	 surveillance	 is	 already	 conducted	 at	 sentinel	 sites	 such	 as	 Mahosot	Hospital.	However	the	number	of	cerebrospinal	and	blood	samples	 is	 low.	Ways	 to	 improve	 this	 could	 be	 through	 increasing	 clinician	 awareness	 of	the	 importance	 of	 Hib	 surveillance	 and	 financial	 support	 for	 testing.	Considering	 the	available	resources,	 this	 is	achievable	with	 the	support	of	senior	paediatric	staff.	
• Surveillance	is	limited	to	monitor	Hib	disease	in	Lao	PDR,	making	it	difficult	to	 investigate	 the	 association	 of	 antibody	 levels	 to	 risk	 of	 disease.	Due	 to	resource	constraints	and	logistical	difficulties,	rather	than	investigating	the	antibody	 levels	 required	 for	 protection	 against	 Hib	 disease,	 it	 is	recommended	 that	 NIP	 take	 its	 advice	 from	 other	 countries	 in	 a	 similar	situation	on	changes	they	want	to	make	on	their	current	policies	for	routine	immunisation.		
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		This	 chapter	 was	 removed	 due	 to	 the	 data	 and	 information	 presented	 from	 an	ongoing	outbreak	at	 the	 time	of	writing.	Therefore	 the	data	and	 information	had	not	been	formally	vetted	and	assessed	by	the	custodians	of	the	data.			The	custodians	of	the	data	(National	Immunisation	Program	of	Lao	PDR,	National	Centre	 of	 Laboratory	 and	 Epidemiology	 of	 Lao	 PDR	 and	 the	 World	 Health	Organization	 Lao	PDR	Country	 office,	whom	act	 as	 secretariat	 to	 the	Ministry	 of	Health	 Lao	 PDR)	 have	 requested	 for	 the	 data	 and	 information	 presented	 in	 this	chapter	to	be	restricted	indefinitely.		There	will	 be	 formal	 reports	 and	publications	prepared	 and	disseminated	 to	 the	public	once	the	outbreak	is	completed	and	formally	assessed.	
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1.	Prologue	
1.1.	Role	and	lessons	learned	The	 Master	 of	 Applied	 Epidemiology	 (MAE)	 program	 included	 2	 teaching	requirements:		 1. Lessons	 from	 the	 field	 (LFF)	 –	 a	 teaching	 exercise	 based	 on	 a	 real-life	situation	 encountered	 on	 the	 field	 delivered	 as	 a	 teleconference	 session;	and	2. Teaching	 session	 for	 first-year	 MAE	 cohort	 –	 group	 work	 based	 on	 a	timeframe	of	a	3	hour	teaching	session	on	a	chosen	topic		In	 addition	 to	 the	MAE	 requirements,	 I	 assisted	 in	 the	 teaching	 sessions	 for	 the	journal	 club	 program	 at	 the	 Laos-Oxford-Mahosot	 Hospital-	 Wellcome	 Trust-	Research	 Unit	 (LOMWRU),	 People’s	 Democratic	 Republic	 of	 (Lao	 PDR)	 Field	Epidemiology	 Training	 Program	 cohort	 8	 (FETP8)	 and	 was	 responsible	 for	teaching	staff	employed	for	the	PneuCAPTIVE	project	(Chapter	2).			One	of	the	most	challenging	aspects	of	my	work	was	calculating	vaccine	coverage.	Thus	for	my	LFF	I	decided	to	run	a	session	on	vaccine	coverage	and	the	difficulties	that	can	be	faced	when	working	with	administrative	data	in	a	low-resource	setting.	As	the	MAE	cohort	of	2015	was	large	and	had	2	international	MAEs,	for	the	sake	of	ease	 (the	group	was	 spread	over	many	different	 timezones)	 and	also	 as	both	Dr	Tambri	 Housen,	 based	 in	 Medcicins	 Sans	 Frontier	 (MSF)	 India,	 and	 myself	 had	planned	 to	cover	similar	 topics	based	on	our	placements	we	decided	 to	combine	our	LFF	session.	Thus	our	LFF	was	titled	“Vaccine	coverage	–	Select,	wait	and	??”	(Appendix	A).	The	aim	of	the	LFF	was	to	walk	our	MAE	LFF	group	on	the	process	of	sampling	and	common	methods	 related	 to	vaccine	 coverage	estimation	and	 then	using	real	data,	how	to	extract	information	and	consideration	of	other	methods	of	vaccine	 coverage	 estimation.	My	 role	 in	 the	LFF	was	 to	prepare	 and	present	 the	introduction	 section	 dealing	 with	 the	 theoretical	 concepts	 of	 sampling	 and	different	 methods	 of	 calculating	 vaccine	 coverage.	 I	 was	 then	 responsible	 for	walking	the	group	through	the	real	data	I	had	collected	in	the	field.			
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The	 teaching	 session	 for	 the	 first	 years	 was	 developed	 in	 collaboration	 with	 a	group	of	my	colleagues	from	my	cohort	(Dr	Tanyth	de	Gooyer,	Dr	Tambri	Housen,	Dr	 Craig	 Thompson,	 Anthony	 Draper,	 Dr	 Alicia	 Arnott)	 on	 the	 topic	 of	‘Administering	 questionnaires	 when	 conducting	 an	 outbreak	 investigation’	(Appendix	B).	We	developed	the	session	based	on	our	experiences	in	the	field	and	theoretical	 training	 from	 the	 MAE	 program.	 The	 aims	 of	 the	 session	 were	 to	introduce	 some	 of	 the	 considerations	 (and	 pitfalls)	 associated	 with	 conducting	interviews	as	part	of	outbreak	investigations	and	to	provide	a	practical	experience	of	 interviewing.	 The	 preparation	 of	 the	 session	was	 difficult	 as	we	were	 spread	both	 in	 Australia	 and	 internationally.	 The	 session	 was	 structured	 with	 an	introduction,	 practice	 interviews	 and	 reflections	 on	 the	 session.	 From	 the	evaluation,	the	session	was	very	successful	with	the	overall	session	receiving	4.7/5	by	the	MAE	2016	cohort.			Being	 based	 in	 Lao	 PDR,	 there	were	many	 opportunities	 to	 assist	 in	 training	 of	local	staff	on	epidemiological	concepts.	I	helped	with	training	of	local	staff	both	at	LOMWRU	and	the	FETP	managed	jointly	by	the	World	Health	Organization	(WHO)	Laos	PDR	country	office	and	the	National	Centre	for	Laboratory	and	Epidemiology	(NCLE)	 in	 the	 Ministry	 of	 Health	 (MoH).	 For	 the	 training	 at	 LOMWRU,	 it	 was	identified	 that	 staff	 attending	 the	 regular	 journal	 club	 session	 each	 month	 had	limited	 training	 in	 epidemiological	 concepts,	 making	 it	 difficult	 to	 critically	appraise	journals	each	month.	To	improve	the	understanding	and	encourage	more	engagement	 of	 local	 staff	 with	 the	 journal	 club,	 a	 series	 of	 lectures	 addressing	study	design,	sampling,	statistical	analyses	and	limitations	were	presented	to	local	staff	 to	 improve	 their	 epidemiological	 knowledge.	 I	 was	 asked	 to	 present	 the	session	 on	 bias	 and	 confounding.	 The	 slides	 used	 are	 in	 Appendix	 C.	 During	my	time	interacting	with	the	surveillance	team	at	WHO,	I	offered	to	help	out	with	the	FETP	cohort	in	2016.	I	assisted	in	their	data	analysis	sessions	held	at	NCLE.			As	part	of	my	employment	I	acted	in	a	coordinator	position	for	the	PneuCAPTIVE	study	 (Chapter	2)	based	 in	Lao	PDR.	 In	 this	 role	 I	was	 responsible	 for	a	 team	of	staff	 working	 on	 the	 non-clinical	 aspects	 of	 the	 study.	 This	 meant	 that	 I	 was	responsible	 for	all	 the	 training	of	our	 staff	 for	 the	contact	 serosurvey	and	health	centre	immunisation	register	data	collection.	For	the	contact	serosurvey	staff	had	
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to	 be	 trained	 on	 the	 identification	 and	 consent	 process	 of	 contacts,	 subsequent	data	collection	on	dedicated	 forms	and	entry	of	data	 into	 the	relevant	databases.	For	the	health	centre	immunisation	register	data	collection	staff	had	to	be	trained	on	the	process	of	understanding	the	data	contained	in	the	registries,	as	each	health	centre	 recorded	 the	 data	 differently,	 how	 to	 collect	 the	 data	 contained	 in	 the	registries	and	finally	the	data	entry	process.	The	data	for	both	the	serosurvey	and	health	 centre	 registries	 were	 double	 data	 entered	 into	 Epidata	 databases.	
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